{"PMC5637349": [["CorrectionFollowing publication of the original article [1], the authors were alerted by a colleague of a column duplication in Table 1.", [["a column duplication", "TREATMENT", 104, 124]]], ["Since the summary row was correct, though, the interpretation and the conclusion of the article were not affected.", [["the interpretation", "TEST", 43, 61]]]], "PMC7190299": [["IntroductionRespiratory syncytial virus (RSV) is one of the major causes of pediatric respiratory tract infections [1].", [["respiratory tract", "ANATOMY", 86, 103], ["IntroductionRespiratory syncytial virus (RSV)", "DISEASE", 0, 45], ["respiratory tract infections", "DISEASE", 86, 114], ["IntroductionRespiratory syncytial virus", "ORGANISM", 0, 39], ["RSV", "ORGANISM", 41, 44], ["IntroductionRespiratory syncytial virus", "SPECIES", 0, 39], ["RSV", "SPECIES", 41, 44], ["IntroductionRespiratory syncytial virus (RSV)", "PROBLEM", 0, 45], ["pediatric respiratory tract infections", "PROBLEM", 76, 114], ["syncytial virus", "OBSERVATION", 24, 39], ["respiratory tract", "ANATOMY", 86, 103]]], ["RSV is estimated to cause approximately 30.5 million annual cases among infants less than one, of which 3.3 million require hospitalization [1].", [["RSV", "DISEASE", 0, 3], ["RSV", "ORGANISM", 0, 3], ["infants", "ORGANISM", 72, 79], ["infants", "SPECIES", 72, 79], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3]]], ["We have recently shown that RSV accounts for 16% of influenza-like illnesses in Lebanon, where children under the age of 2 years were at the highest risk for infection [2].", [["RSV", "DISEASE", 28, 31], ["influenza-like illnesses", "DISEASE", 52, 76], ["infection", "DISEASE", 158, 167], ["RSV", "ORGANISM", 28, 31], ["children", "ORGANISM", 95, 103], ["children", "SPECIES", 95, 103], ["RSV", "SPECIES", 28, 31], ["RSV", "PROBLEM", 28, 31], ["influenza", "PROBLEM", 52, 61], ["infection", "PROBLEM", 158, 167], ["RSV", "OBSERVATION", 28, 31], ["infection", "OBSERVATION", 158, 167]]], ["Recurrent infections later in life are inevitable and are usually asymptomatic or accompanied by mild symptoms [3].IntroductionRSV is an enveloped Pneumovirus belonging to the Paramyxoviridae family with a linear, non-segmented, single-stranded, (\u2212) sense RNA genome coding for 11 viral proteins [4].", [["infections", "DISEASE", 10, 20], ["IntroductionRSV", "CHEMICAL", 115, 130], ["Paramyxoviridae family", "DNA", 176, 198], ["linear, non-segmented, single-stranded, (\u2212) sense RNA genome", "DNA", 206, 266], ["viral proteins", "PROTEIN", 281, 295], ["Recurrent infections", "PROBLEM", 0, 20], ["mild symptoms", "PROBLEM", 97, 110], ["11 viral proteins", "PROBLEM", 278, 295], ["infections", "OBSERVATION", 10, 20], ["mild", "OBSERVATION_MODIFIER", 97, 101]]], ["The two envelop proteins, glycoproteins G and fusion protein F constitute the viral antigens that trigger the humoral and cellular immune response of the host [5].", [["cellular", "ANATOMY", 122, 130], ["glycoproteins G", "GENE_OR_GENE_PRODUCT", 26, 41], ["fusion protein F", "GENE_OR_GENE_PRODUCT", 46, 62], ["cellular", "CELL", 122, 130], ["envelop proteins", "PROTEIN", 8, 24], ["glycoproteins G", "PROTEIN", 26, 41], ["fusion protein F", "PROTEIN", 46, 62], ["viral antigens", "PROTEIN", 78, 92], ["The two envelop proteins", "TREATMENT", 0, 24], ["glycoproteins G", "TREATMENT", 26, 41], ["fusion protein F", "PROBLEM", 46, 62], ["the viral antigens", "PROBLEM", 74, 92], ["cellular immune", "OBSERVATION", 122, 137]]], ["The G protein mediates attachment of RSV to its host cell, while the F protein triggers the fusion of the viral envelop with the cell plasma membrane during viral penetration.", [["cell", "ANATOMY", 53, 57], ["cell plasma membrane", "ANATOMY", 129, 149], ["G protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["RSV", "ORGANISM", 37, 40], ["host cell", "CELL", 48, 57], ["F", "GENE_OR_GENE_PRODUCT", 69, 70], ["cell plasma membrane", "CELLULAR_COMPONENT", 129, 149], ["G protein", "PROTEIN", 4, 13], ["F protein", "PROTEIN", 69, 78], ["RSV", "SPECIES", 37, 40], ["The G protein mediates", "TREATMENT", 0, 22], ["RSV", "PROBLEM", 37, 40], ["the F protein", "TEST", 65, 78], ["the fusion", "TREATMENT", 88, 98], ["the cell plasma membrane", "TREATMENT", 125, 149], ["viral penetration", "PROBLEM", 157, 174], ["RSV", "OBSERVATION", 37, 40], ["host cell", "OBSERVATION", 48, 57], ["viral", "OBSERVATION", 106, 111], ["viral penetration", "OBSERVATION", 157, 174]]], ["Moreover, the F protein mediates the fusion between neighboring cells resulting in syncytia formation, which is the most common method of virus propagation [5].IntroductionRSV infection starts as a mild upper respiratory tract infection [6,7].", [["cells", "ANATOMY", 64, 69], ["syncytia", "ANATOMY", 83, 91], ["upper respiratory tract", "ANATOMY", 203, 226], ["infection", "DISEASE", 176, 185], ["upper respiratory tract infection", "DISEASE", 203, 236], ["F protein", "GENE_OR_GENE_PRODUCT", 14, 23], ["cells", "CELL", 64, 69], ["syncytia", "CELL", 83, 91], ["upper respiratory", "ORGANISM_SUBDIVISION", 203, 220], ["tract", "ORGANISM_SUBDIVISION", 221, 226], ["F protein", "PROTEIN", 14, 23], ["the F protein mediates the fusion", "TREATMENT", 10, 43], ["neighboring cells", "PROBLEM", 52, 69], ["syncytia formation", "PROBLEM", 83, 101], ["IntroductionRSV infection", "PROBLEM", 160, 185], ["a mild upper respiratory tract infection", "PROBLEM", 196, 236], ["syncytia formation", "OBSERVATION", 83, 101], ["infection", "OBSERVATION", 176, 185], ["mild", "OBSERVATION_MODIFIER", 198, 202], ["upper", "ANATOMY_MODIFIER", 203, 208], ["respiratory tract", "ANATOMY", 209, 226], ["infection", "OBSERVATION", 227, 236]]], ["However, the infection can progress to lower respiratory tract infection, characterized by severe symptoms and pathogenesis such as epithelial cell necrosis, sloughing of desquamated cells into the bronchiolar lumen, submucosal and adventitial tissue edema as well as accumulation of macrophages and neutrophils in the peribronchiolar and perivascular regions [8].", [["lower respiratory tract", "ANATOMY", 39, 62], ["epithelial cell", "ANATOMY", 132, 147], ["cells", "ANATOMY", 183, 188], ["bronchiolar lumen", "ANATOMY", 198, 215], ["submucosal", "ANATOMY", 217, 227], ["adventitial tissue", "ANATOMY", 232, 250], ["macrophages", "ANATOMY", 284, 295], ["neutrophils", "ANATOMY", 300, 311], ["peribronchiolar", "ANATOMY", 319, 334], ["perivascular regions", "ANATOMY", 339, 359], ["infection", "DISEASE", 13, 22], ["respiratory tract infection", "DISEASE", 45, 72], ["necrosis", "DISEASE", 148, 156], ["edema", "DISEASE", 251, 256], ["tract", "ORGANISM_SUBDIVISION", 57, 62], ["epithelial cell", "CELL", 132, 147], ["cells", "CELL", 183, 188], ["bronchiolar lumen", "TISSUE", 198, 215], ["submucosal", "MULTI-TISSUE_STRUCTURE", 217, 227], ["adventitial tissue", "TISSUE", 232, 250], ["macrophages", "CELL", 284, 295], ["neutrophils", "CELL", 300, 311], ["peribronchiolar", "CELL", 319, 334], ["perivascular regions", "CELLULAR_COMPONENT", 339, 359], ["desquamated cells", "CELL_TYPE", 171, 188], ["macrophages", "CELL_TYPE", 284, 295], ["neutrophils", "CELL_TYPE", 300, 311], ["the infection", "PROBLEM", 9, 22], ["lower respiratory tract infection", "PROBLEM", 39, 72], ["severe symptoms", "PROBLEM", 91, 106], ["pathogenesis", "PROBLEM", 111, 123], ["epithelial cell necrosis", "PROBLEM", 132, 156], ["sloughing of desquamated cells into the bronchiolar lumen", "PROBLEM", 158, 215], ["submucosal and adventitial tissue edema", "PROBLEM", 217, 256], ["accumulation of macrophages and neutrophils in the peribronchiolar and perivascular regions", "PROBLEM", 268, 359], ["infection", "OBSERVATION", 13, 22], ["lower", "ANATOMY_MODIFIER", 39, 44], ["respiratory tract", "ANATOMY", 45, 62], ["infection", "OBSERVATION", 63, 72], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["symptoms", "OBSERVATION", 98, 106], ["epithelial cell necrosis", "OBSERVATION", 132, 156], ["sloughing", "OBSERVATION_MODIFIER", 158, 167], ["desquamated cells", "OBSERVATION", 171, 188], ["bronchiolar", "ANATOMY", 198, 209], ["lumen", "ANATOMY_MODIFIER", 210, 215], ["submucosal", "ANATOMY_MODIFIER", 217, 227], ["adventitial tissue", "ANATOMY", 232, 250], ["edema", "OBSERVATION", 251, 256], ["accumulation", "OBSERVATION_MODIFIER", 268, 280], ["macrophages", "OBSERVATION", 284, 295], ["neutrophils", "OBSERVATION_MODIFIER", 300, 311], ["peribronchiolar", "ANATOMY_MODIFIER", 319, 334], ["perivascular", "ANATOMY_MODIFIER", 339, 351]]], ["Besides, excessive mucus secretion and syncytia formation represent the main hallmarks of RSV infection [8,9].", [["mucus", "ANATOMY", 19, 24], ["syncytia", "ANATOMY", 39, 47], ["RSV infection", "DISEASE", 90, 103], ["mucus", "ORGANISM_SUBSTANCE", 19, 24], ["syncytia", "CELLULAR_COMPONENT", 39, 47], ["RSV", "ORGANISM", 90, 93], ["RSV", "SPECIES", 90, 93], ["excessive mucus secretion", "PROBLEM", 9, 34], ["syncytia formation", "PROBLEM", 39, 57], ["RSV infection", "PROBLEM", 90, 103], ["excessive", "OBSERVATION_MODIFIER", 9, 18], ["mucus secretion", "OBSERVATION", 19, 34], ["syncytia formation", "OBSERVATION", 39, 57], ["main", "OBSERVATION_MODIFIER", 72, 76], ["hallmarks", "OBSERVATION_MODIFIER", 77, 86], ["RSV infection", "OBSERVATION", 90, 103]]], ["Excessive mucus secretion upon RSV infection leads to the formation of mucus plugs, pulmonary obstruction, and shortness of breath [10].IntroductionMost of the data currently available on RSV are from studies in monolayer (2D) cultures.", [["mucus", "ANATOMY", 10, 15], ["mucus", "ANATOMY", 71, 76], ["pulmonary", "ANATOMY", 84, 93], ["RSV infection", "DISEASE", 31, 44], ["pulmonary obstruction", "DISEASE", 84, 105], ["shortness of breath", "DISEASE", 111, 130], ["mucus", "ORGANISM_SUBSTANCE", 10, 15], ["RSV", "ORGANISM", 31, 34], ["mucus plugs", "PATHOLOGICAL_FORMATION", 71, 82], ["pulmonary", "ORGAN", 84, 93], ["RSV", "ORGANISM", 188, 191], ["monolayer", "CELL", 212, 221], ["monolayer (2D) cultures", "CELL_LINE", 212, 235], ["RSV", "SPECIES", 31, 34], ["RSV", "SPECIES", 188, 191], ["Excessive mucus secretion", "PROBLEM", 0, 25], ["RSV infection", "PROBLEM", 31, 44], ["mucus plugs", "PROBLEM", 71, 82], ["pulmonary obstruction", "PROBLEM", 84, 105], ["shortness of breath", "PROBLEM", 111, 130], ["the data", "TEST", 156, 164], ["RSV", "PROBLEM", 188, 191], ["cultures", "TEST", 227, 235], ["mucus secretion", "OBSERVATION", 10, 25], ["RSV infection", "OBSERVATION", 31, 44], ["mucus plugs", "OBSERVATION", 71, 82], ["pulmonary", "ANATOMY", 84, 93], ["obstruction", "OBSERVATION", 94, 105]]], ["2D cell culture models lack the complex biological processes that occur in vivo; therefore, the pathogenesis of RSV in these flat models may not be representative of what happens in vivo [11,12].", [["cell culture", "ANATOMY", 3, 15], ["RSV", "DISEASE", 112, 115], ["RSV", "ORGANISM", 112, 115], ["RSV", "SPECIES", 112, 115], ["2D cell culture models", "TEST", 0, 22], ["the complex biological processes", "PROBLEM", 28, 60], ["RSV", "PROBLEM", 112, 115], ["RSV", "OBSERVATION", 112, 115]]], ["Studies have demonstrated that cells undergo different biologic responses when grown in 3D compared with 2D settings [13,14].", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["Studies", "TEST", 0, 7], ["2D settings", "TEST", 105, 116]]], ["They can differ in their morphology, with an altered cytoskeletal organization and cell adhesion.", [["cytoskeletal", "ANATOMY", 53, 65], ["cell", "ANATOMY", 83, 87], ["cytoskeletal", "CELLULAR_COMPONENT", 53, 65], ["cell", "CELL", 83, 87], ["an altered cytoskeletal organization", "PROBLEM", 42, 78], ["cell adhesion", "PROBLEM", 83, 96], ["altered", "OBSERVATION_MODIFIER", 45, 52], ["cytoskeletal organization", "OBSERVATION", 53, 78], ["cell adhesion", "OBSERVATION", 83, 96]]], ["Other changes include different proliferation rates, signaling processes and differentiation potential.", [["Other changes", "PROBLEM", 0, 13], ["different proliferation rates", "PROBLEM", 22, 51], ["signaling processes", "PROBLEM", 53, 72], ["different", "OBSERVATION_MODIFIER", 22, 31], ["proliferation rates", "OBSERVATION", 32, 51], ["signaling processes", "OBSERVATION", 53, 72]]], ["Many of these differences are believed to result from the fact that cells grown as monolayers on flat plastic surfaces are not subjected to the cell\u2013cell and cell\u2013matrix interactions, soluble factors, matrix composition and stiffness, oxygen and nutrient gradients, protein concentration gradients and mechanical stresses, as they would in their source tissues [10].IntroductionSince the early 2000s, an increasing number of evidence emerged about 3D cell cultures remarkably recapitulating the host cell response to microbial infections in vivo [[15], [16], [17]].", [["cells", "ANATOMY", 68, 73], ["monolayers", "ANATOMY", 83, 93], ["cell\u2013cell", "ANATOMY", 144, 153], ["cell\u2013matrix", "ANATOMY", 158, 169], ["matrix", "ANATOMY", 201, 207], ["tissues", "ANATOMY", 353, 360], ["cell cultures", "ANATOMY", 451, 464], ["cell", "ANATOMY", 500, 504], ["oxygen", "CHEMICAL", 235, 241], ["infections", "DISEASE", 527, 537], ["oxygen", "CHEMICAL", 235, 241], ["cells", "CELL", 68, 73], ["monolayers", "CELL", 83, 93], ["cell\u2013cell", "CELL", 144, 153], ["cell\u2013matrix", "SIMPLE_CHEMICAL", 158, 169], ["matrix", "CELLULAR_COMPONENT", 201, 207], ["oxygen", "SIMPLE_CHEMICAL", 235, 241], ["tissues", "TISSUE", 353, 360], ["3D cell cultures", "CELL", 448, 464], ["host cell", "CELL", 495, 504], ["[15], [16], [17]]", "SIMPLE_CHEMICAL", 547, 564], ["soluble factors", "PROTEIN", 184, 199], ["3D cell cultures", "CELL_LINE", 448, 464], ["flat plastic surfaces", "TREATMENT", 97, 118], ["stiffness", "PROBLEM", 224, 233], ["oxygen and nutrient gradients", "TREATMENT", 235, 264], ["protein concentration gradients", "TREATMENT", 266, 297], ["mechanical stresses", "PROBLEM", 302, 321], ["3D cell cultures", "TEST", 448, 464], ["microbial infections", "PROBLEM", 517, 537], ["mechanical stresses", "OBSERVATION", 302, 321], ["host cell", "OBSERVATION", 495, 504]]], ["3D cultures have been successful in studying various viruses and were the first definitive model for human norovirus and hepatitis C virus; however, to date, there are no reports to investigate RSV growth and pathogenesis in 3D cultures [[17], [18], [19]].", [["norovirus and hepatitis C virus", "DISEASE", 107, 138], ["human norovirus", "ORGANISM", 101, 116], ["hepatitis C virus", "ORGANISM", 121, 138], ["RSV", "ORGANISM", 194, 197], ["[17], [18], [19]]", "SIMPLE_CHEMICAL", 238, 255], ["3D cultures", "CELL_LINE", 0, 11], ["3D cultures", "CELL_LINE", 225, 236], ["human", "SPECIES", 101, 106], ["hepatitis C virus", "SPECIES", 121, 138], ["human norovirus", "SPECIES", 101, 116], ["hepatitis C virus", "SPECIES", 121, 138], ["RSV", "SPECIES", 194, 197], ["3D cultures", "TEST", 0, 11], ["various viruses", "PROBLEM", 45, 60], ["human norovirus", "PROBLEM", 101, 116], ["hepatitis C virus", "PROBLEM", 121, 138], ["RSV growth", "PROBLEM", 194, 204], ["3D cultures", "TEST", 225, 236]]], ["In this study, a scaffold-free 3D culture system was adopted using ultra-low attachment (ULA) plates to generate a practical and economic A549 spheroids model and test its permissiveness to RSV.Cell culture ::: Materials and methodsAfrican green monkey kidney cells (Vero cells, ATCC CCL-81), human Alveolar epithelial type II cells (A549; ATCC CCL-185) and human laryngeal carcinoma cells (Hep2 cells, ATCC CCL-23, a kind gift from Dr. Ralph Tripp, University of Georgia) were cultured in Dulbecco modified Eagle medium-high glucose (DMEM, D5796-Sigma) supplemented with 10% fetal bovine serum (F9665-Sigma) and 1% of 100 U/ml penicillin/streptomycin (pen/strep, MS006W100N Biowest) and maintained in 5% CO2 at 37 \u00b0C.A549 spheroid formation ::: Materials and methodsA549 cells cultured in monolayers were dissociated and suspended in complete medium containing 0.25% methylcellulose (M0512-Sigma) as a thickening agent [20].", [["A549 spheroids", "ANATOMY", 138, 152], ["Cell", "ANATOMY", 194, 198], ["kidney cells", "ANATOMY", 253, 265], ["Vero cells", "ANATOMY", 267, 277], ["ATCC CCL-81", "ANATOMY", 279, 290], ["Alveolar epithelial type II cells", "ANATOMY", 299, 332], ["A549", "ANATOMY", 334, 338], ["ATCC CCL-185", "ANATOMY", 340, 352], ["laryngeal carcinoma cells", "ANATOMY", 364, 389], ["Hep2 cells", "ANATOMY", 391, 401], ["ATCC CCL-23", "ANATOMY", 403, 414], ["fetal bovine serum", "ANATOMY", 576, 594], ["A549 spheroid", "ANATOMY", 718, 731], ["A549 cells", "ANATOMY", 767, 777], ["monolayers", "ANATOMY", 790, 800], ["RSV", "DISEASE", 190, 193], ["laryngeal carcinoma", "DISEASE", 364, 383], ["glucose", "CHEMICAL", 526, 533], ["penicillin", "CHEMICAL", 628, 638], ["streptomycin", "CHEMICAL", 639, 651], ["CO2", "CHEMICAL", 705, 708], ["methylcellulose", "CHEMICAL", 868, 883], ["M0512", "CHEMICAL", 885, 890], ["glucose", "CHEMICAL", 526, 533], ["penicillin", "CHEMICAL", 628, 638], ["streptomycin", "CHEMICAL", 639, 651], ["CO2", "CHEMICAL", 705, 708], ["methylcellulose", "CHEMICAL", 868, 883], ["A549 spheroids", "CELL", 138, 152], ["RSV", "ORGANISM", 190, 193], ["Cell", "CELL", 194, 198], ["monkey", "ORGANISM", 246, 252], ["kidney cells", "CELL", 253, 265], ["Vero cells", "CELL", 267, 277], ["ATCC CCL-81", "CELL", 279, 290], ["human", "ORGANISM", 293, 298], ["Alveolar epithelial type II cells", "CELL", 299, 332], ["A549", "CELL", 334, 338], ["ATCC CCL-185", "CELL", 340, 352], ["human", "ORGANISM", 358, 363], ["laryngeal carcinoma cells", "CELL", 364, 389], ["Hep2 cells", "CELL", 391, 401], ["ATCC CCL-23", "CELL", 403, 414], ["glucose", "SIMPLE_CHEMICAL", 526, 533], ["bovine", "ORGANISM", 582, 588], ["serum", "ORGANISM_SUBSTANCE", 589, 594], ["penicillin", "SIMPLE_CHEMICAL", 628, 638], ["streptomycin", "SIMPLE_CHEMICAL", 639, 651], ["CO2", "SIMPLE_CHEMICAL", 705, 708], ["A549 spheroid", "CELL", 718, 731], ["A549 cells", "CELL", 767, 777], ["monolayers", "CELL", 790, 800], ["methylcellulose", "SIMPLE_CHEMICAL", 868, 883], ["M0512-Sigma", "SIMPLE_CHEMICAL", 885, 896], ["3D culture system", "CELL_LINE", 31, 48], ["A549 spheroids model", "CELL_LINE", 138, 158], ["African green monkey kidney cells", "CELL_LINE", 232, 265], ["Vero cells", "CELL_LINE", 267, 277], ["ATCC CCL-81", "CELL_LINE", 279, 290], ["human Alveolar epithelial type II cells", "CELL_LINE", 293, 332], ["A549", "CELL_LINE", 334, 338], ["ATCC CCL-185", "CELL_LINE", 340, 352], ["human laryngeal carcinoma cells", "CELL_TYPE", 358, 389], ["Hep2 cells", "CELL_LINE", 391, 401], ["ATCC CCL-23", "CELL_LINE", 403, 414], ["A549 cells", "CELL_LINE", 767, 777], ["human", "SPECIES", 293, 298], ["human", "SPECIES", 358, 363], ["bovine", "SPECIES", 582, 588], ["RSV", "SPECIES", 190, 193], ["African green monkey", "SPECIES", 232, 252], ["ATCC CCL-81", "SPECIES", 279, 290], ["human", "SPECIES", 293, 298], ["ATCC CCL-185", "SPECIES", 340, 352], ["human", "SPECIES", 358, 363], ["ATCC CCL-23", "SPECIES", 403, 414], ["bovine", "SPECIES", 582, 588], ["this study", "TEST", 3, 13], ["free 3D culture system", "TEST", 26, 48], ["ultra-low attachment (ULA) plates", "TREATMENT", 67, 100], ["a practical and economic A549 spheroids model", "TREATMENT", 113, 158], ["RSV", "PROBLEM", 190, 193], ["Cell culture", "TEST", 194, 206], ["kidney cells", "TEST", 253, 265], ["Vero cells", "TEST", 267, 277], ["ATCC CCL", "TEST", 279, 287], ["human Alveolar epithelial type II cells", "PROBLEM", 293, 332], ["A549", "TEST", 334, 338], ["ATCC CCL", "TEST", 340, 348], ["human laryngeal carcinoma cells", "PROBLEM", 358, 389], ["Hep2 cells", "TEST", 391, 401], ["ATCC CCL", "TEST", 403, 411], ["fetal bovine serum", "TEST", 576, 594], ["penicillin", "TREATMENT", 628, 638], ["streptomycin", "TREATMENT", 639, 651], ["strep", "PROBLEM", 657, 662], ["methodsA549 cells", "TEST", 760, 777], ["monolayers", "TEST", 790, 800], ["a thickening agent", "TREATMENT", 901, 919], ["A549 spheroids", "OBSERVATION", 138, 152], ["kidney", "ANATOMY", 253, 259], ["Alveolar epithelial", "ANATOMY", 299, 318], ["laryngeal", "ANATOMY", 364, 373], ["carcinoma", "OBSERVATION", 374, 383], ["spheroid formation", "OBSERVATION", 723, 741], ["A549 cells", "OBSERVATION", 767, 777]]], ["Seeding densities of 10 \u00d7 103, 25 \u00d7 103 or 50 \u00d7 103 cells were prepared in 200 \u03bcl of the 0.25% methylcellulose nutritive medium and seeded in 96-well round-bottom ultra-low attachment (ULA) plates (7007 Corning).", [["cells", "ANATOMY", 52, 57], ["methylcellulose", "CHEMICAL", 95, 110], ["cells", "CELL", 52, 57], ["Seeding densities", "TEST", 0, 17], ["the 0.25% methylcellulose nutritive medium", "TREATMENT", 85, 127], ["bottom ultra-low attachment (ULA) plates", "TREATMENT", 156, 196], ["densities", "OBSERVATION", 8, 17], ["low attachment", "OBSERVATION_MODIFIER", 169, 183]]], ["Each well forms a single spheroid whose size varies depending on the initial cell seeding density.", [["spheroid", "ANATOMY", 25, 33], ["cell", "ANATOMY", 77, 81], ["cell", "CELL", 77, 81], ["a single spheroid whose size varies", "PROBLEM", 16, 51], ["the initial cell seeding density", "PROBLEM", 65, 97], ["single spheroid", "OBSERVATION_MODIFIER", 18, 33], ["size", "OBSERVATION_MODIFIER", 40, 44], ["initial cell", "OBSERVATION", 69, 81], ["seeding density", "OBSERVATION", 82, 97]]], ["The cells were then incubated for seven days with media change every other day for the duration of the experiment.Spheroid viability ::: Materials and methodsA549 Spheroids\u2019 growth and viability were assessed on days 3, 5, and 7 post-seeding.", [["cells", "ANATOMY", 4, 9], ["Spheroid", "ANATOMY", 114, 122], ["A549", "ANATOMY", 158, 162], ["cells", "CELL", 4, 9], ["A549 Spheroids", "CELL", 158, 172], ["media change", "TREATMENT", 50, 62], ["growth", "OBSERVATION_MODIFIER", 174, 180]]], ["The culture media was aspirated, and spheroids were washed with 1X PBS (D1408-500 ml Sigma).", [["spheroids", "ANATOMY", 37, 46], ["spheroids", "CELL", 37, 46], ["The culture media", "TEST", 0, 17], ["spheroids", "TREATMENT", 37, 46], ["1X PBS", "TREATMENT", 64, 70]]], ["The spheroids were dissociated into single-cell suspensions by treatment with 0.25% trypsin/ EDTA (T4049-500 ml Sigma) for 15 min, followed by gentle pipetting.", [["spheroids", "ANATOMY", 4, 13], ["cell", "ANATOMY", 43, 47], ["EDTA", "CHEMICAL", 93, 97], ["EDTA", "CHEMICAL", 93, 97], ["spheroids", "CELL", 4, 13], ["single-cell", "CELL", 36, 47], ["trypsin", "SIMPLE_CHEMICAL", 84, 91], ["EDTA", "SIMPLE_CHEMICAL", 93, 97], ["trypsin", "PROTEIN", 84, 91], ["The spheroids", "PROBLEM", 0, 13], ["single-cell suspensions", "TREATMENT", 36, 59], ["treatment", "TREATMENT", 63, 72], ["0.25% trypsin/ EDTA", "TREATMENT", 78, 97], ["gentle pipetting", "TREATMENT", 143, 159], ["spheroids", "OBSERVATION_MODIFIER", 4, 13], ["single-cell suspensions", "OBSERVATION", 36, 59]]], ["Then complete media was added, and the single-cell suspensions of the corresponding spheroids were centrifuged at 1100 RPM for 5 min.", [["cell", "ANATOMY", 46, 50], ["spheroids", "ANATOMY", 84, 93], ["spheroids", "CELL", 84, 93], ["complete media", "TREATMENT", 5, 19], ["the single-cell suspensions", "TREATMENT", 35, 62]]], ["The cell pellets were resuspended in 300 \u03bcl of 1:1 mixture of complete media and trypan blue (T8154-100 ml Sigma).", [["cell", "ANATOMY", 4, 8], ["trypan blue", "CHEMICAL", 81, 92], ["trypan blue", "CHEMICAL", 81, 92], ["cell", "CELL", 4, 8], ["trypan blue", "SIMPLE_CHEMICAL", 81, 92], ["The cell pellets", "TREATMENT", 0, 16], ["complete media", "TREATMENT", 62, 76], ["trypan blue", "TREATMENT", 81, 92], ["cell pellets", "OBSERVATION", 4, 16]]], ["Viable cell count was determined using a hemocytometer.", [["cell", "ANATOMY", 7, 11], ["Viable cell", "CELL", 0, 11], ["Viable cell count", "TEST", 0, 17], ["a hemocytometer", "TEST", 39, 54], ["cell count", "OBSERVATION", 7, 17]]], ["Alternatively, the cell pellets were resuspended in a 0.02 \u03bcM calcein-AM solution (C3099 Life Technologies) and incubated at room temperature for 20 min in the dark.", [["cell", "ANATOMY", 19, 23], ["calcein", "CHEMICAL", 62, 69], ["calcein-AM", "CHEMICAL", 62, 72], ["cell", "CELL", 19, 23], ["calcein-AM", "SIMPLE_CHEMICAL", 62, 72], ["the cell pellets", "TREATMENT", 15, 31], ["a 0.02 \u03bcM calcein-AM solution", "TREATMENT", 52, 81]]], ["Following incubation, the cells were pelleted, resuspended in 800 \u03bcl of PBS and passed through the Guava EasyCyte8 Flow Cytometer.", [["cells", "ANATOMY", 26, 31], ["cells", "CELL", 26, 31], ["the cells", "TREATMENT", 22, 31], ["PBS", "TREATMENT", 72, 75]]], ["A total of 5000 live events were excited at 488 nm per sample and measured for green fluorescence at 530 nm.", [["green fluorescence", "TEST", 79, 97]]], ["Gating analysis was performed using FlowJo (FlowJo LLC) cytometry analysis software and a representative density-plot graph was shown.Virus propagation and titration ::: Materials and methodsVero cells were used for virus propagation.", [["Vero cells", "ANATOMY", 191, 201], ["Virus", "ORGANISM", 134, 139], ["Vero cells", "CELL", 191, 201], ["Vero cells", "CELL_LINE", 191, 201], ["Gating analysis", "TEST", 0, 15], ["cytometry analysis software", "TEST", 56, 83], ["a representative density-plot graph", "PROBLEM", 88, 123], ["Materials", "TREATMENT", 170, 179], ["methodsVero cells", "TREATMENT", 184, 201], ["virus propagation", "TREATMENT", 216, 233], ["Vero cells", "OBSERVATION", 191, 201]]], ["These cells were inoculated with human RSV subgroup A (RSVA 2001/2\u201320, IRR) at 0.5 multiplicity of infection (MOI).", [["cells", "ANATOMY", 6, 11], ["infection", "DISEASE", 99, 108], ["cells", "CELL", 6, 11], ["human", "ORGANISM", 33, 38], ["RSV", "ORGANISM", 39, 42], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["RSV", "SPECIES", 39, 42], ["IRR", "TEST", 71, 74], ["infection", "PROBLEM", 99, 108], ["infection", "OBSERVATION", 99, 108]]], ["The virus was then harvested upon extensive syncytia formation (5\u20138 days) by a single freeze-thaw lysis cycle followed by centrifugation and collection of the supernatant.", [["syncytia", "ANATOMY", 44, 52], ["supernatant", "ANATOMY", 159, 170], ["syncytia", "CELL", 44, 52], ["The virus", "PROBLEM", 0, 9], ["extensive syncytia formation", "PROBLEM", 34, 62], ["a single freeze-thaw lysis cycle", "TREATMENT", 77, 109], ["centrifugation", "TREATMENT", 122, 136], ["virus", "OBSERVATION", 4, 9], ["extensive", "OBSERVATION_MODIFIER", 34, 43], ["syncytia formation", "OBSERVATION", 44, 62]]], ["The virus stock was quantified by using plaque assay.", [["plaque", "ANATOMY", 40, 46], ["The virus stock", "TREATMENT", 0, 15], ["plaque assay", "TEST", 40, 52], ["virus stock", "OBSERVATION", 4, 15], ["plaque", "OBSERVATION", 40, 46]]], ["In brief, Hep2 cells seeded on a 6-well plate were inoculated with 200 \u03bcl of 10-fold serial dilutions of the virus stock for 2 h with gentle shaking every 15 min.", [["Hep2 cells", "ANATOMY", 10, 20], ["Hep2 cells", "CELL", 10, 20], ["Hep2 cells", "CELL_LINE", 10, 20], ["Hep2 cells", "PROBLEM", 10, 20], ["a 6-well plate", "TREATMENT", 31, 45], ["the virus stock", "TREATMENT", 105, 120], ["Hep2 cells", "OBSERVATION", 10, 20]]], ["Afterward, the cells were covered with 2 ml of newly prepared 0.15% agarose nutritive overlay and incubated for 7 days.", [["cells", "ANATOMY", 15, 20], ["cells", "CELL", 15, 20], ["agarose", "SIMPLE_CHEMICAL", 68, 75], ["newly prepared 0.15% agarose nutritive overlay", "TREATMENT", 47, 93]]], ["Plaques were visualized by staining the cells with a crystal violet solution containing 5% formaldehyde.Infectivity and growth kinetics of RSV in 3D spheroids ::: Materials and methodsThree-day-old A549 spheroids were inoculated using RSV at a MOI = 1 (in a volume of 20 \u03bcl) and incubated for 2 h to allow virus adsorption.", [["Plaques", "ANATOMY", 0, 7], ["cells", "ANATOMY", 40, 45], ["spheroids", "ANATOMY", 149, 158], ["A549 spheroids", "ANATOMY", 198, 212], ["formaldehyde", "CHEMICAL", 91, 103], ["formaldehyde", "CHEMICAL", 91, 103], ["cells", "CELL", 40, 45], ["formaldehyde", "SIMPLE_CHEMICAL", 91, 103], ["RSV", "ORGANISM", 139, 142], ["3D spheroids", "CELL", 146, 158], ["A549 spheroids", "CELL", 198, 212], ["RSV", "ORGANISM", 235, 238], ["A549 spheroids", "CELL_LINE", 198, 212], ["RSV", "SPECIES", 139, 142], ["RSV", "SPECIES", 235, 238], ["Plaques", "PROBLEM", 0, 7], ["a crystal violet solution", "TREATMENT", 51, 76], ["RSV", "PROBLEM", 139, 142], ["old A549 spheroids", "PROBLEM", 194, 212], ["RSV", "PROBLEM", 235, 238], ["virus adsorption", "TREATMENT", 306, 322], ["growth", "OBSERVATION_MODIFIER", 120, 126], ["kinetics", "OBSERVATION_MODIFIER", 127, 135], ["RSV", "OBSERVATION", 139, 142]]], ["The inoculum was then removed and the spheroids were washed with DMEM and incubated for 7 days in 200 \u03bcl of DMEM containing 5% FBS and 1% pen/strep.", [["spheroids", "ANATOMY", 38, 47], ["FBS", "ANATOMY", 127, 130], ["spheroids", "CELL", 38, 47], ["FBS", "ORGANISM_SUBSTANCE", 127, 130], ["The inoculum", "TREATMENT", 0, 12], ["the spheroids", "TREATMENT", 34, 47], ["DMEM", "TREATMENT", 65, 69], ["DMEM", "TREATMENT", 108, 112], ["5% FBS", "TREATMENT", 124, 130], ["strep", "PROBLEM", 142, 147], ["inoculum", "OBSERVATION", 4, 12], ["spheroids", "OBSERVATION_MODIFIER", 38, 47], ["strep", "OBSERVATION", 142, 147]]], ["Plaque assay was used to assess the spheroids\u2019 infectious virus yield at days 1, 3, 5 and 7 post-inoculation.", [["Plaque", "ANATOMY", 0, 6], ["spheroids", "ANATOMY", 36, 45], ["spheroids", "CELL", 36, 45], ["Plaque assay", "TEST", 0, 12], ["the spheroids", "PROBLEM", 32, 45], ["infectious virus", "PROBLEM", 47, 63], ["infectious", "OBSERVATION", 47, 57]]], ["At each time point, five spheroids were pooled with their supernatant, broken down into cell suspensions by vigorous pipetting and cells lysed by flash freezing to ensure the release of virions from the cells.", [["spheroids", "ANATOMY", 25, 34], ["supernatant", "ANATOMY", 58, 69], ["cell suspensions", "ANATOMY", 88, 104], ["cells", "ANATOMY", 131, 136], ["virions", "ANATOMY", 186, 193], ["cells", "ANATOMY", 203, 208], ["spheroids", "CELL", 25, 34], ["cell", "CELL", 88, 92], ["cells", "CELL", 131, 136], ["cells", "CELL", 203, 208], ["five spheroids", "PROBLEM", 20, 34], ["their supernatant", "TREATMENT", 52, 69], ["cell suspensions", "TREATMENT", 88, 104], ["vigorous pipetting and cells", "TREATMENT", 108, 136], ["flash freezing", "TREATMENT", 146, 160], ["cell suspensions", "OBSERVATION", 88, 104], ["vigorous pipetting", "OBSERVATION", 108, 126]]], ["The resulting cell lysate was then centrifuged and the plaque assay was performed on the supernatant as shown above to determine the viral yield in terms of plaque forming units (pfu) per milliliter (ml).Immunofluorescent staining of spheroids ::: Materials and methodsAfter 3 and 7 days post-inoculation, spheroids were fixed with 4% paraformaldehyde (416785000 ACROS) for 15 min and permeabilized with 0.2% Triton X-100 (T9284-100 ml Sigma) in PBS for 20 min.", [["cell lysate", "ANATOMY", 14, 25], ["plaque", "ANATOMY", 55, 61], ["supernatant", "ANATOMY", 89, 100], ["plaque", "ANATOMY", 157, 163], ["spheroids", "ANATOMY", 234, 243], ["spheroids", "ANATOMY", 306, 315], ["416785000 ACROS", "CHEMICAL", 353, 368], ["Triton X-100", "CHEMICAL", 409, 421], ["paraformaldehyde", "CHEMICAL", 335, 351], ["cell lysate", "CELL", 14, 25], ["spheroids", "CELL", 234, 243], ["spheroids", "CELL", 306, 315], ["paraformaldehyde", "SIMPLE_CHEMICAL", 335, 351], ["Triton X-100", "SIMPLE_CHEMICAL", 409, 421], ["plaque forming units", "PROTEIN", 157, 177], ["The resulting cell lysate", "TEST", 0, 25], ["the plaque assay", "TEST", 51, 67], ["Immunofluorescent staining", "TEST", 204, 230], ["spheroids", "PROBLEM", 306, 315], ["4% paraformaldehyde", "TREATMENT", 332, 351], ["cell lysate", "OBSERVATION", 14, 25], ["plaque", "OBSERVATION", 55, 61], ["plaque", "OBSERVATION", 157, 163], ["spheroids", "OBSERVATION_MODIFIER", 234, 243]]], ["Spheroids were blocked with blocking solution [1% BSA (A3912-100 g Sigma) and 0.1% Triton X-100 in PBS] for 1 h followed by overnight incubation with a mixture of mouse anti-RSV fusion protein antibody (MAB8599-Merck Millipore) at 1:200 and rabbit anti-human MUC1 antibody (12123-T24 Sino Biological) at 1:2500 in blocking buffer.", [["Triton X-100", "CHEMICAL", 83, 95], ["BSA", "SIMPLE_CHEMICAL", 50, 53], ["Triton X-100", "SIMPLE_CHEMICAL", 83, 95], ["mouse", "ORGANISM", 163, 168], ["anti-RSV", "GENE_OR_GENE_PRODUCT", 169, 177], ["rabbit", "ORGANISM", 241, 247], ["MUC1", "GENE_OR_GENE_PRODUCT", 259, 263], ["mouse anti-RSV fusion protein antibody", "PROTEIN", 163, 201], ["MAB8599", "PROTEIN", 203, 210], ["Merck Millipore", "PROTEIN", 211, 226], ["rabbit anti-human MUC1 antibody", "PROTEIN", 241, 272], ["mouse", "SPECIES", 163, 168], ["rabbit", "SPECIES", 241, 247], ["mouse", "SPECIES", 163, 168], ["rabbit", "SPECIES", 241, 247], ["Spheroids", "TREATMENT", 0, 9], ["blocking solution", "TREATMENT", 28, 45], ["mouse anti-RSV fusion protein antibody", "TEST", 163, 201], ["Merck Millipore", "TEST", 211, 226], ["rabbit anti-human MUC1 antibody", "TEST", 241, 272]]], ["The samples were then thoroughly washed with PBS/Tween (0.1%) (BP337-500-Fisher BioReagents) and incubated for 1 h with the corresponding fluorescent secondary antibodies (1:250) [Alexa fluor 488-goat anti-mouse IgG antibody (A11002-Life Technologies) and Alexa fluor 594-donkey anti-rabbit IgG antibody (A21207-Life Technologies)].", [["samples", "ANATOMY", 4, 11], ["Tween", "CHEMICAL", 49, 54], ["Alexa fluor 488", "CHEMICAL", 180, 195], ["Alexa fluor 488", "SIMPLE_CHEMICAL", 180, 195], ["Alexa fluor 594", "SIMPLE_CHEMICAL", 256, 271], ["fluorescent secondary antibodies", "PROTEIN", 138, 170], ["1:250", "PROTEIN", 172, 177], ["Alexa fluor 488-goat anti-mouse IgG antibody", "PROTEIN", 180, 224], ["A11002", "PROTEIN", 226, 232], ["Alexa fluor 594-donkey anti-rabbit IgG antibody", "PROTEIN", 256, 303], ["goat", "SPECIES", 196, 200], ["anti-mouse", "SPECIES", 201, 211], ["donkey", "SPECIES", 272, 278], ["anti-rabbit", "SPECIES", 279, 290], ["goat", "SPECIES", 196, 200], ["Alexa fluor 594-donkey", "SPECIES", 256, 278], ["The samples", "TEST", 0, 11], ["PBS/Tween", "TREATMENT", 45, 54], ["BP337", "TEST", 63, 68], ["the corresponding fluorescent secondary antibodies", "TEST", 120, 170], ["Alexa fluor", "TEST", 180, 191], ["goat anti-mouse IgG antibody", "TEST", 196, 224], ["A11002", "TEST", 226, 232], ["Alexa fluor", "TEST", 256, 267], ["donkey anti-rabbit IgG antibody", "TEST", 272, 303]]], ["Finally, the immunostained spheroids were mounted with the Fluoroshield with DAPI histology mounting medium (F6057-Sigma), before being visualized by the LSM710 laser scanning confocal microscope (Zeiss).", [["spheroids", "ANATOMY", 27, 36], ["DAPI", "CHEMICAL", 77, 81], ["spheroids", "CELL", 27, 36], ["Fluoroshield", "SIMPLE_CHEMICAL", 59, 71], ["DAPI", "SIMPLE_CHEMICAL", 77, 81], ["the immunostained spheroids", "PROBLEM", 9, 36]]], ["The fluorescence intensities of MUC1 and RSV-F captured on the images were quantified by employing ZEN blue edition (Zeiss) and presented as fold change values in infected spheroids as compared to their time matching controls.Statistical analysis ::: Materials and methodsAll experiments were done at least two times in triplicates (unless otherwise indicated) and the data were presented as mean \u00b1 SD.", [["spheroids", "ANATOMY", 172, 181], ["ZEN blue", "CHEMICAL", 99, 107], ["MUC1", "GENE_OR_GENE_PRODUCT", 32, 36], ["RSV-F", "GENE_OR_GENE_PRODUCT", 41, 46], ["spheroids", "CELL", 172, 181], ["MUC1", "PROTEIN", 32, 36], ["RSV", "SPECIES", 41, 44], ["The fluorescence intensities", "TEST", 0, 28], ["MUC1", "TEST", 32, 36], ["the images", "TEST", 59, 69], ["fold change values", "PROBLEM", 141, 159], ["infected spheroids", "PROBLEM", 163, 181], ["infected spheroids", "OBSERVATION", 163, 181]]], ["The statistical significance of differences between groups was performed by Student\u2019s t-test using SPSS statistical software version 24 (SPSS, Inc., Chicago, IL, USA).", [["SPSS statistical software version", "TEST", 99, 132], ["SPSS", "TEST", 137, 141]]], ["A P-value <0.05 was considered to indicate a statistically significant difference.Generation of A549 spheroids using ultra-low attachment (ULA) plates ::: ResultsThree starting cell-seeding densities were used; namely, 10 \u00d7 103, 25 \u00d7 103, and 50 \u00d7 103 cells/well in 96 well, ultra-low attachment (ULA) plates (Fig. 1A), and the resulting spheroids were followed up until day 7 in culture.", [["A549 spheroids", "ANATOMY", 96, 110], ["cell", "ANATOMY", 177, 181], ["cells", "ANATOMY", 252, 257], ["spheroids", "ANATOMY", 338, 347], ["A549 spheroids", "CELL", 96, 110], ["cell", "CELL", 177, 181], ["cells", "CELL", 252, 257], ["spheroids", "CELL", 338, 347], ["A549 spheroids", "CELL_LINE", 96, 110], ["A P-value", "TEST", 0, 9], ["a statistically significant difference", "PROBLEM", 43, 81], ["A549 spheroids", "TREATMENT", 96, 110], ["cells", "TEST", 252, 257], ["ultra", "TEST", 275, 280], ["the resulting spheroids", "PROBLEM", 324, 347], ["culture", "TEST", 380, 387], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["difference", "OBSERVATION", 71, 81], ["A549 spheroids", "OBSERVATION", 96, 110], ["seeding densities", "OBSERVATION", 182, 199], ["spheroids", "OBSERVATION_MODIFIER", 338, 347]]], ["Well-formed spheroids were visible for the 25 \u00d7 103 and 50 \u00d7 103 cell seeding densities at day 3 post-seeding, becoming more compact on day 7 (Fig. 1B).", [["spheroids", "ANATOMY", 12, 21], ["cell", "ANATOMY", 65, 69], ["spheroids", "CELL", 12, 21], ["cell", "CELL", 65, 69], ["50 \u00d7 103 cell seeding densities", "PROBLEM", 56, 87], ["-formed", "OBSERVATION_MODIFIER", 4, 11], ["spheroids", "OBSERVATION_MODIFIER", 12, 21], ["103 cell", "OBSERVATION_MODIFIER", 61, 69], ["seeding densities", "OBSERVATION", 70, 87], ["more compact", "OBSERVATION_MODIFIER", 120, 132]]], ["However, the 10 \u00d7 103 cell seeding density failed to produce well-formed spheroids even after 7 days of incubation and therefore were abandoned.Generation of A549 spheroids using ultra-low attachment (ULA) plates ::: ResultsThe cell count and viability of spheroids were assessed using trypan blue exclusion assay (Fig. 1C).", [["cell", "ANATOMY", 22, 26], ["spheroids", "ANATOMY", 73, 82], ["A549 spheroids", "ANATOMY", 158, 172], ["cell", "ANATOMY", 228, 232], ["spheroids", "ANATOMY", 256, 265], ["trypan blue", "CHEMICAL", 286, 297], ["trypan blue", "CHEMICAL", 286, 297], ["cell", "CELL", 22, 26], ["spheroids", "CELL", 73, 82], ["A549 spheroids", "CELL", 158, 172], ["cell", "CELL", 228, 232], ["spheroids", "CELL", 256, 265], ["A549 spheroids", "CELL_LINE", 158, 172], ["the 10 \u00d7 103 cell seeding density", "PROBLEM", 9, 42], ["well-formed spheroids", "PROBLEM", 61, 82], ["incubation", "TREATMENT", 104, 114], ["A549 spheroids", "TREATMENT", 158, 172], ["The cell count", "TEST", 224, 238], ["trypan blue", "TEST", 286, 297], ["density", "OBSERVATION", 35, 42], ["well-formed", "OBSERVATION_MODIFIER", 61, 72], ["spheroids", "OBSERVATION", 73, 82], ["A549 spheroids", "OBSERVATION", 158, 172], ["cell count", "OBSERVATION", 228, 238], ["viability", "OBSERVATION_MODIFIER", 243, 252]]], ["Three days post-seeding, the 25 \u00d7 103 spheroids grew to reach \u223c33 \u00d7 103 viable cells (86% viability).", [["spheroids", "ANATOMY", 38, 47], ["cells", "ANATOMY", 79, 84], ["spheroids", "CELL", 38, 47], ["cells", "CELL", 79, 84], ["\u223c33 \u00d7 103 viable cells", "CELL_LINE", 62, 84], ["spheroids", "TEST", 38, 47], ["viable cells", "TEST", 72, 84]]], ["The 50 \u00d7 103 cell spheroids contained 37 \u00d7 103 viable cells (78% viability).", [["cell spheroids", "ANATOMY", 13, 27], ["cells", "ANATOMY", 54, 59], ["cell spheroids", "CELL", 13, 27], ["cells", "CELL", 54, 59], ["50 \u00d7 103 cell spheroids", "CELL_LINE", 4, 27], ["cell spheroids", "TEST", 13, 27], ["viable cells", "TEST", 47, 59]]], ["Throughout the 7 days, the 25 \u00d7 103 cell spheroids maintained a constant viable cell count of \u223c33 \u00d7 103 cells, although their viability gradually yet significantly decreased, reaching 65% by day 7 (Fig. 1C).", [["cell spheroids", "ANATOMY", 36, 50], ["cell", "ANATOMY", 80, 84], ["cells", "ANATOMY", 104, 109], ["cell spheroids", "CELL", 36, 50], ["cell", "CELL", 80, 84], ["cells", "CELL", 104, 109], ["25 \u00d7 103 cell spheroids", "CELL_LINE", 27, 50], ["the 25 \u00d7 103 cell spheroids", "TREATMENT", 23, 50], ["a constant viable cell count", "TEST", 62, 90], ["their viability", "TEST", 120, 135], ["viability", "OBSERVATION_MODIFIER", 126, 135], ["gradually", "OBSERVATION_MODIFIER", 136, 145], ["significantly", "OBSERVATION_MODIFIER", 150, 163], ["decreased", "OBSERVATION_MODIFIER", 164, 173]]], ["As for the 50 \u00d7 103 cell spheroids, a gradual and significant decline in viability was recorded throughout the 7 days.", [["cell spheroids", "ANATOMY", 20, 34], ["cell spheroids", "CELL", 20, 34], ["50 \u00d7 103 cell spheroids", "CELL_LINE", 11, 34], ["the 50 \u00d7 103 cell spheroids", "PROBLEM", 7, 34], ["significant decline in viability", "PROBLEM", 50, 82], ["cell spheroids", "OBSERVATION", 20, 34], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["decline", "OBSERVATION_MODIFIER", 62, 69], ["viability", "OBSERVATION_MODIFIER", 73, 82]]], ["The viable cell count significantly dropped to 18 \u00d7 103 cells only by day 7 with 56% viability.", [["cell", "ANATOMY", 11, 15], ["cells", "ANATOMY", 56, 61], ["cell", "CELL", 11, 15], ["cells", "CELL", 56, 61], ["The viable cell count", "TEST", 0, 21], ["cell count", "OBSERVATION", 11, 21]]], ["Comparative viability analysis of the 25 \u00d7 103 and 50 \u00d7 103 cell spheroids showed significantly lower viability of the bigger spheroids than the smaller ones.", [["cell spheroids", "ANATOMY", 60, 74], ["spheroids", "ANATOMY", 126, 135], ["cell spheroids", "CELL", 60, 74], ["spheroids", "CELL", 126, 135], ["50 \u00d7 103 cell spheroids", "CELL_LINE", 51, 74], ["Comparative viability analysis", "TEST", 0, 30], ["50 \u00d7 103 cell spheroids", "TEST", 51, 74], ["significantly lower viability of the bigger spheroids", "PROBLEM", 82, 135], ["significantly", "OBSERVATION_MODIFIER", 82, 95], ["lower", "OBSERVATION_MODIFIER", 96, 101], ["viability", "OBSERVATION_MODIFIER", 102, 111], ["bigger spheroids", "OBSERVATION", 119, 135], ["smaller", "OBSERVATION_MODIFIER", 145, 152]]], ["Therefore, the 25 \u00d7 103A549 spheroids were adopted for the rest of the study.Generation of A549 spheroids using ultra-low attachment (ULA) plates ::: ResultsThe viability profile of 25 \u00d7 103 cell spheroids was further validated using flow cytometry.", [["103A549 spheroids", "ANATOMY", 20, 37], ["A549 spheroids", "ANATOMY", 91, 105], ["cell spheroids", "ANATOMY", 191, 205], ["103A549 spheroids", "CELL", 20, 37], ["A549 spheroids", "CELL", 91, 105], ["\u00d7 103 cell spheroids", "CELL", 185, 205], ["25 \u00d7 103A549 spheroids", "CELL_LINE", 15, 37], ["A549 spheroids", "CELL_LINE", 91, 105], ["25 \u00d7 103 cell spheroids", "CELL_LINE", 182, 205], ["the study", "TEST", 67, 76], ["A549 spheroids", "TREATMENT", 91, 105], ["The viability profile", "TEST", 157, 178], ["cell spheroids", "TEST", 191, 205], ["flow cytometry", "TEST", 234, 248], ["A549 spheroids", "OBSERVATION", 91, 105], ["viability", "OBSERVATION_MODIFIER", 161, 170]]], ["Similar to the data obtained by using trypan blue, we observed a steady time-dependent decline in the viability of the spheroids between days 3 to 7, where the healthy population dropped from 94.4% to 77.5%, respectively (Fig. 2).RSV infection of A549 spheroids ::: ResultsWe next sought to determine if the A549 spheroids are susceptible and permissive for RSV infection.", [["spheroids", "ANATOMY", 119, 128], ["A549 spheroids", "ANATOMY", 247, 261], ["A549 spheroids", "ANATOMY", 308, 322], ["trypan blue", "CHEMICAL", 38, 49], ["RSV infection", "DISEASE", 230, 243], ["RSV infection", "DISEASE", 358, 371], ["trypan blue", "CHEMICAL", 38, 49], ["trypan blue", "SIMPLE_CHEMICAL", 38, 49], ["spheroids", "CELL", 119, 128], ["RSV", "ORGANISM", 230, 233], ["A549 spheroids", "CELL", 247, 261], ["A549 spheroids", "CELL", 308, 322], ["RSV", "ORGANISM", 358, 361], ["A549 spheroids", "CELL_LINE", 247, 261], ["A549 spheroids", "CELL_LINE", 308, 322], ["RSV", "SPECIES", 230, 233], ["RSV", "SPECIES", 358, 361], ["trypan blue", "TEST", 38, 49], ["a steady time-dependent decline", "PROBLEM", 63, 94], ["the healthy population", "TEST", 156, 178], ["RSV infection of A549 spheroids", "PROBLEM", 230, 261], ["the A549 spheroids", "PROBLEM", 304, 322], ["RSV infection", "PROBLEM", 358, 371], ["dependent", "OBSERVATION_MODIFIER", 77, 86], ["decline", "OBSERVATION_MODIFIER", 87, 94], ["viability", "OBSERVATION_MODIFIER", 102, 111], ["spheroids", "OBSERVATION_MODIFIER", 119, 128], ["infection", "OBSERVATION", 234, 243], ["A549 spheroids", "OBSERVATION", 247, 261], ["permissive for", "UNCERTAINTY", 343, 357], ["RSV", "OBSERVATION_MODIFIER", 358, 361], ["infection", "OBSERVATION", 362, 371]]], ["As such, 3-day-old spheroids were inoculated with RSV (1 MOI) and immunostained at days 3 and 7 post-inoculation (Fig. 3).", [["spheroids", "ANATOMY", 19, 28], ["spheroids", "CELL", 19, 28], ["RSV", "ORGANISM", 50, 53], ["RSV", "SPECIES", 50, 53], ["old spheroids", "PROBLEM", 15, 28], ["RSV", "PROBLEM", 50, 53]]], ["A prominent RSV-F protein staining was noted at day 3 post-inoculation (Fig. 3A) that disseminated towards the core of the spheroid by day 7 post-inoculation (Fig. 3B).", [["spheroid", "ANATOMY", 123, 131], ["RSV-F", "GENE_OR_GENE_PRODUCT", 12, 17], ["spheroid", "CELL", 123, 131], ["RSV-F protein", "PROTEIN", 12, 25], ["RSV", "SPECIES", 12, 15], ["A prominent RSV-F protein staining", "PROBLEM", 0, 34], ["prominent", "OBSERVATION_MODIFIER", 2, 11], ["RSV", "OBSERVATION", 12, 15], ["F protein staining", "OBSERVATION", 16, 34], ["spheroid", "OBSERVATION_MODIFIER", 123, 131]]], ["Mild syncytia formation induced by RSV infection was also noted at the spheroid rim at 3 days post-inoculation (Fig. 3A insets).", [["syncytia", "ANATOMY", 5, 13], ["spheroid rim", "ANATOMY", 71, 83], ["syncytia", "DISEASE", 5, 13], ["RSV infection", "DISEASE", 35, 48], ["RSV", "ORGANISM", 35, 38], ["RSV", "SPECIES", 35, 38], ["Mild syncytia formation", "PROBLEM", 0, 23], ["RSV infection", "PROBLEM", 35, 48], ["syncytia", "OBSERVATION", 5, 13], ["RSV infection", "OBSERVATION", 35, 48], ["spheroid", "OBSERVATION_MODIFIER", 71, 79], ["rim", "OBSERVATION_MODIFIER", 80, 83]]], ["The intensity of RSV-F protein staining increased by 2-fold on day 7 compared to day 3 post-inoculation (Fig. 3C).", [["RSV-F", "GENE_OR_GENE_PRODUCT", 17, 22], ["RSV", "SPECIES", 17, 20], ["RSV-F protein staining", "TEST", 17, 39], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["RSV", "OBSERVATION", 17, 20], ["increased", "OBSERVATION_MODIFIER", 40, 49]]], ["These findings indicate that the virus has effectively infected the spheroids spreading towards its center throughout infection.", [["spheroids", "ANATOMY", 68, 77], ["infection", "DISEASE", 118, 127], ["spheroids", "CELL", 68, 77], ["the virus", "PROBLEM", 29, 38], ["the spheroids", "PROBLEM", 64, 77], ["infection", "PROBLEM", 118, 127], ["virus", "OBSERVATION", 33, 38], ["effectively", "OBSERVATION_MODIFIER", 43, 54], ["infected", "OBSERVATION", 55, 63], ["spheroids", "OBSERVATION_MODIFIER", 68, 77], ["spreading", "OBSERVATION_MODIFIER", 78, 87], ["infection", "OBSERVATION", 118, 127]]], ["Additionally, a 2.6-fold increase in MUC1 expression was noted in the spheroids on day 3 post-infection compared to mock (uninfected).", [["spheroids", "ANATOMY", 70, 79], ["infection", "DISEASE", 94, 103], ["MUC1", "GENE_OR_GENE_PRODUCT", 37, 41], ["spheroids", "CELL", 70, 79], ["MUC1", "PROTEIN", 37, 41], ["a 2.6-fold increase in MUC1 expression", "PROBLEM", 14, 52], ["the spheroids", "PROBLEM", 66, 79], ["infection", "PROBLEM", 94, 103], ["2.6-fold", "OBSERVATION_MODIFIER", 16, 24], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["MUC1 expression", "OBSERVATION", 37, 52], ["spheroids", "OBSERVATION_MODIFIER", 70, 79], ["infection", "OBSERVATION", 94, 103]]], ["MUC1 production further increased, reaching 3.25-fold at day 7 post-inoculation relative to mock (Fig. 3D).", [["MUC1", "GENE_OR_GENE_PRODUCT", 0, 4], ["MUC1", "PROTEIN", 0, 4], ["MUC1 production", "PROBLEM", 0, 15], ["increased", "OBSERVATION_MODIFIER", 24, 33]]], ["These results are indicative of a progressive infection established in the form of virus dissemination within the spheroids and gradual mucin accumulation, a hallmark of RSV infection.RSV infection of A549 spheroids ::: ResultsAfter establishing and demonstrating successful infection of spheroids with RSV, plaque assay was performed to investigate growth kinetics of RSV in spheroids after 1, 3, 5, and 7 days of infection (Fig. 4).", [["spheroids", "ANATOMY", 114, 123], ["A549 spheroids", "ANATOMY", 201, 215], ["spheroids", "ANATOMY", 288, 297], ["plaque", "ANATOMY", 308, 314], ["spheroids", "ANATOMY", 376, 385], ["infection", "DISEASE", 46, 55], ["RSV infection", "DISEASE", 170, 183], ["RSV infection", "DISEASE", 184, 197], ["infection", "DISEASE", 275, 284], ["infection", "DISEASE", 415, 424], ["spheroids", "CELL", 114, 123], ["mucin", "GENE_OR_GENE_PRODUCT", 136, 141], ["RSV", "ORGANISM", 170, 173], ["RSV", "ORGANISM", 184, 187], ["A549 spheroids", "CELL", 201, 215], ["spheroids", "CELL", 288, 297], ["RSV", "ORGANISM", 303, 306], ["RSV", "ORGANISM", 369, 372], ["spheroids", "CELL", 376, 385], ["A549 spheroids", "CELL_LINE", 201, 215], ["RSV", "SPECIES", 170, 173], ["RSV", "SPECIES", 184, 187], ["RSV", "SPECIES", 303, 306], ["RSV", "SPECIES", 369, 372], ["a progressive infection", "PROBLEM", 32, 55], ["virus dissemination", "PROBLEM", 83, 102], ["the spheroids", "PROBLEM", 110, 123], ["gradual mucin accumulation", "PROBLEM", 128, 154], ["RSV infection", "PROBLEM", 170, 183], ["RSV infection of A549 spheroids", "PROBLEM", 184, 215], ["successful infection of spheroids", "PROBLEM", 264, 297], ["RSV", "PROBLEM", 303, 306], ["plaque assay", "TEST", 308, 320], ["growth kinetics", "PROBLEM", 350, 365], ["RSV in spheroids", "PROBLEM", 369, 385], ["infection", "PROBLEM", 415, 424], ["indicative of", "UNCERTAINTY", 18, 31], ["progressive", "OBSERVATION_MODIFIER", 34, 45], ["infection", "OBSERVATION", 46, 55], ["virus", "OBSERVATION_MODIFIER", 83, 88], ["dissemination", "OBSERVATION", 89, 102], ["spheroids", "OBSERVATION_MODIFIER", 114, 123], ["gradual", "OBSERVATION_MODIFIER", 128, 135], ["mucin accumulation", "OBSERVATION", 136, 154], ["hallmark", "OBSERVATION_MODIFIER", 158, 166], ["RSV", "OBSERVATION_MODIFIER", 170, 173], ["infection", "OBSERVATION", 174, 183], ["infection", "OBSERVATION", 188, 197], ["A549 spheroids", "OBSERVATION", 201, 215], ["successful", "OBSERVATION_MODIFIER", 264, 274], ["infection", "OBSERVATION", 275, 284], ["spheroids", "OBSERVATION_MODIFIER", 288, 297], ["RSV", "OBSERVATION", 303, 306], ["plaque", "OBSERVATION", 308, 314], ["RSV", "OBSERVATION", 369, 372], ["infection", "OBSERVATION", 415, 424]]], ["The data revealed productive viral replication in the spheroids, yielding 5.25 log10 PFU/ml unit at day 1 post-inoculation.", [["spheroids", "ANATOMY", 54, 63], ["spheroids", "CELL", 54, 63], ["The data", "TEST", 0, 8], ["productive viral replication in the spheroids", "PROBLEM", 18, 63], ["productive", "OBSERVATION_MODIFIER", 18, 28], ["viral replication", "OBSERVATION", 29, 46], ["spheroids", "OBSERVATION_MODIFIER", 54, 63]]], ["The virus yield slightly dropped from 4.93 log10 at day 3 and reaching 4 log10 PFU/ml on days 5 and 7 post-inoculation, suggesting that spheroids are capable of sustaining infection for up to 7 days post-inoculation.DiscussionAnimal models have been routinely used to study RSV-induced respiratory diseases; even though useful, they do not fully mimic viral pathogenesis in vivo [[21], [22], [23], [24], [25], [26]].", [["spheroids", "ANATOMY", 136, 145], ["respiratory", "ANATOMY", 286, 297], ["infection", "DISEASE", 172, 181], ["respiratory diseases", "DISEASE", 286, 306], ["spheroids", "CELL", 136, 145], ["RSV", "ORGANISM", 274, 277], ["[21], [22], [23], [24], [25], [26]]", "SIMPLE_CHEMICAL", 380, 415], ["RSV", "SPECIES", 274, 277], ["The virus yield", "TEST", 0, 15], ["spheroids", "PROBLEM", 136, 145], ["sustaining infection", "PROBLEM", 161, 181], ["RSV", "PROBLEM", 274, 277], ["respiratory diseases", "PROBLEM", 286, 306], ["virus", "OBSERVATION", 4, 9], ["slightly", "OBSERVATION_MODIFIER", 16, 24], ["spheroids", "OBSERVATION", 136, 145], ["infection", "OBSERVATION", 172, 181], ["respiratory", "ANATOMY", 286, 297], ["diseases", "OBSERVATION", 298, 306]]], ["This can be attributable to the molecular, cellular, and physiological differences between animals and humans.", [["cellular", "ANATOMY", 43, 51], ["cellular", "CELL", 43, 51], ["humans", "ORGANISM", 103, 109], ["humans", "SPECIES", 103, 109], ["humans", "SPECIES", 103, 109], ["molecular", "OBSERVATION_MODIFIER", 32, 41], ["cellular", "OBSERVATION_MODIFIER", 43, 51]]], ["3D culture techniques have been used for many years in a wide variety of biomedical applications ranging from cancer and stem cell biology to tissue engineering and regenerative medicine [17,[27], [28], [29], [30], [31], [32]].", [["cancer", "ANATOMY", 110, 116], ["stem cell", "ANATOMY", 121, 130], ["tissue", "ANATOMY", 142, 148], ["cancer", "DISEASE", 110, 116], ["cancer", "CANCER", 110, 116], ["stem cell", "CELL", 121, 130], ["tissue", "TISSUE", 142, 148], ["[27], [28], [29], [30]", "SIMPLE_CHEMICAL", 191, 213], ["[31]", "SIMPLE_CHEMICAL", 215, 219], ["3D culture techniques", "TEST", 0, 21], ["biomedical applications", "TREATMENT", 73, 96], ["cancer", "PROBLEM", 110, 116], ["stem cell", "OBSERVATION", 121, 130]]], ["3D cultures promote direct cell-cell contact, interactions of cells with the extracellular matrix (ECM), and in vivo-like exchange of soluble factors, thus allowing cells to more closely resemble the in vivo parental tissue as opposed to their 2D monolayer counterparts [[13], [14], [15]].", [["3D cultures", "ANATOMY", 0, 11], ["cell", "ANATOMY", 27, 31], ["cell", "ANATOMY", 32, 36], ["cells", "ANATOMY", 62, 67], ["extracellular matrix", "ANATOMY", 77, 97], ["ECM", "ANATOMY", 99, 102], ["cells", "ANATOMY", 165, 170], ["tissue", "ANATOMY", 217, 223], ["cell", "CELL", 27, 31], ["cell", "CELL", 32, 36], ["cells", "CELL", 62, 67], ["extracellular matrix", "CELLULAR_COMPONENT", 77, 97], ["ECM", "CELLULAR_COMPONENT", 99, 102], ["cells", "CELL", 165, 170], ["tissue", "TISSUE", 217, 223], ["monolayer", "CELL", 247, 256], ["[13], [14], [15]]", "SIMPLE_CHEMICAL", 271, 288], ["3D cultures", "CELL_LINE", 0, 11], ["soluble factors", "PROTEIN", 134, 149], ["3D cultures", "TEST", 0, 11], ["soluble factors", "TREATMENT", 134, 149]]], ["Despite their success, the use of 3D technology in studying microbial infections is still in its infancy.Discussion3D culture models have well demonstrated utility for studying bacterial and viral pathogens.", [["microbial infections", "DISEASE", 60, 80], ["3D technology", "TREATMENT", 34, 47], ["microbial infections", "PROBLEM", 60, 80], ["Discussion3D culture models", "TEST", 105, 132], ["studying bacterial and viral pathogens", "PROBLEM", 168, 206], ["infections", "OBSERVATION", 70, 80], ["viral pathogens", "OBSERVATION", 191, 206]]], ["Previous studies revealed that spheroids are more representative models for Pseudomonas aeruginosa and Salmonella enterica compared to monolayer cultures in terms of invasiveness, histopathology, and immunopathology [33,34].", [["spheroids", "ANATOMY", 31, 40], ["monolayer cultures", "ANATOMY", 135, 153], ["immunopathology", "DISEASE", 200, 215], ["spheroids", "CELL", 31, 40], ["Pseudomonas aeruginosa", "ORGANISM", 76, 98], ["Salmonella enterica", "ORGANISM", 103, 122], ["monolayer cultures", "CELL", 135, 153], ["monolayer cultures", "CELL_LINE", 135, 153], ["Pseudomonas aeruginosa", "SPECIES", 76, 98], ["Salmonella enterica", "SPECIES", 103, 122], ["Pseudomonas aeruginosa", "SPECIES", 76, 98], ["Salmonella enterica", "SPECIES", 103, 122], ["Previous studies", "TEST", 0, 16], ["spheroids", "PROBLEM", 31, 40], ["Pseudomonas aeruginosa", "PROBLEM", 76, 98], ["Salmonella enterica", "PROBLEM", 103, 122], ["monolayer cultures", "TEST", 135, 153], ["invasiveness", "PROBLEM", 166, 178], ["histopathology", "TEST", 180, 194], ["immunopathology", "PROBLEM", 200, 215], ["spheroids", "OBSERVATION", 31, 40]]], ["Cells grown in spheroids were also shown to be the first definitive model for human norovirus [18] and hepatitis C virus studies [19], which lacked a suitable cell culture and murine study models.", [["Cells", "ANATOMY", 0, 5], ["spheroids", "ANATOMY", 15, 24], ["cell culture", "ANATOMY", 159, 171], ["hepatitis C", "DISEASE", 103, 114], ["Cells", "CELL", 0, 5], ["spheroids", "CELL", 15, 24], ["human", "ORGANISM", 78, 83], ["norovirus", "ORGANISM", 84, 93], ["hepatitis C virus", "ORGANISM", 103, 120], ["cell culture", "CELL", 159, 171], ["murine", "ORGANISM", 176, 182], ["human", "SPECIES", 78, 83], ["hepatitis C virus", "SPECIES", 103, 120], ["murine", "SPECIES", 176, 182], ["human", "SPECIES", 78, 83], ["hepatitis C virus", "SPECIES", 103, 120], ["Cells grown in spheroids", "PROBLEM", 0, 24], ["human norovirus", "PROBLEM", 78, 93], ["hepatitis C virus studies", "TEST", 103, 128], ["a suitable cell culture", "TEST", 148, 171], ["murine study models", "TEST", 176, 195]]], ["These viruses were capable of replicating and triggering a cytopathic effect in the 3D spheroid.", [["3D spheroid", "ANATOMY", 84, 95], ["3D spheroid", "CELL", 84, 95], ["These viruses", "PROBLEM", 0, 13], ["a cytopathic effect in the 3D spheroid", "PROBLEM", 57, 95], ["viruses", "OBSERVATION", 6, 13], ["cytopathic", "OBSERVATION_MODIFIER", 59, 69], ["spheroid", "OBSERVATION_MODIFIER", 87, 95]]], ["Moreover, influenza virus, human immunodeficiency virus (HIV), and coronavirus have all been successfully studied in 3D cultures [17].", [["influenza virus, human immunodeficiency virus (HIV), and coronavirus", "DISEASE", 10, 78], ["influenza virus", "ORGANISM", 10, 25], ["human immunodeficiency virus", "ORGANISM", 27, 55], ["HIV", "ORGANISM", 57, 60], ["coronavirus", "ORGANISM", 67, 78], ["influenza virus", "SPECIES", 10, 25], ["human immunodeficiency virus (HIV", "SPECIES", 27, 60], ["coronavirus", "SPECIES", 67, 78], ["influenza virus", "SPECIES", 10, 25], ["human immunodeficiency virus", "SPECIES", 27, 55], ["HIV", "SPECIES", 57, 60], ["influenza virus", "PROBLEM", 10, 25], ["human immunodeficiency virus (HIV)", "PROBLEM", 27, 61], ["coronavirus", "PROBLEM", 67, 78], ["3D cultures", "TEST", 117, 128], ["influenza virus", "OBSERVATION", 10, 25]]], ["Recently, Zou et al. [35] developed human adult stem cell (ASC)-derived airway 3D that can be utilized to assess infectivity of emerging influenza viruses to human.", [["adult stem cell", "ANATOMY", 42, 57], ["ASC", "ANATOMY", 59, 62], ["airway 3D", "ANATOMY", 72, 81], ["influenza viruses", "DISEASE", 137, 154], ["human", "ORGANISM", 36, 41], ["adult stem cell", "CELL", 42, 57], ["ASC", "CELL", 59, 62], ["airway 3D", "CELL", 72, 81], ["influenza viruses", "ORGANISM", 137, 154], ["human", "ORGANISM", 158, 163], ["human adult stem cell (ASC)-derived airway 3D", "CELL_LINE", 36, 81], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 158, 163], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 158, 163], ["human adult stem cell (ASC)", "TREATMENT", 36, 63], ["emerging influenza viruses", "PROBLEM", 128, 154], ["stem cell", "OBSERVATION", 48, 57], ["airway", "ANATOMY", 72, 78]]], ["Another work by Imle and colleagues introduced a 3D culture of primary human CD4 T lymphocytes as an ex vivo model system to study HIV-1 in tissue-like microenvironments [36].", [["CD4 T lymphocytes", "ANATOMY", 77, 94], ["tissue", "ANATOMY", 140, 146], ["human", "ORGANISM", 71, 76], ["CD4 T lymphocytes", "CELL", 77, 94], ["HIV-1", "ORGANISM", 131, 136], ["tissue", "TISSUE", 140, 146], ["primary human CD4 T lymphocytes", "CELL_TYPE", 63, 94], ["human", "SPECIES", 71, 76], ["HIV-1", "SPECIES", 131, 136], ["human", "SPECIES", 71, 76], ["HIV-1", "SPECIES", 131, 136], ["a 3D culture", "TEST", 47, 59], ["study HIV", "TEST", 125, 134]]], ["Here, we established a simple and economic 3D spheroid culture of alveolar type II epithelial cells (A549) as a model to study RSV infection.", [["alveolar type II epithelial cells", "ANATOMY", 66, 99], ["A549", "ANATOMY", 101, 105], ["RSV infection", "DISEASE", 127, 140], ["alveolar type II epithelial cells", "CELL", 66, 99], ["A549", "CELL", 101, 105], ["RSV", "ORGANISM", 127, 130], ["alveolar type II epithelial cells", "CELL_TYPE", 66, 99], ["A549", "CELL_LINE", 101, 105], ["RSV", "SPECIES", 127, 130], ["economic 3D spheroid culture", "TEST", 34, 62], ["alveolar type II epithelial cells", "PROBLEM", 66, 99], ["RSV infection", "PROBLEM", 127, 140], ["alveolar type II epithelial cells", "OBSERVATION", 66, 99], ["infection", "OBSERVATION", 131, 140]]], ["This culture model can provide a tool for investigating the cellular and molecular mechanisms underlying RSV pathogenesis and to potentially test the effectiveness of antiviral molecules.DiscussionSyncytia formation and excessive mucin (MUC1) production are the hallmarks of RSV infection in vivo [8,9].", [["cellular", "ANATOMY", 60, 68], ["RSV infection", "DISEASE", 275, 288], ["cellular", "CELL", 60, 68], ["RSV", "ORGANISM", 105, 108], ["mucin", "GENE_OR_GENE_PRODUCT", 230, 235], ["MUC1", "GENE_OR_GENE_PRODUCT", 237, 241], ["RSV", "ORGANISM", 275, 278], ["antiviral molecules", "PROTEIN", 167, 186], ["MUC1", "PROTEIN", 237, 241], ["RSV", "SPECIES", 105, 108], ["RSV", "SPECIES", 275, 278], ["This culture model", "TEST", 0, 18], ["RSV pathogenesis", "PROBLEM", 105, 121], ["antiviral molecules", "TREATMENT", 167, 186], ["DiscussionSyncytia formation", "PROBLEM", 187, 215], ["excessive mucin (MUC1) production", "TREATMENT", 220, 253], ["RSV infection", "PROBLEM", 275, 288], ["RSV", "OBSERVATION", 105, 108], ["antiviral molecules", "OBSERVATION", 167, 186], ["excessive", "OBSERVATION_MODIFIER", 220, 229], ["RSV infection", "OBSERVATION", 275, 288]]], ["In vitro, when A549 monolayers were infected with RSV, MUC1 secretion was only recorded for up to 3 days, after which it started to decline [37,38].", [["A549 monolayers", "ANATOMY", 15, 30], ["A549 monolayers", "CELL", 15, 30], ["RSV", "ORGANISM", 50, 53], ["MUC1", "GENE_OR_GENE_PRODUCT", 55, 59], ["A549 monolayers", "CELL_LINE", 15, 30], ["MUC1", "PROTEIN", 55, 59], ["RSV", "SPECIES", 50, 53], ["A549 monolayers", "PROBLEM", 15, 30], ["RSV", "PROBLEM", 50, 53], ["MUC1 secretion", "PROBLEM", 55, 69]]], ["Contrary, studies performed on monolayers of primary human airway epithelial cells report syncytium formation and increased mucin production for up to 6 days post-infection [[39], [40], [41]].", [["monolayers", "ANATOMY", 31, 41], ["airway epithelial cells", "ANATOMY", 59, 82], ["syncytium", "ANATOMY", 90, 99], ["monolayers", "CELL", 31, 41], ["human", "ORGANISM", 53, 58], ["airway epithelial cells", "CELL", 59, 82], ["syncytium", "CELL", 90, 99], ["mucin", "GENE_OR_GENE_PRODUCT", 124, 129], ["primary human airway epithelial cells", "CELL_TYPE", 45, 82], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["primary human airway epithelial cells", "TREATMENT", 45, 82], ["syncytium formation", "PROBLEM", 90, 109], ["increased mucin production", "PROBLEM", 114, 140], ["airway", "ANATOMY", 59, 65], ["epithelial cells", "OBSERVATION", 66, 82], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["mucin production", "OBSERVATION", 124, 140]]], ["Our results showed that A549 cells grown in spheroids are susceptible and permissive of RSV, which disseminated to the center of the spheroids and induced excessive mucin secretion for up to 7 days post-infection accompanied with syncytia formation.", [["A549 cells", "ANATOMY", 24, 34], ["spheroids", "ANATOMY", 44, 53], ["spheroids", "ANATOMY", 133, 142], ["syncytia", "ANATOMY", 230, 238], ["A549 cells", "CELL", 24, 34], ["spheroids", "CELL", 44, 53], ["RSV", "ORGANISM", 88, 91], ["spheroids", "CELL", 133, 142], ["mucin", "GENE_OR_GENE_PRODUCT", 165, 170], ["syncytia", "CELL", 230, 238], ["A549 cells", "CELL_LINE", 24, 34], ["RSV", "SPECIES", 88, 91], ["A549 cells", "PROBLEM", 24, 34], ["spheroids", "PROBLEM", 44, 53], ["RSV", "PROBLEM", 88, 91], ["the spheroids", "PROBLEM", 129, 142], ["excessive mucin secretion", "PROBLEM", 155, 180], ["syncytia formation", "PROBLEM", 230, 248], ["A549 cells", "OBSERVATION", 24, 34], ["spheroids", "OBSERVATION_MODIFIER", 44, 53], ["RSV", "OBSERVATION", 88, 91], ["spheroids", "OBSERVATION_MODIFIER", 133, 142], ["excessive", "OBSERVATION_MODIFIER", 155, 164], ["mucin secretion", "OBSERVATION", 165, 180], ["syncytia formation", "OBSERVATION", 230, 248]]], ["This shows that A549 cells in spheroids behave more closely to primary cells than to A549 monolayers in terms of mucin production and syncytia formation upon RSV infection.", [["A549 cells", "ANATOMY", 16, 26], ["spheroids", "ANATOMY", 30, 39], ["primary cells", "ANATOMY", 63, 76], ["A549 monolayers", "ANATOMY", 85, 100], ["syncytia", "ANATOMY", 134, 142], ["RSV infection", "DISEASE", 158, 171], ["A549 cells", "CELL", 16, 26], ["spheroids", "CELL", 30, 39], ["cells", "CELL", 71, 76], ["A549 monolayers", "CELL", 85, 100], ["mucin", "GENE_OR_GENE_PRODUCT", 113, 118], ["syncytia", "CELLULAR_COMPONENT", 134, 142], ["RSV", "ORGANISM", 158, 161], ["A549 cells", "CELL_LINE", 16, 26], ["primary cells", "CELL_TYPE", 63, 76], ["A549 monolayers", "CELL_LINE", 85, 100], ["RSV", "SPECIES", 158, 161], ["A549 cells in spheroids", "PROBLEM", 16, 39], ["A549 monolayers", "TEST", 85, 100], ["mucin production", "PROBLEM", 113, 129], ["syncytia formation", "PROBLEM", 134, 152], ["RSV infection", "PROBLEM", 158, 171], ["A549 cells", "OBSERVATION", 16, 26], ["mucin production", "OBSERVATION", 113, 129], ["syncytia formation", "OBSERVATION", 134, 152], ["RSV infection", "OBSERVATION", 158, 171]]], ["Furthermore, we showed that the infection was productive up to day 7 post-inoculation with the virus progressively spreading towards the center of the spheroid.", [["spheroid", "ANATOMY", 151, 159], ["infection", "DISEASE", 32, 41], ["spheroid", "CELL", 151, 159], ["the infection", "PROBLEM", 28, 41], ["the virus", "PROBLEM", 91, 100], ["infection", "OBSERVATION", 32, 41], ["productive", "OBSERVATION_MODIFIER", 46, 56], ["virus", "OBSERVATION", 95, 100], ["center", "ANATOMY_MODIFIER", 137, 143], ["spheroid", "ANATOMY_MODIFIER", 151, 159]]], ["Notably, the virus yield dropped on day by one log10 pfu/ml, which could be explained by the cell death happening at the core of the spheroids.", [["cell", "ANATOMY", 93, 97], ["spheroids", "ANATOMY", 133, 142], ["death", "DISEASE", 98, 103], ["cell", "CELL", 93, 97], ["spheroids", "CELL", 133, 142], ["the virus yield", "PROBLEM", 9, 24], ["the cell death", "PROBLEM", 89, 103], ["could be explained", "UNCERTAINTY", 67, 85], ["cell death", "OBSERVATION", 93, 103], ["spheroids", "OBSERVATION", 133, 142]]], ["Overall, our data clearly show that A549 spheroids constitute a promising model of RSV infection studies.DiscussionTo our knowledge, this is the first study to develop a 3D culture model for RSV using alveolar epithelial type II cells and show that infected spheroids display some of the key features of RSV infection in vivo, i.e., mucin secretion.", [["A549 spheroids", "ANATOMY", 36, 50], ["alveolar epithelial type II cells", "ANATOMY", 201, 234], ["spheroids", "ANATOMY", 258, 267], ["RSV infection", "DISEASE", 83, 96], ["RSV", "DISEASE", 191, 194], ["RSV infection", "DISEASE", 304, 317], ["A549 spheroids", "CELL", 36, 50], ["RSV", "ORGANISM", 83, 86], ["RSV", "ORGANISM", 191, 194], ["alveolar epithelial type II cells", "CELL", 201, 234], ["spheroids", "CELL", 258, 267], ["RSV", "ORGANISM", 304, 307], ["mucin", "GENE_OR_GENE_PRODUCT", 333, 338], ["A549 spheroids", "CELL_LINE", 36, 50], ["alveolar epithelial type II cells", "CELL_TYPE", 201, 234], ["RSV", "SPECIES", 83, 86], ["RSV", "SPECIES", 191, 194], ["RSV", "SPECIES", 304, 307], ["our data", "TEST", 9, 17], ["A549 spheroids", "PROBLEM", 36, 50], ["RSV infection studies", "PROBLEM", 83, 104], ["a 3D culture model", "TEST", 168, 186], ["RSV", "PROBLEM", 191, 194], ["alveolar epithelial type II cells", "PROBLEM", 201, 234], ["infected spheroids", "PROBLEM", 249, 267], ["RSV infection", "PROBLEM", 304, 317], ["mucin secretion", "PROBLEM", 333, 348], ["A549 spheroids", "OBSERVATION", 36, 50], ["RSV infection", "OBSERVATION", 83, 96], ["alveolar epithelial", "OBSERVATION", 201, 220], ["infected spheroids", "OBSERVATION", 249, 267], ["RSV infection", "OBSERVATION", 304, 317]]], ["Therefore, 3D cultures might be a promising in vitro model candidate for studying RSV that can bridge the gap between monolayers and in vivo models due to its permissiveness, sustainability of RSV infection, and its ability to recapitulate the lung epithelial tissue\u2019s response to infection.", [["monolayers", "ANATOMY", 118, 128], ["lung epithelial tissue", "ANATOMY", 244, 266], ["RSV infection", "DISEASE", 193, 206], ["infection", "DISEASE", 281, 290], ["3D cultures", "CELL", 11, 22], ["RSV", "ORGANISM", 82, 85], ["monolayers", "CELL", 118, 128], ["RSV", "ORGANISM", 193, 196], ["lung epithelial tissue", "TISSUE", 244, 266], ["3D cultures", "CELL_LINE", 11, 22], ["RSV", "SPECIES", 82, 85], ["RSV", "SPECIES", 193, 196], ["3D cultures", "TEST", 11, 22], ["RSV", "PROBLEM", 82, 85], ["its permissiveness", "PROBLEM", 155, 173], ["RSV infection", "PROBLEM", 193, 206], ["the lung epithelial tissue", "PROBLEM", 240, 266], ["infection", "PROBLEM", 281, 290], ["RSV", "OBSERVATION_MODIFIER", 193, 196], ["infection", "OBSERVATION", 197, 206], ["lung", "ANATOMY", 244, 248], ["epithelial tissue", "OBSERVATION", 249, 266], ["infection", "OBSERVATION", 281, 290]]], ["However, this model is not without its limitations such as the lack of vasculature, tissue heterogeneity and fluid flows observed in vivo.", [["vasculature", "ANATOMY", 71, 82], ["tissue", "ANATOMY", 84, 90], ["fluid", "ANATOMY", 109, 114], ["vasculature", "MULTI-TISSUE_STRUCTURE", 71, 82], ["tissue", "TISSUE", 84, 90], ["tissue heterogeneity", "PROBLEM", 84, 104], ["fluid flows", "TEST", 109, 120], ["not without", "UNCERTAINTY", 23, 34], ["vasculature", "ANATOMY", 71, 82], ["tissue", "OBSERVATION_MODIFIER", 84, 90], ["heterogeneity", "OBSERVATION", 91, 104], ["fluid flows", "OBSERVATION", 109, 120]]], ["Therefore, more work is required to make these 3D cultures ideal model systems to study virus-host interactions and maximize their translational utility.FundingThe study was supported by the Council for Scientific Research in Lebanon (CNRS-L) and the Medical Practice Plan (MPP) fund, American University of Beirut, Lebanon.Competing interestsNone declared.Ethical approvalNot required.", [["3D cultures", "CELL_LINE", 47, 58], ["these 3D cultures", "TEST", 41, 58], ["The study", "TEST", 160, 169], ["Ethical approval", "TREATMENT", 357, 373]]]], "4560eb7b1870b3d37c57bac34dd5a81b2f1ba6b9": [["Dear editor, Point-of-Care Ultrasound (POCUS) has become a vital tool for bedside diagnosis and management in patient care.", [["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117], ["Ultrasound", "TEST", 27, 37], ["management in patient care", "TREATMENT", 96, 122]]], ["Although POCUS protocols can be generalized and involve multi-organ assessment, the fundamental component of bedside ultrasound assessment is cardiac POCUS, or similarly termed 'focused cardiac ultrasound'.", [["cardiac", "ANATOMY", 142, 149], ["cardiac", "ANATOMY", 186, 193], ["cardiac", "ORGAN", 186, 193], ["POCUS protocols", "TREATMENT", 9, 24], ["multi-organ assessment", "TEST", 56, 78], ["bedside ultrasound assessment", "TEST", 109, 138], ["cardiac ultrasound", "TEST", 186, 204]]], ["A recent publication by Kirkpatrick et al defined three forms of focused cardiac ultrasound:", [["cardiac", "ANATOMY", 73, 80], ["cardiac", "ORGAN", 73, 80], ["focused cardiac ultrasound", "TEST", 65, 91], ["cardiac", "ANATOMY", 73, 80]]]], "4b46412d2003ac6a4717a2fe401592b5aafaf3a3": [["INTRODUCTIONCoronaviruses [Tyrrell, 19681 cause serious infections in many animal species, examples being hepatitis and encephalitis in mice, bronchitis in chickens, encephalomyelitis in piglets, and severe gastroenteritis in both calves and piglets (for references, see McIntosh [1974] and Hierholzer 119761) .", [["Tyrrell, 19681", "CHEMICAL", 27, 41], ["infections", "DISEASE", 56, 66], ["hepatitis", "DISEASE", 106, 115], ["encephalitis", "DISEASE", 120, 132], ["bronchitis", "DISEASE", 142, 152], ["encephalomyelitis", "DISEASE", 166, 183], ["gastroenteritis", "DISEASE", 207, 222], ["mice", "ORGANISM", 136, 140], ["chickens", "ORGANISM", 156, 164], ["piglets", "ORGANISM", 187, 194], ["calves", "ORGANISM", 231, 237], ["piglets", "ORGANISM", 242, 249], ["mice", "SPECIES", 136, 140], ["chickens", "SPECIES", 156, 164], ["piglets", "SPECIES", 187, 194], ["calves", "SPECIES", 231, 237], ["piglets", "SPECIES", 242, 249], ["mice", "SPECIES", 136, 140], ["chickens", "SPECIES", 156, 164], ["serious infections", "PROBLEM", 48, 66], ["many animal species", "PROBLEM", 70, 89], ["hepatitis", "PROBLEM", 106, 115], ["encephalitis", "PROBLEM", 120, 132], ["bronchitis", "PROBLEM", 142, 152], ["chickens", "PROBLEM", 156, 164], ["encephalomyelitis in piglets", "PROBLEM", 166, 194], ["severe gastroenteritis in both calves", "PROBLEM", 200, 237], ["hepatitis", "OBSERVATION", 106, 115], ["encephalitis", "OBSERVATION", 120, 132], ["bronchitis", "OBSERVATION", 142, 152], ["encephalomyelitis", "OBSERVATION", 166, 183], ["severe", "OBSERVATION_MODIFIER", 200, 206], ["gastroenteritis", "OBSERVATION", 207, 222], ["both", "ANATOMY_MODIFIER", 226, 230], ["calves", "ANATOMY", 231, 237]]], ["In contrast, all of the more than 20 coronavirus strains isolated from man were in association with mild upper respiratory tract infections [Bradburne and Tyrrell, 19711 .", [["upper respiratory tract", "ANATOMY", 105, 128], ["respiratory tract infections", "DISEASE", 111, 139], ["coronavirus", "ORGANISM", 37, 48], ["man", "ORGANISM", 71, 74], ["upper respiratory", "ORGANISM_SUBDIVISION", 105, 122], ["tract", "ORGANISM_SUBDIVISION", 123, 128], ["man", "SPECIES", 71, 74], ["20 coronavirus strains", "PROBLEM", 34, 56], ["mild upper respiratory tract infections", "PROBLEM", 100, 139], ["mild", "OBSERVATION_MODIFIER", 100, 104], ["upper", "ANATOMY_MODIFIER", 105, 110], ["respiratory tract", "ANATOMY", 111, 128], ["infections", "OBSERVATION", 129, 139]]], ["Our present knowledge of the epidemiology and the real clinical significance of human coronaviruses may be superficial, however, due to technical difficulties in diagnosing coronavirus infections [Bradburne and Tyrrell, 19711 .", [["coronavirus infections", "DISEASE", 173, 195], ["human", "ORGANISM", 80, 85], ["coronavirus", "ORGANISM", 173, 184], ["human", "SPECIES", 80, 85], ["human coronaviruses", "SPECIES", 80, 99], ["human coronaviruses", "PROBLEM", 80, 99], ["technical difficulties", "PROBLEM", 136, 158], ["diagnosing coronavirus infections", "PROBLEM", 162, 195]]], ["Indeed, coronaviruses may also cause non-respiratory diseases in man, since they have recently been reported to be associated with nonbacterial gastroenteritis [Caul and Clarke, 19751 and endemic neohritis IAuostolov et al, 19751.", [["non-respiratory", "ANATOMY", 37, 52], ["non-respiratory diseases", "DISEASE", 37, 61], ["nonbacterial gastroenteritis", "DISEASE", 131, 159], ["coronaviruses", "ORGANISM", 8, 21], ["man", "ORGANISM", 65, 68], ["man", "SPECIES", 65, 68], ["coronaviruses", "PROBLEM", 8, 21], ["non-respiratory diseases", "PROBLEM", 37, 61], ["nonbacterial gastroenteritis", "PROBLEM", 131, 159], ["coronaviruses", "OBSERVATION", 8, 21], ["may also cause", "UNCERTAINTY", 22, 36], ["non-respiratory diseases", "OBSERVATION", 37, 61], ["nonbacterial", "OBSERVATION_MODIFIER", 131, 143], ["gastroenteritis", "OBSERVATION", 144, 159]]], ["Most seroepidemiologic studies on human coronavirus antibodies have been carried out using the OC43 virus strain [Bradbourne and Tyrell, 19711 as antigen.", [["human", "ORGANISM", 34, 39], ["coronavirus", "ORGANISM", 40, 51], ["OC43 virus", "ORGANISM", 95, 105], ["human coronavirus antibodies", "PROTEIN", 34, 62], ["human", "SPECIES", 34, 39], ["coronavirus", "SPECIES", 40, 51], ["human coronavirus", "SPECIES", 34, 51], ["OC43 virus", "SPECIES", 95, 105], ["Most seroepidemiologic studies", "TEST", 0, 30], ["human coronavirus antibodies", "TEST", 34, 62], ["the OC43 virus strain", "PROBLEM", 91, 112]]], ["This strain has been adapted to grow in suckling mouse brain, where it readily produces haemagglutinin [Kaye and Dowdle, 19691.", [["brain", "ANATOMY", 55, 60], ["mouse", "ORGANISM", 49, 54], ["brain", "ORGAN", 55, 60], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 88, 102], ["mouse", "SPECIES", 49, 54], ["mouse", "SPECIES", 49, 54], ["suckling mouse brain", "PROBLEM", 40, 60], ["brain", "ANATOMY", 55, 60]]], ["Haemagglutination inhibition (HI) antibodies are thought to be relatively specific for the OC43 strain and surveys using the OC43 virus HI test suggest that this virus is a common agent in many countries [Bradburne and Tyrrell, 1971 ; Kaye et al, 1971; Bradburne and Somerset, 1972; Zakstelskaya et al, 1972; Riski and Estola, 19741.", [["OC43", "GENE_OR_GENE_PRODUCT", 91, 95], ["OC43 virus HI", "ORGANISM", 125, 138], ["Haemagglutination inhibition (HI) antibodies", "PROTEIN", 0, 44], ["OC43 virus HI", "SPECIES", 125, 138], ["Haemagglutination inhibition (HI) antibodies", "PROBLEM", 0, 44], ["the OC43 strain", "PROBLEM", 87, 102], ["the OC43 virus HI test", "TEST", 121, 143], ["this virus", "PROBLEM", 157, 167]]], ["Complement-fixing (CF) antigens produced by the OC43 virus in mouse brain, on the other hand, broadly cross-react with antibodies elicited by most other human coronavirus strains [Bradburne and Tyrrell, 19711 , suggesting that OC43 CF antigen may be suitable for use as a \"group-antigen'' in the general diagnosis of coronavirus infections. alence of OC43 virus strain-related antibodies in different age groups.", [["brain", "ANATOMY", 68, 73], ["coronavirus infections", "DISEASE", 317, 339], ["Complement-fixing (CF) antigens", "GENE_OR_GENE_PRODUCT", 0, 31], ["OC43 virus", "ORGANISM", 48, 58], ["mouse", "ORGANISM", 62, 67], ["brain", "ORGAN", 68, 73], ["human", "ORGANISM", 153, 158], ["coronavirus strains", "ORGANISM", 159, 178], ["OC43 CF antigen", "GENE_OR_GENE_PRODUCT", 227, 242], ["coronavirus", "ORGANISM", 317, 328], ["OC43 virus", "ORGANISM", 351, 361], ["Complement-fixing (CF) antigens", "PROTEIN", 0, 31], ["antibodies", "PROTEIN", 119, 129], ["OC43 CF antigen", "PROTEIN", 227, 242], ["antibodies", "PROTEIN", 377, 387], ["mouse", "SPECIES", 62, 67], ["human", "SPECIES", 153, 158], ["OC43 virus", "SPECIES", 48, 58], ["mouse", "SPECIES", 62, 67], ["human coronavirus", "SPECIES", 153, 170], ["OC43", "SPECIES", 227, 231], ["Complement", "TEST", 0, 10], ["fixing (CF) antigens", "PROBLEM", 11, 31], ["the OC43 virus in mouse brain", "PROBLEM", 44, 73], ["antibodies", "PROBLEM", 119, 129], ["most other human coronavirus strains", "PROBLEM", 142, 178], ["Tyrrell", "TREATMENT", 194, 201], ["OC43 CF antigen", "PROBLEM", 227, 242], ["coronavirus infections", "PROBLEM", 317, 339], ["OC43 virus strain", "PROBLEM", 351, 368], ["OC43 virus", "OBSERVATION", 48, 58], ["brain", "ANATOMY", 68, 73], ["coronavirus infections", "OBSERVATION", 317, 339], ["OC43 virus", "OBSERVATION", 351, 361]]], ["For comparative purposes, the antibodies were measured by the conventional CF and HI serologic techniques as well as the more recently developed radial diffusion haemolysis-in-gel (HIG) and solid-phase radioimmunoassay (RIA) methods.INTRODUCTIONWe have started a survey of coronavirus infections in Finland and report here the prev-SpecimensSera from 295 patients were selected to evenly cover 15 age groups from 5 months or less to more than 60 years of age.", [["coronavirus infections", "DISEASE", 273, 295], ["coronavirus", "ORGANISM", 273, 284], ["patients", "ORGANISM", 355, 363], ["antibodies", "PROTEIN", 30, 40], ["patients", "SPECIES", 355, 363], ["comparative purposes", "TEST", 4, 24], ["the antibodies", "TEST", 26, 40], ["HI serologic techniques", "TEST", 82, 105], ["radial diffusion haemolysis", "TEST", 145, 172], ["solid-phase radioimmunoassay", "TEST", 190, 218], ["coronavirus infections", "PROBLEM", 273, 295]]], ["The specimens had originally been collected in 1976 and 1977 for the serologic diagnosis of suspected viral infections.", [["specimens", "ANATOMY", 4, 13], ["viral infections", "DISEASE", 102, 118], ["specimens", "CANCER", 4, 13], ["The specimens", "TEST", 0, 13], ["suspected viral infections", "PROBLEM", 92, 118], ["viral infections", "OBSERVATION", 102, 118]]], ["They were stored meanwhile at -20\u00b0C and kindly made available by the routine diagnostic laboratory of the Department of Virology, University of Helsinki.Antigen PreparationsThe mouse brain-adapted OC43 virus [Kaye and Dowdle, 19691 was propagated as described previously [&ski et al, 19771 .", [["brain", "ANATOMY", 183, 188], ["mouse", "ORGANISM", 177, 182], ["brain", "ORGAN", 183, 188], ["OC43 virus", "ORGANISM", 197, 207], ["Dowdle, 19691", "CELL", 218, 231], ["mouse", "SPECIES", 177, 182], ["mouse", "SPECIES", 177, 182], ["OC43 virus", "SPECIES", 197, 207], ["Antigen Preparations", "TREATMENT", 153, 173], ["brain", "ANATOMY", 183, 188]]], ["The infected brains were homogenised by vigorous pipetting in ten volumes of cold Melnick A medium and the suspension formed was then centrifuged at 8OOg for 30 minutes at 4\u00b0C. The clarified supernatant was stored at -2OOC and used as antigen in the CF, HI: and HIG tests.Antigen PreparationsBoth OC43 virus-infected and uninfected brain antigens were prepared for use in the RIA.", [["brains", "ANATOMY", 13, 19], ["supernatant", "ANATOMY", 191, 202], ["brain", "ANATOMY", 332, 337], ["Melnick A", "CHEMICAL", 82, 91], ["brains", "ORGAN", 13, 19], ["brain antigens", "CELL", 332, 346], ["The infected brains", "PROBLEM", 0, 19], ["vigorous pipetting", "TREATMENT", 40, 58], ["cold Melnick A medium and the suspension", "TREATMENT", 77, 117], ["HIG tests", "TEST", 262, 271], ["Antigen PreparationsBoth OC43 virus", "TEST", 272, 307], ["infected and uninfected brain antigens", "PROBLEM", 308, 346], ["infected", "OBSERVATION", 4, 12], ["brains", "ANATOMY", 13, 19], ["vigorous", "OBSERVATION_MODIFIER", 40, 48], ["pipetting", "OBSERVATION_MODIFIER", 49, 58], ["OC43 virus", "OBSERVATION", 297, 307], ["infected", "OBSERVATION_MODIFIER", 308, 316], ["brain", "ANATOMY", 332, 337]]], ["Pooled brain material was placed in 0.02 M sodium phosphate (pH 7.4) containing 0.14 M NaCl (PBS), and the cells were disrupted by 20 strokes in a tight-fitting glass homogenizer at 4\u00b0C. The suspensions were then centrifuged at 100,OOOg for 60 minutes at 4\u00b0C. The pellets obtained were resuspended in PBS and stored at -20\u00b0C. Upon thawing, homogenous suspensions were obtained by sonication at 4\u00b0C. Protein concentrations were deter-mined by the method of Lowry et a1 [1951] Using bovine Serum albumin (BSA) as a Standard.Complement Fixation AssayThe standard method [Palmer and Casey, J 969; Bradburne and Tyrrell, 1971 1 was used with minor modifications.", [["brain", "ANATOMY", 7, 12], ["cells", "ANATOMY", 107, 112], ["sodium phosphate", "CHEMICAL", 43, 59], ["NaCl", "CHEMICAL", 87, 91], ["strokes", "DISEASE", 134, 141], ["sodium phosphate", "CHEMICAL", 43, 59], ["NaCl", "CHEMICAL", 87, 91], ["brain material", "MULTI-TISSUE_STRUCTURE", 7, 21], ["sodium phosphate", "SIMPLE_CHEMICAL", 43, 59], ["cells", "CELL", 107, 112], ["bovine", "ORGANISM", 481, 487], ["Serum", "ORGANISM_SUBSTANCE", 488, 493], ["albumin", "GENE_OR_GENE_PRODUCT", 494, 501], ["BSA", "SIMPLE_CHEMICAL", 503, 506], ["bovine", "SPECIES", 481, 487], ["bovine", "SPECIES", 481, 487], ["Pooled brain material", "PROBLEM", 0, 21], ["0.02 M sodium phosphate", "TREATMENT", 36, 59], ["pH", "TEST", 61, 63], ["0.14 M NaCl (PBS", "TREATMENT", 80, 96], ["a tight-fitting glass homogenizer", "TREATMENT", 145, 178], ["The suspensions", "TREATMENT", 187, 202], ["The pellets", "TREATMENT", 260, 271], ["Protein concentrations", "TEST", 399, 421], ["bovine Serum albumin (BSA", "TEST", 481, 506], ["Complement Fixation Assay", "TEST", 522, 547], ["brain", "ANATOMY", 7, 12], ["material", "OBSERVATION", 13, 21], ["glass homogenizer", "OBSERVATION", 161, 178], ["Fixation", "OBSERVATION", 533, 541]]], ["Serial two-fold dilutions of heat-inactivated sera were incubated overnight at 4\u00b0C with 4 units of antigen and 2 units of complement.", [["sera", "ANATOMY", 46, 50], ["sera", "ORGANISM_SUBSTANCE", 46, 50], ["Serial two-fold dilutions of heat", "TREATMENT", 0, 33], ["antigen", "TREATMENT", 99, 106], ["complement", "TREATMENT", 122, 132]]], ["Binding of complement was assayed by means of sensitized sheep red blood cells.", [["red blood cells", "ANATOMY", 63, 78], ["sheep", "ORGANISM", 57, 62], ["red blood cells", "CELL", 63, 78], ["sensitized sheep red blood cells", "CELL_TYPE", 46, 78], ["sheep", "SPECIES", 57, 62], ["sheep", "SPECIES", 57, 62], ["sensitized sheep red blood cells", "TREATMENT", 46, 78]]], ["A titer of 1 :4 or greater was considered positive.Haemagglutination Inhibition TestNonspecific inhibitors of the OC43 virus haemagglutination were first removed from the sera by treatment with phospholipase C (type I, Sigma, St. Louis) as described by Haukenes and Blom [1975] for rubella virus nonspecific HI inhibitors.", [["sera", "ANATOMY", 171, 175], ["rubella virus", "DISEASE", 282, 295], [":4", "GENE_OR_GENE_PRODUCT", 13, 15], ["OC43 virus", "ORGANISM", 114, 124], ["sera", "ORGANISM_SUBSTANCE", 171, 175], ["phospholipase C", "SIMPLE_CHEMICAL", 194, 209], ["St. Louis", "ORGANISM", 226, 235], ["Haukenes", "SIMPLE_CHEMICAL", 253, 261], ["rubella virus", "ORGANISM", 282, 295], ["phospholipase C", "PROTEIN", 194, 209], ["OC43 virus", "SPECIES", 114, 124], ["rubella virus", "SPECIES", 282, 295], ["A titer", "TEST", 0, 7], ["positive", "PROBLEM", 42, 50], ["Haemagglutination Inhibition", "TREATMENT", 51, 79], ["TestNonspecific inhibitors", "TREATMENT", 80, 106], ["the OC43 virus haemagglutination", "TREATMENT", 110, 142], ["rubella virus nonspecific HI inhibitors", "PROBLEM", 282, 321], ["positive", "OBSERVATION", 42, 50], ["OC43 virus", "OBSERVATION", 114, 124]]], ["Serial two-fold dilutions were then made in Dulbecco's phosphate buffered saline containing 0.4% BSA.", [["phosphate", "CHEMICAL", 55, 64], ["phosphate", "CHEMICAL", 55, 64], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 55, 80], ["BSA", "SIMPLE_CHEMICAL", 97, 100], ["Serial two-fold dilutions", "TREATMENT", 0, 25], ["Dulbecco's phosphate buffered saline", "TREATMENT", 44, 80]]], ["Rat erythrocytes (0.75%) in the same buffer were added and haemagglutination was scored after 90 minutes at room temperature.", [["Rat erythrocytes", "ANATOMY", 0, 16], ["Rat erythrocytes", "CELL", 0, 16], ["Rat erythrocytes", "CELL_TYPE", 0, 16], ["Rat", "SPECIES", 0, 3], ["Rat", "SPECIES", 0, 3], ["Rat erythrocytes", "TEST", 0, 16], ["haemagglutination", "TREATMENT", 59, 76]]], ["A titer of 1 :20 or greater was considered positive.Radial Diffusion Haemolysis-in-Gel TestOC43 antigen was kindly mounted in Orivir HIG plates by Mr. P. Heinonen and Mrs. T. ViEnEnen of Orion Diagnostica Ltd., Helsinki, according to published methods [VGninen et al, 1976; Riski et al, 19771 .", [["Radial Diffusion Haemolysis-in-Gel TestOC43 antigen", "PROTEIN", 52, 103], ["A titer", "TEST", 0, 7], ["positive", "PROBLEM", 43, 51], ["Radial Diffusion Haemolysis", "TEST", 52, 79], ["Gel TestOC43 antigen", "TEST", 83, 103], ["positive", "OBSERVATION", 43, 51], ["Diffusion Haemolysis", "OBSERVATION", 59, 79]]], ["Heat-inactivated sera (5 pl) were pipetted into the wells, and after 20 hours at 37\u00b0C the diameter of the haemolysis ring, if any, was measured with a ruler.", [["sera", "ANATOMY", 17, 21], ["haemolysis ring", "ANATOMY", 106, 121], ["haemolysis", "DISEASE", 106, 116], ["sera", "ORGANISM_SUBSTANCE", 17, 21], ["Heat-inactivated sera", "TREATMENT", 0, 21], ["the haemolysis ring", "TREATMENT", 102, 121], ["haemolysis ring", "OBSERVATION", 106, 121]]], ["The smallest haemolysis ring scored positive had a diameter of 2.5 mm.Solid-Phase RadioimmunoassayThe procedure used was an adaptation of previous assays [Kalimo et al, 1976 Arstila et al, 19771 with the iodinated antibodies against human Ig and the assay dilution buffers prepared as described more recently [Meurman and Ziola, 19781 .", [["haemolysis ring", "ANATOMY", 13, 28], ["haemolysis", "DISEASE", 13, 23], ["human", "ORGANISM", 233, 238], ["Ig", "GENE_OR_GENE_PRODUCT", 239, 241], ["iodinated antibodies", "PROTEIN", 204, 224], ["Ig", "PROTEIN", 239, 241], ["human", "SPECIES", 233, 238], ["human", "SPECIES", 233, 238], ["The smallest haemolysis ring", "TEST", 0, 28], ["Solid-Phase Radioimmunoassay", "TEST", 70, 98], ["The procedure", "TREATMENT", 98, 111], ["previous assays", "TEST", 138, 153], ["the iodinated antibodies", "TREATMENT", 200, 224], ["Ig", "TREATMENT", 239, 241], ["the assay dilution buffers", "TREATMENT", 246, 272], ["smallest", "OBSERVATION_MODIFIER", 4, 12], ["haemolysis ring", "OBSERVATION", 13, 28], ["diameter", "OBSERVATION_MODIFIER", 51, 59], ["2.5 mm", "OBSERVATION_MODIFIER", 63, 69]]], ["Briefly, OC43 virus antigen and control antigen were diluted in PBS and adsorbed on 6.4-mm-diameter polystyrene balls (Precision Plastic Ball Co., Chicago) at a concentration of 6 pg per ball.", [["polystyrene", "CHEMICAL", 100, 111], ["OC43 virus", "ORGANISM", 9, 19], ["OC43 virus antigen", "PROTEIN", 9, 27], ["OC43 virus", "SPECIES", 9, 19], ["OC43 virus antigen", "TEST", 9, 27], ["control antigen", "TREATMENT", 32, 47], ["6.4-mm-diameter polystyrene balls", "TREATMENT", 84, 117]]], ["After an overnight incubation at room temperature, unadsorbed antigen was removed and the balls were air-dried.", [["an overnight incubation", "TREATMENT", 6, 29], ["unadsorbed antigen", "TREATMENT", 51, 69]]], ["Serum dilutions (200 pl) in disposable plastic tubes were tested in duplicate with virus and control antigen balls.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum dilutions", "TEST", 0, 15], ["disposable plastic tubes", "TREATMENT", 28, 52], ["virus", "TREATMENT", 83, 88], ["tubes", "OBSERVATION", 47, 52]]], ["After 1 hour at 37\"C, unbound immunoglobulins were aspirated away and the balls were washed twice with 5 ml of tapwater.", [["immunoglobulins", "GENE_OR_GENE_PRODUCT", 30, 45], ["unbound immunoglobulins", "PROTEIN", 22, 45], ["unbound immunoglobulins", "TREATMENT", 22, 45], ["tapwater", "TREATMENT", 111, 119]]], ["'251-labeled antibodies against human IgC (heavy-chain-specific) were then added.", [["IgC", "CHEMICAL", 38, 41], ["human", "ORGANISM", 32, 37], ["IgC", "GENE_OR_GENE_PRODUCT", 38, 41], ["251-labeled antibodies", "PROTEIN", 1, 23], ["human IgC", "PROTEIN", 32, 41], ["heavy-chain", "PROTEIN", 43, 54], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["human IgC", "TREATMENT", 32, 41]]], ["After 1 hour at 37\"C, unbound iodinated antibodies were removed and the balls were again washed.", [["unbound iodinated antibodies", "PROTEIN", 22, 50], ["unbound iodinated antibodies", "TREATMENT", 22, 50], ["the balls", "TREATMENT", 68, 77]]], ["The balls were finally rolled into clean tubes, and bound radiolabel was counted in a Wallac LKB 1280 gamma counter.Solid-Phase RadioimmunoassayPreliminary tests revealed that specific IgG binding to the virus antigen-coated balls did not show a prozone at low dilutions.", [["prozone", "CHEMICAL", 246, 253], ["prozone", "CHEMICAL", 246, 253], ["IgG", "GENE_OR_GENE_PRODUCT", 185, 188], ["prozone", "SIMPLE_CHEMICAL", 246, 253], ["IgG", "PROTEIN", 185, 188], ["clean tubes", "TREATMENT", 35, 46], ["Solid-Phase RadioimmunoassayPreliminary tests", "TEST", 116, 161], ["specific IgG binding", "PROBLEM", 176, 196], ["the virus antigen", "TEST", 200, 217], ["clean tubes", "OBSERVATION", 35, 46]]], ["Consequently, all sera were tested at the single dilution of 1 :32 and the cpm difference between virus and control antigen balls was used as a semiquantitative measurement of the actual OC43 virus IgG levels.", [["sera", "ANATOMY", 18, 22], ["sera", "ORGANISM_SUBSTANCE", 18, 22], ["OC43", "GENE_OR_GENE_PRODUCT", 187, 191], ["IgG", "GENE_OR_GENE_PRODUCT", 198, 201], ["OC43", "PROTEIN", 187, 191], ["IgG", "PROTEIN", 198, 201], ["OC43 virus", "SPECIES", 187, 197], ["all sera", "TEST", 14, 22], ["virus and control antigen balls", "TREATMENT", 98, 129], ["a semiquantitative measurement", "TEST", 142, 172], ["the actual OC43 virus IgG levels", "TEST", 176, 208]]], ["The assay was standardzed in two ways.", [["The assay", "TEST", 0, 9]]], ["First, the absolute amount of iodinated antibodies against human IgG per tube was that needed to give 2,500 cpm bound when incubated for 1 hour at 37\u00b0C with a ball adsorbed with 5 pg of DEAE-Sepharose chromatography-purified human IgG.Solid-Phase RadioimmunoassaySecond, interassay variation was compensated for by relating the cpm difference of the serum specimens to that of a reference serum pool which was included in each assay, A binding difference of 100 cpm or greater was then taken to indicate seropositivity.Prevalence of Coronavirus Antibodies in Different Age GroupsSera from individuals of different ages were tested for the presence of coronavirus antibodies by the CF, HI, HIG, and RIA methods.", [["serum specimens", "ANATOMY", 350, 365], ["serum", "ANATOMY", 389, 394], ["DEAE", "CHEMICAL", 186, 190], ["human", "ORGANISM", 59, 64], ["IgG", "GENE_OR_GENE_PRODUCT", 65, 68], ["tube", "TISSUE", 73, 77], ["Sepharose", "SIMPLE_CHEMICAL", 191, 200], ["human", "ORGANISM", 225, 230], ["IgG", "GENE_OR_GENE_PRODUCT", 231, 234], ["serum specimens", "ORGANISM_SUBSTANCE", 350, 365], ["serum", "ORGANISM_SUBSTANCE", 389, 394], ["individuals", "ORGANISM", 589, 600], ["coronavirus", "ORGANISM", 651, 662], ["iodinated antibodies", "PROTEIN", 30, 50], ["human IgG", "PROTEIN", 59, 68], ["purified human IgG", "PROTEIN", 216, 234], ["Coronavirus Antibodies", "PROTEIN", 533, 555], ["coronavirus antibodies", "PROTEIN", 651, 673], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 225, 230], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 225, 230], ["Coronavirus", "SPECIES", 533, 544], ["coronavirus", "SPECIES", 651, 662], ["iodinated antibodies", "TREATMENT", 30, 50], ["human IgG per tube", "TREATMENT", 59, 77], ["a ball adsorbed", "TREATMENT", 157, 172], ["DEAE-Sepharose chromatography", "TREATMENT", 186, 215], ["interassay variation", "TEST", 271, 291], ["the serum specimens", "TEST", 346, 365], ["a reference serum pool", "TEST", 377, 399], ["seropositivity", "PROBLEM", 504, 518], ["Coronavirus Antibodies", "PROBLEM", 533, 555], ["coronavirus antibodies", "PROBLEM", 651, 673], ["the CF", "TEST", 677, 683], ["HI", "TEST", 685, 687], ["HIG", "TEST", 689, 692], ["RIA methods", "TEST", 698, 709], ["seropositivity", "OBSERVATION", 504, 518], ["Coronavirus Antibodies", "OBSERVATION", 533, 555]]], ["The percentage of individuals found positive in each of the age groups studied is shown in Figure 1 .", [["percentage", "OBSERVATION_MODIFIER", 4, 14], ["positive", "OBSERVATION", 36, 44]]], ["Only one of 20 infants 5 months of age or less had CF antibodies (titer of 1 :4) against the OC43 virus.", [["infants", "ORGANISM", 15, 22], ["OC43 virus", "ORGANISM", 93, 103], ["CF antibodies", "PROTEIN", 51, 64], ["infants", "SPECIES", 15, 22], ["OC43 virus", "SPECIES", 93, 103], ["CF antibodies", "TEST", 51, 64], ["the OC43 virus", "PROBLEM", 89, 103], ["OC43 virus", "OBSERVATION", 93, 103]]], ["Similarly, only one infant had an HI antibody titer of 1:20.", [["infant", "ORGANISM", 20, 26], ["infant", "SPECIES", 20, 26], ["an HI antibody titer", "TEST", 31, 51]]], ["In contrast, the HIG test and the RIA detected OC43 virus antibodies in sera from 8 (40%) and 18 (90%) of these infants, respectively.", [["sera", "ANATOMY", 72, 76], ["OC43", "GENE_OR_GENE_PRODUCT", 47, 51], ["sera", "ORGANISM_SUBSTANCE", 72, 76], ["infants", "ORGANISM", 112, 119], ["OC43 virus antibodies", "PROTEIN", 47, 68], ["infants", "SPECIES", 112, 119], ["OC43 virus", "SPECIES", 47, 57], ["the HIG test", "TEST", 13, 25], ["the RIA", "TEST", 30, 37], ["OC43 virus antibodies", "TEST", 47, 68], ["sera", "TEST", 72, 76]]], ["All 25 children in the two subsequent age groups (6-1 1 months and 12-23 months) were negative for OC43 virus antibodies in each of the four tests.Prevalence of Coronavirus Antibodies in Different Age Groupsprised of children 2 , 3 and 4, and 5 and 6 years old (Fig. 1) .", [["children", "ORGANISM", 7, 15], ["OC43", "GENE_OR_GENE_PRODUCT", 99, 103], ["children", "ORGANISM", 217, 225], ["OC43 virus antibodies", "PROTEIN", 99, 120], ["Coronavirus Antibodies", "PROTEIN", 161, 183], ["children", "SPECIES", 7, 15], ["children", "SPECIES", 217, 225], ["OC43 virus", "SPECIES", 99, 109], ["Coronavirus", "SPECIES", 161, 172], ["OC43 virus antibodies", "PROBLEM", 99, 120], ["the four tests", "TEST", 132, 146], ["Coronavirus Antibodies", "PROBLEM", 161, 183], ["Coronavirus Antibodies", "OBSERVATION", 161, 183]]], ["By the age of 6 years practically all children had antibodies against the OC43 virus as measured by the HlG test and the RIA.", [["children", "ORGANISM", 38, 46], ["OC43 virus", "ORGANISM", 74, 84], ["antibodies", "PROTEIN", 51, 61], ["children", "SPECIES", 38, 46], ["OC43 virus", "SPECIES", 74, 84], ["antibodies", "TREATMENT", 51, 61], ["the OC43 virus", "PROBLEM", 70, 84], ["the HlG test", "TEST", 100, 112]]], ["Slightly lower positive incidences were obtained with the CF and HI tests.", [["Slightly lower positive incidences", "PROBLEM", 0, 34], ["the CF and HI tests", "TEST", 54, 73], ["lower", "OBSERVATION_MODIFIER", 9, 14], ["positive", "OBSERVATION", 15, 23]]], ["The high frequency of antibody positivity seen by age 6 years was sustained through older age groups up to the age of 60 years: thereafter, a tendency for the frequency to decline was observed.Coronavirus Antibody Levels in Different Age GroupsA rapid increase in the antibody prevalence was observed in the three age groups com-The mean OC43 virus antibody levels were calculated for each age group and are shown in Figure 2 .", [["OC43 virus", "ORGANISM", 338, 348], ["OC43 virus", "SPECIES", 338, 348], ["antibody positivity", "PROBLEM", 22, 41], ["Coronavirus Antibody Levels", "TEST", 193, 220], ["rapid increase", "PROBLEM", 246, 260], ["the antibody prevalence", "TEST", 264, 287], ["The mean OC43 virus antibody levels", "TEST", 329, 364], ["high", "OBSERVATION_MODIFIER", 4, 8], ["rapid", "OBSERVATION_MODIFIER", 246, 251], ["increase", "OBSERVATION_MODIFIER", 252, 260]]], ["The mean antibody titers measured by both the CF and Hl test were low, since titers higher than 1:8 in the CF test or 1:40 in the HI test were uncommon.", [["The mean antibody titers", "TEST", 0, 24], ["Hl test", "TEST", 53, 60], ["titers", "TEST", 77, 83], ["the CF test", "TEST", 103, 114]]], ["In contrast, a much greater variation in antibody levels was seen if the HIG test or the RIA were used.Coronavirus Antibody Levels in Different Age Groupstinctive pattern for each of the four antibody assays (Fig. 2) .", [["a much greater variation in antibody levels", "PROBLEM", 13, 56], ["the HIG test", "TEST", 69, 81], ["the RIA", "TREATMENT", 85, 92], ["Coronavirus Antibody Levels", "TEST", 103, 130], ["the four antibody assays", "TEST", 183, 207]]], ["The highest CF titers were found between ages 3 and 9 years, after which there was a slight tendency for the mean titers to decrease.", [["The highest CF titers", "TEST", 0, 21], ["a slight tendency", "PROBLEM", 83, 100], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["slight", "OBSERVATION_MODIFIER", 85, 91], ["tendency", "OBSERVATION_MODIFIER", 92, 100]]], ["Mean titers obtained by the HI test steadily increased up to the group 10-14 years old and then remained constant until a drop was seen in the over 60 age group.", [["Mean titers", "TEST", 0, 11], ["the HI test", "TEST", 24, 35]]], ["A similar pattern of mean antibody levels was obtained with the HIG test.", [["mean antibody levels", "TEST", 21, 41], ["the HIG test", "TEST", 60, 72], ["mean antibody", "OBSERVATION", 21, 34]]], ["The change of the mean antibody curve from the increase-phase to the plateau-phase at the age group 10 to 14 years was much more distinct for the HIG test than for the HI test, owing to the greater antibody range measured with the HIG test.", [["the mean antibody curve", "TEST", 14, 37], ["the HIG test", "TEST", 142, 154], ["the HI test", "TEST", 164, 175], ["the HIG test", "TEST", 227, 239], ["mean", "OBSERVATION_MODIFIER", 18, 22], ["antibody curve", "OBSERVATION", 23, 37], ["increase", "OBSERVATION_MODIFIER", 47, 55]]], ["An apparently biphasic mean antibody curve was obtained with the RIA.", [["An apparently biphasic mean antibody curve", "TEST", 0, 42]]], ["The mean antibody level increased sharply with children 24-35 months old and then plateaued for the 3to 10-year-olds.", [["children", "SPECIES", 47, 55], ["The mean antibody level", "TEST", 0, 23]]], ["A second increase in the mean antibody levels was then observed after 10 years of age.Coronavirus Antibody Levels in Different Age GroupsThe mean OC43 antibody levels of the different age groups were found to form a dis-DISCUSSIONSeveral points concerning the present results deserve comment.", [["OC43 antibody", "GENE_OR_GENE_PRODUCT", 146, 159], ["OC43 antibody", "PROTEIN", 146, 159], ["A second increase", "PROBLEM", 0, 17], ["the mean antibody levels", "TEST", 21, 45], ["Coronavirus Antibody Levels", "TEST", 86, 113], ["The mean OC43 antibody levels", "TEST", 137, 166], ["second", "OBSERVATION_MODIFIER", 2, 8], ["increase", "OBSERVATION_MODIFIER", 9, 17], ["mean antibody", "OBSERVATION", 25, 38]]], ["It is obvious that coronavirus infections are widespread in Finland, as essentially everyone older than 5 years had measurable antibodies against the OC43 virus antigen.", [["coronavirus infections", "DISEASE", 19, 41], ["coronavirus", "ORGANISM", 19, 30], ["OC43 virus", "ORGANISM", 150, 160], ["antibodies", "PROTEIN", 127, 137], ["OC43 virus antigen", "PROTEIN", 150, 168], ["OC43 virus", "SPECIES", 150, 160], ["coronavirus infections", "PROBLEM", 19, 41], ["measurable antibodies", "PROBLEM", 116, 137], ["the OC43 virus antigen", "PROBLEM", 146, 168], ["obvious that", "UNCERTAINTY", 6, 18], ["coronavirus", "OBSERVATION_MODIFIER", 19, 30], ["infections", "OBSERVATION", 31, 41], ["widespread", "OBSERVATION_MODIFIER", 46, 56], ["OC43 virus", "OBSERVATION", 150, 160]]], ["In light of this, the complete lack of coronavirus antibodies in the 6to 23-month-olds was an unexpected finding.", [["coronavirus", "ORGANISM", 39, 50], ["coronavirus antibodies", "PROTEIN", 39, 61], ["coronavirus antibodies", "TEST", 39, 61], ["coronavirus antibodies", "OBSERVATION", 39, 61]]], ["This observation may be explained by two different epidemiologic situations: Either children younger than 2 years do not contact coronavirus infections or, more likely, there has been very little coronavirus circulation in Finland during the last two years.", [["coronavirus infections", "DISEASE", 129, 151], ["children", "ORGANISM", 84, 92], ["coronavirus", "ORGANISM", 129, 140], ["coronavirus", "ORGANISM", 196, 207], ["children", "SPECIES", 84, 92], ["coronavirus infections", "PROBLEM", 129, 151], ["very", "OBSERVATION_MODIFIER", 184, 188], ["little", "OBSERVATION_MODIFIER", 189, 195], ["coronavirus", "OBSERVATION", 196, 207]]], ["If the latter is true, sera collected some years ago from children younger than 2 years (ie, from the age-mates of the 5-to 6-DISCUSSIONyear-old children of this study) should possess coronavirus antibodies much more frequently than was found for the 6t o 23-month-olds in this study.", [["sera", "ANATOMY", 23, 27], ["sera", "ORGANISM_SUBSTANCE", 23, 27], ["children", "ORGANISM", 58, 66], ["children", "ORGANISM", 145, 153], ["coronavirus", "ORGANISM", 184, 195], ["coronavirus antibodies", "PROTEIN", 184, 206], ["children", "SPECIES", 58, 66], ["children", "SPECIES", 145, 153], ["coronavirus", "SPECIES", 184, 195], ["this study", "TEST", 157, 167], ["coronavirus antibodies", "PROBLEM", 184, 206], ["this study", "TEST", 273, 283]]], ["This question will be answered as soon as appropriate specimens have been assembled from various serum archives.DISCUSSIONAnother epidemiologic question arises when the age group plots of antibody frequency and the mean antibody levels are compared.", [["specimens", "ANATOMY", 54, 63], ["serum", "ANATOMY", 97, 102], ["specimens", "CANCER", 54, 63], ["serum", "ORGANISM_SUBSTANCE", 97, 102], ["antibody frequency", "TEST", 188, 206], ["the mean antibody levels", "TEST", 211, 235]]], ["While the antibody frequency curve reaches a maximum at about 6 years, the mean antibody levels continue to increase up to the 10-14 years group.", [["the antibody frequency curve", "TEST", 6, 34], ["the mean antibody levels", "TEST", 71, 95]]], ["This difference can readily be seen with the HIG test results and is particularly evident with the RIA results owing to the biphasic nature of the mean antibody level curve.DISCUSSIONIt has been suggested that the OC43 virus typically infects preschool children while the 229E strain is more frequently associated with infections of adolescents and young adults [Bradburne and Tyrrell, 19711 .", [["infections", "DISEASE", 319, 329], ["OC43 virus", "ORGANISM", 214, 224], ["children", "ORGANISM", 253, 261], ["children", "SPECIES", 253, 261], ["adolescents", "SPECIES", 333, 344], ["OC43 virus", "SPECIES", 214, 224], ["the HIG test", "TEST", 41, 53], ["the RIA", "TEST", 95, 102], ["the mean antibody level curve", "TEST", 143, 172], ["the OC43 virus", "PROBLEM", 210, 224], ["the 229E strain", "PROBLEM", 268, 283]]], ["If this is true, the two rapid increases in the RIA mean antibody The number of sera tested was 18 or more in each age group, except for the groups 6-11 months and 12-23 months of age, where the number of specimens was 15 and 10, respectively.", [["sera", "ANATOMY", 80, 84], ["specimens", "ANATOMY", 205, 214], ["sera", "ORGANISM_SUBSTANCE", 80, 84], ["specimens", "CANCER", 205, 214], ["RIA mean antibody", "PROTEIN", 48, 65], ["the two rapid increases", "PROBLEM", 17, 40], ["the RIA mean antibody", "TEST", 44, 65], ["sera tested", "TEST", 80, 91], ["specimens", "TEST", 205, 214], ["rapid", "OBSERVATION_MODIFIER", 25, 30], ["increases", "OBSERVATION_MODIFIER", 31, 40]]], ["HI) haemagglutina tion inhibition; CF) complement fixation; HIG) radial diffusion haemolysis-in-gel; RIA) solid-phase radioimmunoassay.DISCUSSION15 25 40 60 '12 I 2 3 5 7 1 0 20 30 50 AGE (YEARS) Fig. 2 .", [["HI) haemagglutina tion inhibition", "TREATMENT", 0, 33], ["complement fixation", "TREATMENT", 39, 58], ["HIG", "TEST", 60, 63], ["radial diffusion haemolysis", "TEST", 65, 92], ["RIA) solid-phase radioimmunoassay", "TEST", 101, 134]]], ["Mean levels of OC43-related coronavirus antibodies in different age groups.", [["OC43", "GENE_OR_GENE_PRODUCT", 15, 19], ["coronavirus", "ORGANISM", 28, 39], ["OC43", "PROTEIN", 15, 19], ["coronavirus antibodies", "PROTEIN", 28, 50], ["coronavirus", "SPECIES", 28, 39], ["Mean levels", "TEST", 0, 11], ["OC43", "TEST", 15, 19], ["coronavirus antibodies", "PROBLEM", 28, 50], ["OC43", "OBSERVATION", 15, 19], ["coronavirus antibodies", "OBSERVATION", 28, 50]]], ["Two top panels show the geometric means of HI and C F titres, respectively.", [["C F", "GENE_OR_GENE_PRODUCT", 50, 53], ["Two top panels", "TEST", 0, 14]]], ["In the HIG, an arithmetic mean of the diameters of hemolysis rings (mm) induced by individual sera is shown for each age group.", [["sera", "ANATOMY", 94, 98], ["hemolysis", "DISEASE", 51, 60], ["sera", "ORGANISM_SUBSTANCE", 94, 98], ["hemolysis rings", "PROBLEM", 51, 66], ["individual sera", "TEST", 83, 98], ["diameters", "OBSERVATION_MODIFIER", 38, 47], ["hemolysis rings", "OBSERVATION", 51, 66]]], ["In the RIA, all sera were tested a t a single dilution (1:32) and bound I was quantitated by '211-labeled antihuman Ig.", [["sera", "ANATOMY", 16, 20], ["sera", "ORGANISM_SUBSTANCE", 16, 20], ["antihuman", "ORGANISM", 106, 115], ["Ig", "GENE_OR_GENE_PRODUCT", 116, 118], ["antihuman Ig", "PROTEIN", 106, 118], ["RIA", "ANATOMY", 7, 10]]], ["For further details see Methods. levels could be due t o two age-related coronavirus epidemics.", [["coronavirus epidemics", "DISEASE", 73, 94], ["coronavirus", "ORGANISM", 73, 84], ["levels", "TEST", 33, 39], ["coronavirus epidemics", "PROBLEM", 73, 94], ["coronavirus epidemics", "OBSERVATION", 73, 94]]], ["It is more likely, however, that the second epidemic wave was not caused by the 229E virus, but by a third human coronavirus strain, since cross-reactions between the OC43 and 229E strains were not very strong in the RIA.", [["229E virus", "ORGANISM", 80, 90], ["human", "ORGANISM", 107, 112], ["coronavirus strain", "ORGANISM", 113, 131], ["OC43", "GENE_OR_GENE_PRODUCT", 167, 171], ["human", "SPECIES", 107, 112], ["coronavirus", "SPECIES", 113, 124], ["229E virus", "SPECIES", 80, 90], ["human coronavirus", "SPECIES", 107, 124], ["the 229E virus", "PROBLEM", 76, 90], ["a third human coronavirus strain", "PROBLEM", 99, 131], ["cross-reactions", "TEST", 139, 154], ["the OC43", "TEST", 163, 171], ["229E strains", "TEST", 176, 188], ["more likely", "UNCERTAINTY", 6, 17], ["coronavirus strain", "OBSERVATION", 113, 131], ["OC43", "ANATOMY", 167, 171]]], ["For instance, we found several sera with relatively high antibody levels against the 229E virus which did not react at all with OC43 virus antigen-coated balls and vice versa (unpublished results).", [["sera", "ANATOMY", 31, 35], ["sera", "ORGANISM_SUBSTANCE", 31, 35], ["229E virus", "ORGANISM", 85, 95], ["OC43 virus antigen", "PROTEIN", 128, 146], ["229E virus", "SPECIES", 85, 95], ["OC43 virus", "SPECIES", 128, 138], ["several sera", "TEST", 23, 35], ["relatively high antibody levels", "PROBLEM", 41, 72], ["the 229E virus", "PROBLEM", 81, 95], ["OC43 virus antigen", "TEST", 128, 146]]], ["It is also possible, of course, that the second sharp mean antibody increase seen with the RIA results is simply due to reinfection by the OC43 virus strain.DISCUSSIONThe present results provide further evidence of the presence in sera of nonspecific inhibitors of coronavirus haemagglutination [Hovi, 19781 .", [["sera", "ANATOMY", 231, 235], ["Hovi, 19781", "CHEMICAL", 296, 307], ["OC43 virus", "ORGANISM", 139, 149], ["sera", "ORGANISM_SUBSTANCE", 231, 235], ["coronavirus", "ORGANISM", 265, 276], ["coronavirus", "SPECIES", 265, 276], ["OC43 virus", "SPECIES", 139, 149], ["the second sharp mean antibody increase", "PROBLEM", 37, 76], ["the RIA", "TEST", 87, 94], ["reinfection", "PROBLEM", 120, 131], ["the OC43 virus strain", "PROBLEM", 135, 156], ["nonspecific inhibitors", "PROBLEM", 239, 261], ["coronavirus haemagglutination", "PROBLEM", 265, 294], ["also possible", "UNCERTAINTY", 6, 19], ["sharp", "OBSERVATION_MODIFIER", 48, 53], ["reinfection", "OBSERVATION", 120, 131], ["OC43 virus", "OBSERVATION", 139, 149]]], ["For example, most of the sera of children 6-23 months of age negative in the RIA all had a moderate titer in the HI test if the sera were not pretreated before testing (data not shown).", [["sera", "ANATOMY", 25, 29], ["sera", "ANATOMY", 128, 132], ["sera", "ORGANISM_SUBSTANCE", 25, 29], ["children", "ORGANISM", 33, 41], ["sera", "ORGANISM_SUBSTANCE", 128, 132], ["children", "SPECIES", 33, 41], ["a moderate titer", "PROBLEM", 89, 105], ["the HI test", "TEST", 109, 120], ["the sera", "TEST", 124, 132], ["testing (data", "TEST", 160, 173]]], ["The phospholipase C treatment does not, however, completely remove the nonspecific inhibitors, since all children 6-23 months of age had an apparent HI titer of 1 :10 even after treatment.", [["phospholipase C", "GENE_OR_GENE_PRODUCT", 4, 19], ["children", "ORGANISM", 105, 113], ["phospholipase C", "PROTEIN", 4, 19], ["children", "SPECIES", 105, 113], ["The phospholipase C treatment", "TREATMENT", 0, 29], ["the nonspecific inhibitors", "TREATMENT", 67, 93], ["treatment", "TREATMENT", 178, 187]]], ["An important aspect of the present study concerns the comparison of the different serologic methods employed.", [["the present study", "TEST", 23, 40]]], ["The HI test has been used relatively widely for serologic screening of OC43 virus antibodies.", [["OC43 virus", "ORGANISM", 71, 81], ["OC43 virus antibodies", "PROTEIN", 71, 92], ["OC43 virus", "SPECIES", 71, 81], ["The HI test", "TEST", 0, 11], ["serologic screening", "TEST", 48, 67], ["OC43 virus antibodies", "PROBLEM", 71, 92]]], ["Rooster red blood cells were originally used in our labora-tory to titer the virus haemagglutinin [Riski and Estola, 19741 .", [["red blood cells", "ANATOMY", 8, 23], ["blood cells", "CELL", 12, 23], ["virus haemagglutinin", "ORGANISM", 77, 97], ["Rooster red blood cells", "CELL_TYPE", 0, 23], ["Rooster red blood cells", "PROBLEM", 0, 23], ["Estola", "TEST", 109, 115], ["blood cells", "OBSERVATION", 12, 23]]], ["Large variation in the sensitivity of erythrocytes from different birds was subsequently found, however, and a change to rat erythrocytes was made [Hovi, 1978 ; also see Kaye and Dowdle, 1969 1.DISCUSSIONUse of rat erythrocytes and phospholipase C pretreatment of the sera has resulted in a more accurate and reproducible test [Hovi, 19781 .DISCUSSIONAlthough most of the individuals in the present study had coronavirus OC43 HI antibodies, the titers were low, suggesting that most of the OC43 infections had occurred some time before.", [["erythrocytes", "ANATOMY", 38, 50], ["erythrocytes", "ANATOMY", 125, 137], ["erythrocytes", "ANATOMY", 215, 227], ["sera", "ANATOMY", 268, 272], ["infections", "DISEASE", 495, 505], ["erythrocytes", "CELL", 38, 50], ["birds", "ORGANISM", 66, 71], ["rat", "ORGANISM", 121, 124], ["erythrocytes", "CELL", 125, 137], ["rat", "ORGANISM", 211, 214], ["erythrocytes", "CELL", 215, 227], ["phospholipase C", "GENE_OR_GENE_PRODUCT", 232, 247], ["sera", "ORGANISM_SUBSTANCE", 268, 272], ["individuals", "ORGANISM", 372, 383], ["coronavirus", "ORGANISM", 409, 420], ["OC43", "ORGANISM", 490, 494], ["erythrocytes", "CELL_TYPE", 38, 50], ["rat erythrocytes", "CELL_TYPE", 121, 137], ["rat erythrocytes", "CELL_TYPE", 211, 227], ["phospholipase C", "PROTEIN", 232, 247], ["coronavirus OC43 HI antibodies", "PROTEIN", 409, 439], ["rat", "SPECIES", 121, 124], ["rat", "SPECIES", 211, 214], ["coronavirus", "SPECIES", 409, 420], ["rat", "SPECIES", 121, 124], ["rat", "SPECIES", 211, 214], ["OC43", "SPECIES", 421, 425], ["OC43", "SPECIES", 490, 494], ["Large variation", "PROBLEM", 0, 15], ["the sensitivity of erythrocytes", "PROBLEM", 19, 50], ["a change to rat erythrocytes", "PROBLEM", 109, 137], ["rat erythrocytes", "PROBLEM", 211, 227], ["phospholipase C pretreatment", "TREATMENT", 232, 260], ["the sera", "TEST", 264, 272], ["coronavirus OC43 HI antibodies", "TEST", 409, 439], ["the titers", "TEST", 441, 451], ["the OC43 infections", "PROBLEM", 486, 505], ["variation", "OBSERVATION_MODIFIER", 6, 15], ["OC43", "OBSERVATION_MODIFIER", 490, 494], ["infections", "OBSERVATION", 495, 505]]], ["The low HI titers in the present sera thus were in contrast to the moderately high OC43 virus H1 titers of 1 : 160 to 1 :320 that have been found more recently in some convalescent sera.", [["sera", "ANATOMY", 33, 37], ["sera", "ANATOMY", 181, 185], ["sera", "ORGANISM_SUBSTANCE", 33, 37], ["OC43 virus H1", "ORGANISM", 83, 96], [":320", "GENE_OR_GENE_PRODUCT", 120, 124], ["sera", "ORGANISM_SUBSTANCE", 181, 185], ["OC43 virus H1", "SPECIES", 83, 96], ["The low HI titers", "PROBLEM", 0, 17], ["the moderately high OC43 virus H1 titers", "PROBLEM", 63, 103], ["low HI", "OBSERVATION_MODIFIER", 4, 10], ["moderately", "OBSERVATION_MODIFIER", 67, 77], ["high", "OBSERVATION_MODIFIER", 78, 82], ["OC43 virus", "OBSERVATION", 83, 93]]], ["Titer variation found with the OC43 virus CF test was similar to that found with the HI test.", [["OC43 virus", "SPECIES", 31, 41], ["Titer variation", "TEST", 0, 15], ["the OC43 virus CF test", "TEST", 27, 49], ["the HI test", "TEST", 81, 92]]], ["The majority of the sera had CF antibodies, but titers higher than 1: 16 were rare.", [["sera", "ANATOMY", 20, 24], ["sera", "ORGANISM_SUBSTANCE", 20, 24], ["CF antibodies", "PROTEIN", 29, 42], ["the sera", "TEST", 16, 24], ["CF antibodies", "TEST", 29, 42], ["titers", "TEST", 48, 54]]], ["As in the case of HI antibodies, titers as high as 1 : 128 or 1 :256 have been measured in certain convalescent sera.DISCUSSIONMuch greater variation in OC43 virus antibody levels was found when the HIG or RIA methods were used.", [["sera", "ANATOMY", 112, 116], ["HI antibodies", "GENE_OR_GENE_PRODUCT", 18, 31], ["sera", "ORGANISM_SUBSTANCE", 112, 116], ["OC43", "GENE_OR_GENE_PRODUCT", 153, 157], ["HI antibodies", "PROTEIN", 18, 31], ["OC43 virus antibody", "PROTEIN", 153, 172], ["OC43 virus", "SPECIES", 153, 163], ["HI antibodies", "TEST", 18, 31], ["titers", "TEST", 33, 39], ["greater variation", "PROBLEM", 132, 149], ["OC43 virus antibody levels", "TEST", 153, 179], ["the HIG", "TEST", 195, 202], ["RIA methods", "TREATMENT", 206, 217], ["OC43 virus", "OBSERVATION", 153, 163]]], ["This probably is a reflection of the greater sensitivity of these two methods compared to the HI and CF tests.", [["the HI and CF tests", "TEST", 90, 109], ["greater", "OBSERVATION_MODIFIER", 37, 44]]], ["It is also possible that the HIG test and the RIA detect antibodies against more of the OC43 virus antigens than do the two older serologic methods.", [["OC43 virus", "ORGANISM", 88, 98], ["antibodies", "PROTEIN", 57, 67], ["OC43 virus antigens", "PROTEIN", 88, 107], ["OC43 virus", "SPECIES", 88, 98], ["the HIG test", "TEST", 25, 37], ["the RIA detect antibodies", "TEST", 42, 67], ["the OC43 virus antigens", "PROBLEM", 84, 107], ["also possible", "UNCERTAINTY", 6, 19]]], ["Consequently, apart from usefulness in seroepidemiologic surveys such as the present one, the HIG and RIA methods may also be valuable tools in the diagnosis of acute coronavirus infections.", [["coronavirus infections", "DISEASE", 167, 189], ["coronavirus", "ORGANISM", 167, 178], ["seroepidemiologic surveys", "TEST", 39, 64], ["the HIG and RIA methods", "TEST", 90, 113], ["acute coronavirus infections", "PROBLEM", 161, 189], ["acute", "OBSERVATION_MODIFIER", 161, 166], ["coronavirus", "OBSERVATION", 167, 178]]], ["Preliminary application of these two assays in this regard has yielded very promising results.", [["these two assays", "TEST", 27, 43]]]], "29d776d7a6f03cf59887534629dcbe5014f09aed": [["BackgroundThe emergence of online consumer geoinformatics services Mainstream Web search engines like Google http:// www.google.com/ and MSN Search http:// search.msn.com/ have recently joined the geographic search bandwagon by releasing their own dedicated geographic interfaces, which run in standard Web browsers and also provide the general public with detailed satellite imagery/aerial photography map layers that were once only available to experts and select user communities.Google Maps and Google EarthGoogle released Google Maps (http://maps.google.com/ -a localized UK version is also available; see, for example, Paddington Station, London, W2 1RH (Satellite): http:maps.google.co.uk/maps?q=paddington+sta tion&spn=0.018368,0.039669&t=k&hl=en).", [["UK", "GENE_OR_GENE_PRODUCT", 577, 579], ["Google Maps", "DNA", 527, 538], ["Google Maps", "TEST", 483, 494]]], ["Google also released Google Earth http://earth.google.com/, a fat client, standalone 3D (three-dimensional) desktop application that offers anyone with Internet access a planet's worth of imagery and other geographic information, allowing users to virtually sightsee exotic locales like Paris, France, and Maui (Hawaii), Grand Canyon and Niagara Falls in the USA, as well as viewing points of interest such as local restaurants, hospitals, schools, and more.", [["fat", "TISSUE", 62, 65], ["standalone 3D", "TREATMENT", 74, 87]]], ["Google Earth uses KML (Keyhole Markup Language) to store data [1] .Google Maps and Google Earth(It is noteworthy that NASA is also offering its own World Wind 3D application http://worldwind.arc.nasa.gov/ that lets users zoom from satellite altitude into any place on Earth.)", [["Google Maps", "TEST", 67, 78]]], ["Thanks to Google Maps API (Application Programming Interface -http://www.google.com/apis/maps/), many third party applications and custom annotated maps have begun to appear [2] .", [["custom annotated maps", "TEST", 131, 152]]], ["Two good UK examples of such applications/custom annotated maps are the Health QOF (Quality and Outcomes Framework) Database map http:/ /www.gpcontract.co.uk/map.html and London July 2005 Terrorist Attacks map http://geepster.com/london.php.", [["such applications", "TREATMENT", 24, 41], ["Database map", "TEST", 116, 128], ["Attacks", "PROBLEM", 198, 205]]], ["(But because Google Maps has its roots in XML (eXtensible Markup Language), users were also able to produce their own custom annotated Google maps, e.g., based on their own GPS (Global Positioning System) locational data, and to even tie in images and video to create interactive multimedia maps, well before the API was publicly documented [3] .)", [["Google maps", "DNA", 135, 146], ["Google maps", "TEST", 135, 146], ["locational data", "TEST", 205, 220]]], ["Smugmug, a photo hosting Web site, plots geocoded photographs to their actual locations on Google Maps (or Google Earth via a KML Google Earth feed: http:www.smugmug.com/hacfeed.mg?Type=geoAll&for-mat=kml20&Size=Tiny), and allows location-based searching of photographs all over the world [4] .", [["Google Maps", "TEST", 91, 102]]], ["All smugmug RSS (Really Simple Syndication) feeds are now geoenabled.", [["All smugmug RSS", "TREATMENT", 0, 15], ["Simple Syndication) feeds", "TREATMENT", 24, 49]]], ["Maps http://maps.yahoo.com/ and http://maps.yahoo.net/ and an associated API http://developer.yahoo.net/maps/.", [["Maps http://maps.yahoo.com/ and http://maps.yahoo.net/", "PROBLEM", 0, 54]]], ["Maps service does not offer any satellite imagery/aerial photography, but this might change in the near future.", [["aerial photography", "TEST", 50, 68]]], ["Maps.", [["Maps", "TEST", 0, 4]]], ["Maps API.Web browser toolbars and other developmentsDedicated Web browser toolbars and extensions have also started to appear, e.g., MutantMaps http://www.mutant design.co.uk/maps/help.htm, a Mozilla Firefox toolbar that allows navigation between five popular mapping sites (Google Maps, MSN Virtual Earth, MultiMap.co.uk, TerraServer.com and 192.com) while preserving user's longitude, latitude and zoom levels, and gMapIt, another Mozilla Firefox extension that allows users to find directions from Google Maps based on publicly listed US phone numbers http://www.gmacker.com/web/content/ mapit/mapit.htm.Web browser toolbars and other developmentsAlong the same vein, Amazon.com is now also providing A9 Block View http://a9.com/-/company/Yellow Pages.jsp, an online Yellow Pages/map service that offers US maps with street-level photos.ESRI's responseSome commentators have recently wondered if users will soon eschew ArcGIS and ArcIMS (see http:// www.esri.com/software/arcgis/index.html and http:// www.esri.com/software/arcgis/arcims/index.html) in favour of using Google Maps API and MSN Virtual Earth API to quickly create Web map applications.", [["vein", "ANATOMY", 665, 669], ["vein", "MULTI-TISSUE_STRUCTURE", 665, 669], ["TerraServer.com", "DNA", 323, 338], ["Maps API", "TEST", 0, 8], ["a Mozilla Firefox toolbar", "TREATMENT", 190, 215], ["MultiMap.co.uk", "TEST", 307, 321], ["latitude and zoom levels", "TEST", 387, 411], ["gMapIt", "TREATMENT", 417, 423], ["another Mozilla Firefox extension", "TREATMENT", 425, 458], ["US maps", "TEST", 807, 814], ["Web map applications", "TREATMENT", 1132, 1152], ["same vein", "ANATOMY", 660, 669]]], ["ESRI's response to all of the recent online consumer geoinformatics services described in this article was to announce (in 2005) its new partnership with National Geographic http://www.nationalgeographic.com/, GlobeXplorer http://www.globexplorer.com/, and TeleAtlas http:// www.teleatlas.com/, plus Geospatial One Stop (GOShttp://www.geo-one-stop.gov/) and a few other partners like MDA (MacDonald, Dettwiler and Associates Ltd.http://www.mda.ca/), to upgrade the National Geographic MapMachine http://plasma.nationalgeo graphic.com/mapmachine/, a map service/online atlas that provides global map coverage for an extensive set of Earth science themes.", [["MDA", "CHEMICAL", 384, 387], ["MDA", "CHEMICAL", 384, 387], ["MDA", "SIMPLE_CHEMICAL", 384, 387], ["mapmachine", "DNA", 534, 544], ["global map coverage", "TREATMENT", 588, 607]]], ["MapMachine was first launched in November 1999, and is powered by ESRI's ArcWeb Services http://www.esri.com/software/arcwebservices/.", [["MapMachine", "TREATMENT", 0, 10]]], ["The planned upgrade aims at bringing satellite imagery, aerial photos, and street-level data to MapMachine users.", [["aerial photos", "TEST", 56, 69]]], ["The next generation of MapMachine will also provide a link to GOS data and metadata to help users discover information about their area of interest or study.", [["MapMachine", "SIMPLE_CHEMICAL", 23, 33], ["MapMachine", "TREATMENT", 23, 33]]], ["MapMachine will include capabilities for 3D globe services, allowing GIS users to \"pull in\" their own map services to overlay onto a globe.", [["MapMachine", "TREATMENT", 0, 10], ["3D globe services", "TREATMENT", 41, 58], ["globe", "ANATOMY", 133, 138]]], ["Also planned is the addition of ESRI's MapStudio http:// www.mapstudio.com/, an ArcWeb Services application used by many daily newspapers to create maps for printing, to enable users to create customised maps [7] .MethodsWe wanted to experiment with the programmable interfaces provided by Google and MSN by mapping the headquarters locations of England's 28 Strategic Health Authorities (SHA), and associating these locations on the resultant maps with relevant online information about the corresponding SHAs from England's National Health Service (NHS) Web site http://www.nhs.uk/England/ AuthoritiesTrusts/Sha/list.aspx.GeocodingThe programmable mapping interfaces provided by Google and MSN currently only accept longitude and latitude coordinates and do not provide their own geocoding services.", [["Sha", "PROTEIN", 610, 613], ["ESRI", "TREATMENT", 32, 36], ["The programmable mapping interfaces", "TREATMENT", 633, 668]]], ["The worldKit geocoder http://brainoff.com/geocoder/, a free online worldwide city geocoder, also uses jibble.org list for UK postcode geocoding.Google Maps API version of our SHA mapGuided by Google Maps API online documentation http:/ /www.google.com/apis/maps/documentation/ and Gottipati's online tutorial [6] , we produced the Google Maps API version of our interactive SHA map.", [["brainoff.com/geocoder/", "TREATMENT", 29, 51]]], ["Google Maps API lets developers embed Google Maps in their own Web pages with JavaScript.Google Maps API version of our SHA mapWe had to first visit Google's sign-up page http:// www.google.com/apis/maps/signup.html to get a free API key for the Web site where our maps were to be published.", [["Web site", "DNA", 246, 254], ["our maps", "TEST", 261, 269]]], ["The map features all the standard Google Maps controls for zooming, panning (also possible by dragging the map), and displaying/switching satellite and hybrid views.", [["The map features", "TEST", 0, 16], ["zooming, panning", "TREATMENT", 59, 75]]], ["The inset shows an example of the tooltips that appear when the mouse hovers over the markers (or pins) on the map.Google Earth KML version of our SHA mapThe development of the Google Earth KML version of our maps was again guided by Google's online documentation available at http://code.google.com/apis.html#earth.", [["mouse", "ORGANISM", 64, 69], ["mouse", "SPECIES", 64, 69], ["mouse", "SPECIES", 64, 69], ["The inset", "TREATMENT", 0, 9], ["the tooltips", "TREATMENT", 30, 42], ["the map", "TEST", 107, 114], ["our SHA map", "TREATMENT", 143, 154], ["our maps", "TEST", 205, 213]]], ["KML is an XML-based language.", [["language", "OBSERVATION", 20, 28]]], ["A new MIME (Multipurpose Internet Mail Extensions) type (application/ vnd.google-earth.kml+xml kml) must be added to the server hosting the KML feed file to help client Web browsers like Internet Explorer associate the file with the appropriate client application (Google Earth) rather than opening it as a plain XML file.MSN Virtual Earth Map Control version of our SHA mapFinally, we created a third version of our maps using MSN Virtual Earth Map Control (download control at http:// virtualearth.msn.com/js/MapControl.js), and guided by Part 1 of Roodyn's excellent tutorial available from Via Virtual Earth, Virtual Earth developer resource centre http:/ /www.viavirtualearth.com/ [8] .MSN Virtual Earth Map Control version of our SHA mapIt should be noted that not all possible features of the programmable mapping interfaces provided by Google and MSN have been explored or demonstrated in our exercise and its outputs (see 'Results' below).", [["earth.kml", "DNA", 81, 90], ["xml kml", "PROTEIN", 91, 98], ["A new MIME (Multipurpose Internet Mail Extensions", "TREATMENT", 0, 49], ["Virtual Earth Map Control (download control", "TREATMENT", 432, 475], ["Virtual Earth Map", "TREATMENT", 695, 712], ["our SHA map", "TREATMENT", 732, 743], ["new", "OBSERVATION_MODIFIER", 2, 5]]], ["For example, it is also possible to add VML (Vector Markup Language) polyline overlays to maps created using Google Maps API.", [["maps", "TEST", 90, 94], ["Google Maps API", "TEST", 109, 124]]], ["This is all part of what Dangermond describes as a \"geodata-rich society\" that will have access to more geospatial information of all kinds, including, in addition to imagery, GPS/location data, geo-demographic data, and data from real-time monitoring [10] .", [["GPS/location data", "TEST", 176, 193], ["demographic data", "TEST", 199, 215]]], ["The Internet is already the 'foundation medium' to access, link and use all these data.DiscussionSatellite imagery and remote sensing are quickly entering the mainstream.", [["all these data", "TEST", 72, 86]]], ["Today, satellite imagery data are abundantly available from multiple sources, including companies such as Space Imaging http:// www.spaceimaging.com/, Orbimage http://orbim age.com/, DigitalGlobe http://digitalglobe.com/, GlobeXplorer http://www.globexplorer.com/, Spot Image http:// www.spot.com/, ImageSat International http:// www.imagesatintl.com/, and EarthSat (http://www.earth sat.com/ -an MDA company), and are used in hundred of applications.", [["MDA", "CHEMICAL", 397, 400], ["satellite imagery data", "TEST", 7, 29], ["Space Imaging", "TEST", 106, 119]]], ["But thanks to online consumer services like Terraserver http://www.terraserver.com/, Google Earth, and Microsoft Virtual Earth (see 'Background' section above), satellite imagery has also been made familiar and accessible to millions of people.The wikification of GIS, maps and satellite imagery/aerial photography: imaging and geospatial information for the wide massesThere is no doubt the different online consumer geoinformatics services that have been presented in the 'Background' section of this article, including the different geographic search interfaces from major Web search engine providers, have significantly contributed (in record time) to raising the general public interest in geography and satellite imagery.", [["people", "ORGANISM", 237, 243], ["people", "SPECIES", 237, 243], ["maps", "TEST", 269, 273], ["satellite imagery/aerial photography", "TEST", 278, 314], ["imaging", "TEST", 316, 323], ["the wide masses", "PROBLEM", 355, 370], ["masses", "OBSERVATION", 364, 370], ["no doubt", "UNCERTAINTY", 379, 387]]], ["As millions of people start \"playing\" with these new online \"gadgets\" or \"toys\" from Google and Microsoft, many of them will soon start thinking about becoming active participants, sharing information and collaborating online (notions that have been rightly associated with the Web for quite a long time), rather than just being satisfied with a passive information consumer/ viewer role.", [["people", "ORGANISM", 15, 21], ["people", "SPECIES", 15, 21], ["participants", "SPECIES", 167, 179]]], ["(The reader should note that it has been estimated that about 800 million persons are online today worldwide [11] .)", [["persons", "ORGANISM", 74, 81], ["persons", "SPECIES", 74, 81]]], ["However, although Google Maps API (and similar API offerings from other providers) enables users to deeply customize the standard provider's interface (Google Maps), and to create their own custom annotated maps (custom applications based on Google Maps), such APIs remain difficult for the non-expert, average user to exploit.", [["Google Maps API", "TEST", 18, 33], ["Google Maps", "TEST", 242, 253], ["such APIs", "PROBLEM", 256, 265]]], ["The KML feed featured in this screenshot is available at http://www.healthcybermap.org/GoogleEarthKML/sha.kml and is intended to be opened by Google Earth desktop application, which can be downloaded at http://earth.google.com/.Screenshot of Google Earth KML version of England's SHA Locatorprogramming expertise to use them can also be built using the existing APIs.)Screenshot of Google Earth KML version of England's SHA LocatorThe current 'wiki' concept is not far from this vision.", [["The KML feed", "TREATMENT", 0, 12]]], ["A blog (WeBLOG) is a Web site that contains dated entries in reverse chronological order (most recent first) about a particular topic.", [["Web site", "DNA", 21, 29], ["a Web site", "PROBLEM", 19, 29]]], ["Functioning as an online journal, blogs can be written by one person or a group of contributors.", [["person", "SPECIES", 62, 68]]], ["Entries contain commentary and links to other Web sites, and images as well as a search facility may also be included ([13] -see the 'blog' entry in Wikipedia at http://en.wikipedia.org/wiki/Blog).Screenshot of Google Earth KML version of England's SHA LocatorWikis, and in particular Wikipedia, have grown very popular in recent months and years [14] .", [["Web sites", "DNA", 46, 55]]], ["Along the same lines, it is not difficult to imagine the development in the very near future of 'geowikis', 'mapwikis', geo-enabled blogs, 'mapblogs' (imagine, for example, people with an Internet-connected, GPS-enabled mobile device wanting to blog their movements, and share their activity spaces and geo-referenced news with other online users for various purposes), and even geoenabled, mappable Web/RSS feeds and map feeds (see the Smugmug KML photo feed example mentioned in the 'Background' section above).", [["people", "ORGANISM", 173, 179], ["people", "SPECIES", 173, 179], ["mobile device", "TREATMENT", 220, 233], ["map feeds", "TREATMENT", 418, 427], ["the Smugmug KML photo feed", "TREATMENT", 433, 459], ["same lines", "OBSERVATION", 10, 20]]], ["In fact some early geowiki examples have already found their way on the Web; see, for example, http://www.wikyblog.com/Map/Guest/ Home, http://www.geowiki.com/, and also worldKit GeoWiki, a publicly editable map application http:// brainoff.com/worldkit/doc/geowiki.php (a simple online demo of worldKit GeoWiki to which anyone can add their own data is available at http://brainoff.com/worldkit/ geowiki/).Screenshot of Google Earth KML version of England's SHA LocatorAnother example is the Katrina Information Map http:// scipionus.com/, which was built using Google Maps [15] .", [["a publicly editable map application", "TREATMENT", 188, 223], ["Google Maps", "TEST", 563, 574]]], ["Katrina Information Map was conceived for use by people Like the main MSN Virtual Earth service, our custom map allows users to move the map around by dragging it, to zoom in and out with the mouse wheel, and to zoom in by double-clicking on a location.", [["people", "ORGANISM", 49, 55], ["mouse", "ORGANISM", 192, 197], ["people", "SPECIES", 49, 55], ["mouse", "SPECIES", 192, 197], ["mouse", "SPECIES", 192, 197]]], ["Clicking a Strategic Health Authority 'S' marker (or pin) on the map will display the corresponding Summary Information page from England's National Health Service (NHS) Web site (e.g., http://www.nhs.uk/England/Authoritie sTrusts/Sha/showTrust.aspx?id=Q25 for Leicestershire, Northamptonshire and Rutland SHA). affected by Hurricane Katrina (August 2005) and their relatives who have, or are trying to find, information about the status of specific locations affected by the storm and its aftermath.", [["Leicestershire", "TREATMENT", 261, 275]]], ["This is what this author calls the ultimate \"wikification\" of GIS, maps and satellite imagery/aerial photography.", [["maps", "TEST", 67, 71], ["satellite imagery/aerial photography", "TEST", 76, 112]]], ["If the majestic Tate Museum in London is currently posting captions from its visitors next to its greatest works of art [16] , why shouldn't online maps (even those from very reputable sources like the National Geographic Society) allow a similar approach?!Associated individual privacy, national security, data confidentiality, and copyrights/digital rights management issuesAs geospatial technology progresses and becomes more readily available to the wide masses around the world who are connected to the Internet, the interrelated issues of GIS and map data confidentiality/individual privacy, and even national security start to surface, calling for further examination of, and research into these delicate aspects of Internet GIS and Web maps [5, [17] [18] [19] [20] [21] [22] .Associated individual privacy, national security, data confidentiality, and copyrights/digital rights management issuesFor example, in public health worldwide, any public identification of an individual's health status and residence, regardless of level of contagion or risk, is usually prohibited with very few exceptions, e.g., Megan's Law in the US, which allows the release of residential information on registered child sex offenders to the public by local government [17, 23] .", [["masses", "CANCER", 459, 465], ["surface", "CELLULAR_COMPONENT", 634, 641], ["[17] [18] [19] [20] [21] [22]", "SIMPLE_CHEMICAL", 753, 782], ["copyrights/digital rights management", "TREATMENT", 333, 369], ["issues", "PROBLEM", 370, 376], ["the wide masses", "PROBLEM", 450, 465], ["map data", "TEST", 553, 561], ["further examination", "TEST", 655, 674], ["Web maps", "TEST", 740, 748], ["copyrights/digital rights management", "TREATMENT", 860, 896], ["masses", "OBSERVATION", 459, 465]]], ["SARS (Severe Acute Respiratory Syndrome) mapping in Hong Kong in 2003 using disaggregate case data at individual building level in near real time was another noticeable exception to this well-established public health confidentiality rule, and also a unique and rare GIS opportunity that resulted in some very comprehensive public Internet mapping services [24] .Associated individual privacy, national security, data confidentiality, and copyrights/digital rights management issuesIt is noteworthy that Google Maps API terms and conditions http://www.google.com/apis/maps/signup.html state, \"There are some uses of the API that we just don't want to see.", [["SARS", "DISEASE", 0, 4], ["Acute Respiratory Syndrome", "DISEASE", 13, 39], ["SARS (Severe Acute Respiratory Syndrome", "PROBLEM", 0, 39], ["copyrights/digital rights management", "TREATMENT", 439, 475], ["issues", "PROBLEM", 476, 482], ["Severe", "OBSERVATION_MODIFIER", 6, 12], ["Acute", "OBSERVATION_MODIFIER", 13, 18], ["Respiratory Syndrome", "OBSERVATION", 19, 39]]], ["For instance, we do not want to see maps that identify the places to buy illegal drugs in a city, or any similar illegal activity.", [["illegal activity", "OBSERVATION", 113, 129]]], ["We also want to respect people's privacy, so the API should not be used to identify private information about private individuals.\"Associated individual privacy, national security, data confidentiality, and copyrights/digital rights management issuesOn another level, following the September 2001 terrorist events in the US, many federal and local spatial databases, e.g., \"critical infrastructure\" spatial data, were assessed by their holding agencies as a potential liability to national security and withdrawn from the Internet or public dissemination.", [["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30], ["copyrights/digital rights management", "TREATMENT", 207, 243]]], ["The current concern is to find an appropriate balance between public access to spatial information and protection of information considered a priority for national security [17, 23] .Associated individual privacy, national security, data confidentiality, and copyrights/digital rights management issuesBut despite all these undeniable, legitimate and real concerns about Internet GIS and map data privacy and confidentiality, many of the doubts and misgivings that are raised concerning these aspects of Internet GIS seem to be ill founded, or at least exaggerated.", [["copyrights/digital rights management", "TREATMENT", 259, 295]]], ["Entchev [19] has wisely stated, \"Let us not cripple the GIS system to meet some vague privacy perceptions\".Associated individual privacy, national security, data confidentiality, and copyrights/digital rights management issuesAnother thorny Internet GIS issue that needs to be addressed is that of data and map copyrights.", [["copyrights/digital rights management", "TREATMENT", 183, 219], ["issues", "PROBLEM", 220, 226], ["map copyrights", "TEST", 307, 321]]], ["Copyrighted geo-data and maps are usually more difficult and expensive to acquire and use.Associated individual privacy, national security, data confidentiality, and copyrights/digital rights management issuesBut as geo-data become more important in everything from blogs through mobile phones to finding lost people, free maps could make more and more of a difference [14] .", [["people", "ORGANISM", 310, 316], ["people", "SPECIES", 310, 316], ["maps", "TEST", 25, 29], ["copyrights/digital rights management", "TREATMENT", 166, 202], ["issues", "PROBLEM", 203, 209]]], ["Microsoft also provides an alternative ad-supported, but still free, \"commercialized\" version of their MSN Virtual Earth Map Control for commercial Web sites [26] .Associated individual privacy, national security, data confidentiality, and copyrights/digital rights management issuesThe Open Geospatial Consortium's (OGC) work on Geospatial Digital Rights Management (GeoDRM) is also poised to become an important enabler in the context of geo-data and map copyrights [27] .", [["copyrights/digital rights management", "TREATMENT", 240, 276], ["Geospatial Digital Rights Management", "TREATMENT", 330, 366], ["map copyrights", "TEST", 453, 467]]], ["A great deal of work has already been done in the area of data ownership and rights management for the online e-book, video and music industries, with some mature working solutions already in existence from companies like www.microsoft.com/windows/windowsmedia/drm/ default.aspx and http://www.microsoft.com/windows/ie/ downloads/addon/rm.mspx) and Adobe https://aracti vate.adobe.com/.", [["rights management", "TREATMENT", 77, 94], ["some mature working solutions", "TREATMENT", 151, 180]]], ["The lack of a GeoDRM capability has been identified as a major barrier to the broader adoption of Web-based geospatial technologies.", [["a GeoDRM capability", "PROBLEM", 12, 31]]], ["The mission of OGC GeoDRM Working Group is to coordinate and mature the development and validation of work being done on digital rights management for the geospatial community [27] .ConclusionGoogle and MSN's worldwide distribution of \"free\" geospatial tools, imagery, maps and, eventually, in future versions of their products, analysis capabilities, is to be commended.", [["digital rights management", "TREATMENT", 121, 146], ["\"free\" geospatial tools", "PROBLEM", 235, 258], ["maps", "TEST", 269, 273], ["analysis capabilities", "TEST", 329, 350]]], ["Building on the powerful and universal visual language of geography, they succeeded in making their customizable multi-purpose maps and imagery of the world familiar and accessible to millions of ordinary Web users around the globe from outside the fields of specialized geosciences.", [["globe", "ANATOMY", 226, 231]]]], "PMC7368608": [["Age and Socio-Economic Related Risk Factors ::: IntroductionEstimates suggest that approximately three quarters of mental health comorbidities that affect adults across the life course emerge during adolescence and young adulthood [7].", [["mental health comorbidities", "PROBLEM", 115, 142]]], ["Adolescents\u2019 mental health status can have profound impacts on their future health, social, and economic circumstances as adults, particularly in contexts of poverty and vulnerability [10].", [["poverty", "DISEASE", 158, 165], ["Adolescents", "SPECIES", 0, 11]]], ["The development of poor mental health outcomes during this period is influenced by neurological, hormonal, and physical changes associated with puberty, combined with changes in adolescents\u2019 social environments [11].", [["neurological", "ANATOMY", 83, 95], ["puberty", "DISEASE", 144, 151], ["adolescents", "SPECIES", 178, 189], ["poor mental health outcomes", "PROBLEM", 19, 46], ["neurological, hormonal, and physical changes", "PROBLEM", 83, 127], ["poor", "OBSERVATION_MODIFIER", 19, 23]]], ["Evidence from South Africa and other countries in the sub-Saharan African region show that age-specific risk factors for depression and anxiety disorders include lower socio-economic status, lack of social capital and support, substance use, and exposure to violence and traumatic events [12].", [["depression", "DISEASE", 121, 131], ["anxiety disorders", "DISEASE", 136, 153], ["violence", "DISEASE", 258, 266], ["depression", "PROBLEM", 121, 131], ["anxiety disorders", "PROBLEM", 136, 153], ["lower socio-economic status", "PROBLEM", 162, 189], ["traumatic events", "PROBLEM", 271, 287]]], ["Adolescents growing up in the context of socio-economically adverse communities are faced with a range of additional psychosocial and health risks that may evoke stress and negatively affect their mental health; these risks include exposure to HIV, substance use, violence, and other stressors [13].", [["violence", "DISEASE", 264, 272], ["Adolescents", "SPECIES", 0, 11], ["HIV", "SPECIES", 244, 247], ["HIV", "SPECIES", 244, 247]]], ["Poverty has been shown to be associated with heightened vulnerability to experiencing poor mental health, including mood and anxiety disorders [13].Age and Socio-Economic Related Risk Factors ::: IntroductionIn addition to age-related factors and socio-economic factors, gender-related factors, including sexual and reproductive biology, also play a role in contributing to mental health risks.", [["Poverty", "DISEASE", 0, 7], ["mood and anxiety disorders", "DISEASE", 116, 142], ["socio-economic factors", "PROTEIN", 247, 269], ["poor mental health", "PROBLEM", 86, 104], ["mood and anxiety disorders", "PROBLEM", 116, 142], ["IntroductionIn", "TREATMENT", 196, 210], ["socio-economic factors", "PROBLEM", 247, 269]]], ["Adolescent pregnancy poses a significant mental health burden, predisposing AGYW to adverse mental health outcomes, with depression and anxiety being the most common [14].", [["AGYW", "DISEASE", 76, 80], ["depression", "DISEASE", 121, 131], ["anxiety", "DISEASE", 136, 143], ["Adolescent pregnancy", "PROBLEM", 0, 20], ["a significant mental health burden", "PROBLEM", 27, 61], ["adverse mental health outcomes", "PROBLEM", 84, 114], ["depression", "PROBLEM", 121, 131], ["anxiety", "PROBLEM", 136, 143], ["significant", "OBSERVATION_MODIFIER", 29, 40]]], ["In resource-deprived settings in sub-Saharan Africa, pregnancy amongst AGYW is associated with adverse mental health outcomes and psychosocial stresses including stigma and discrimination [14].", [["AGYW", "DISEASE", 71, 75], ["adverse mental health outcomes", "PROBLEM", 95, 125], ["psychosocial stresses", "PROBLEM", 130, 151], ["stigma", "PROBLEM", 162, 168]]], ["In the South African context, pregnancy may exacerbate existing social and contextual stressors, adding additional stressors such as interpersonal relationship challenges, regret around \u2018unintended\u2019 pregnancies, and depression [15].", [["depression", "DISEASE", 216, 226], ["depression", "PROBLEM", 216, 226]]], ["Globally, suicide is the second leading cause of mortality among females aged 10\u201324 years; with low and middle income countries accounting for over 75% of global suicide deaths [11].", [["deaths", "DISEASE", 170, 176], ["global suicide deaths", "PROBLEM", 155, 176]]], ["Rates of suicidal ideation, defined as the thought of killing oneself, are highest among adolescents on the African continent, with HIV as a contributing factor [11].Age and Socio-Economic Related Risk Factors ::: IntroductionThe syndemic theory of health refers to the clustering of risk factors, or co-occurring and intersecting epidemics embedded in the particular social context in which an individual is situated, which combine and interact to create vulnerability to health outcomes that are worse than any one risk factor alone would cause [16, 17].", [["suicidal ideation", "DISEASE", 9, 26], ["HIV", "SPECIES", 132, 135], ["suicidal ideation", "PROBLEM", 9, 26], ["HIV", "PROBLEM", 132, 135]]], ["By focusing on the \u2018biosocial complex\u2019, the interconnected and co-occurring health issues, as well as the social and environmental factors that promote and enhance negative health outcomes, the syndemic theory can help to explain the way in which risk behaviours which lead to negative SRH outcomes, namely HIV infection and \u2018unintended\u2019 pregnancy, are situated within co-occurring and interacting psychosocial health conditions, including psychological distress and poor mental health [9, 18, 19].Age and Socio-Economic Related Risk Factors ::: IntroductionThe immense physical, neurocognitive, mental, and social changes that occur during adolescence not only affect mental health, but also influence sexual behaviour; during this period of transitioning to adulthood, adolescents are at increased risk of HIV infection [18].", [["HIV infection", "DISEASE", 307, 320], ["psychological distress", "DISEASE", 440, 462], ["physical, neurocognitive, mental, and social changes", "DISEASE", 570, 622], ["HIV infection", "DISEASE", 808, 821], ["HIV", "ORGANISM", 307, 310], ["adolescents", "ORGANISM", 771, 782], ["HIV", "ORGANISM", 808, 811], ["HIV", "SPECIES", 307, 310], ["adolescents", "SPECIES", 771, 782], ["HIV", "SPECIES", 307, 310], ["HIV", "SPECIES", 808, 811], ["HIV infection", "PROBLEM", 307, 320], ["psychological distress", "PROBLEM", 440, 462], ["poor mental health", "PROBLEM", 467, 485], ["HIV infection", "PROBLEM", 808, 821], ["HIV infection", "OBSERVATION", 808, 821]]], ["The association between depressive symptoms and decreased sexual agency and decision-making power in AGYW are compounded by low self-esteem; in turn these are associated with increased risk behaviours, including increased susceptibility to pressure to have sex, comfort seeking, condomless sex, transactional sex, trans-generational sex, substance use, and \u2018unintended\u2019 pregnancy [7, 8, 19\u201321].", [["depressive symptoms", "DISEASE", 24, 43], ["depressive symptoms", "PROBLEM", 24, 43], ["increased risk behaviours", "PROBLEM", 175, 200], ["increased susceptibility to pressure", "PROBLEM", 212, 248]]], ["Some of the mechanisms through which poor mental health symptoms influence sexual risk include substance use, maladaptive coping mechanisms to deal with stress, and impaired decision-making, indicating poor mental health as a prospective predictor of sexual risk [22].", [["impaired decision-making", "DISEASE", 165, 189], ["poor mental health symptoms", "PROBLEM", 37, 64], ["stress", "PROBLEM", 153, 159]]], ["Depressive symptoms in AGYW have also been correlated with a lack of ability to withstand social pressure, including peer pressure to engage in risky behaviours, a tendency to be more subservient and less assertive in sexual relationships, as well as with being more vulnerable to intimate partner violence and abuse [8, 19].", [["Depressive", "DISEASE", 0, 10], ["intimate partner violence", "DISEASE", 281, 306], ["Depressive symptoms", "PROBLEM", 0, 19], ["peer pressure", "TREATMENT", 117, 130]]], ["In addition to the links between depression and increased sexual risk taking, depression is also associated with impeded health seeking behaviour, including HIV testing [23].Age and Socio-Economic Related Risk Factors ::: IntroductionConsidering the overlaps and interactions between mental health and SRH amongst AGYW is critical.", [["depression", "DISEASE", 33, 43], ["depression", "DISEASE", 78, 88], ["HIV", "SPECIES", 157, 160], ["depression", "PROBLEM", 33, 43], ["depression", "PROBLEM", 78, 88], ["HIV testing", "TEST", 157, 168]]], ["Greater insight into the lived subjective experience of depression and stress, and how these are linked to SRH outcomes is needed.", [["depression", "DISEASE", 56, 66], ["depression", "PROBLEM", 56, 66], ["stress", "PROBLEM", 71, 77], ["depression", "OBSERVATION", 56, 66]]], ["There appears to be a gap in the literature pertaining to the ways in which mental health and psychosocial risks, including depression and stress, intersect and overlap with SRH related factors such as distress caused by \u2018unintended\u2019 pregnancy, material/emotional stressors of having a child, or social stigma [16].", [["depression", "DISEASE", 124, 134], ["a gap", "PROBLEM", 20, 25], ["depression", "PROBLEM", 124, 134], ["stress", "PROBLEM", 139, 145], ["distress", "PROBLEM", 202, 210], ["appears to be", "UNCERTAINTY", 6, 19], ["gap", "OBSERVATION", 22, 25]]], ["Various studies explore depression amongst HIV positive women, but there has been little exploration of mental health issues that arise due to, or co-occur with, SRH outcomes.", [["depression", "DISEASE", 24, 34], ["HIV positive", "DISEASE", 43, 55], ["HIV", "ORGANISM", 43, 46], ["women", "ORGANISM", 56, 61], ["HIV", "SPECIES", 43, 46], ["women", "SPECIES", 56, 61], ["HIV", "SPECIES", 43, 46], ["Various studies", "TEST", 0, 15], ["depression", "PROBLEM", 24, 34], ["mental health issues", "PROBLEM", 104, 124]]], ["Although mental health was not an initial focus of the research, upon qualitative enquiry, the significance of poor mental health outcomes impacting on sexual and reproductive health practices emerged as a salient theme, warranting closer examination.", [["poor mental health outcomes", "PROBLEM", 111, 138], ["closer examination", "TEST", 232, 250]]], ["We examined AGYW\u2019s narratives and conceptualizations of their own mental health, that of peers, and of the surrounding emotional and psycho-social support context in order to explore the ways in which these factors might interact with sexual health outcomes.Ethical Considerations ::: MethodsInformed consent was obtained from all participants 18 years and older.", [["participants", "SPECIES", 331, 343]]], ["Participants were provided with a ZAR 50.00 (approximately US$ 3.00) supermarket voucher, transport reimbursement, and refreshments.", [["Participants", "SPECIES", 0, 12]]], ["The study protocol and research tools were approved by the South African Medical Research Council Research Ethics Committee, and by the Associate Director for Science in the Center for Global Health in the Centers for Disease Control and Prevention.", [["The study protocol", "TEST", 0, 18], ["Disease Control", "TREATMENT", 218, 233]]], ["The research team received training on the study protocol and procedures for reporting and managing social harms and adverse events, as outlined in human subject research ethical guidelines.", [["human", "ORGANISM", 148, 153], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["the study protocol", "TEST", 39, 57], ["procedures", "TREATMENT", 62, 72], ["adverse events", "PROBLEM", 117, 131]]], ["During data collection, private-sector social workers were procured to assist with ensuring access to social support services for participants who needed psychosocial support.Data Preparation and Analysis ::: MethodsAudio recordings of IDIs and FGDs were transcribed verbatim into their original language, reviewed by the researcher who conducted the interviewer for accuracy, translated into English and re-reviewed by the interviewer.", [["participants", "SPECIES", 130, 142], ["psychosocial support", "TREATMENT", 154, 174]]], ["Data analysis followed a thematic approach, in which a pre-determined deductive codebook underwent cyclical review and refinement [24\u201326].", [["Data analysis", "TEST", 0, 13]]], ["Weekly research meetings were held throughout the data collection and analysis phases allowing for team debriefing and examination of how thoughts and ideas were evolving as they engaged with the data.", [["analysis phases", "TEST", 70, 85], ["team debriefing", "TEST", 99, 114], ["examination", "TEST", 119, 130]]], ["The objective of these workshops was to review and discuss the preliminary analysis and interpretations, ensure accurate and appropriate interpretation of the data, clarify misunderstandings, and confirm findings and interpretations.", [["the preliminary analysis", "TEST", 59, 83], ["the data", "TEST", 155, 163]]], ["During the workshops, the research team summarised and presented key themes and findings to the participants, who were then invited to give feedback, discuss their interpretation of the findings, and expand or elaborate on themes.", [["participants", "SPECIES", 96, 108]]], ["Facilitated discussions on each theme were captured through notes and audio recordings, transcribed and reviewed, and included in the overall analysis.Demographic Characteristics ::: FindingsAmongst the 237 AGYW respondents aged 15\u201324, the mean age was 17.4 years.", [["audio recordings", "TEST", 70, 86], ["the overall analysis", "TEST", 130, 150]]], ["For reporting of language spoken at home, the top three languages were isiXhosa (39%, N = 92/237), isiZulu (25%, N = 59/237), and siSwati (15%, N = 35/237).", [["siSwati", "TEST", 130, 137]]], ["Overall, 18% (N = 41/232) of the AGYW reported to have had a pregnancy.Demographic Characteristics ::: FindingsEmergent themes in the qualitative data included AGYW narratives and perceptions of depression, stress, and suicide.", [["depression", "DISEASE", 195, 205], ["Overall", "TEST", 0, 7], ["a pregnancy", "PROBLEM", 59, 70], ["depression", "PROBLEM", 195, 205], ["stress", "PROBLEM", 207, 213]]], ["In the accounts of AGYW, poor mental health, including depression and suicidal risk were linked to sexual/romantic relationship challenges, early pregnancy and child-bearing, parenting responsibilities, experiences of violence/abuse, HIV status, and lack of emotional support.", [["depression", "DISEASE", 55, 65], ["violence/abuse", "DISEASE", 218, 232], ["HIV", "SPECIES", 234, 237], ["HIV", "SPECIES", 234, 237], ["poor mental health", "PROBLEM", 25, 43], ["depression", "PROBLEM", 55, 65], ["suicidal risk", "PROBLEM", 70, 83], ["HIV status", "PROBLEM", 234, 244], ["emotional support", "TREATMENT", 258, 275]]], ["Suicide risk emerged as a salient theme and was associated with discovery of pregnancy or an HIV positive status, low self-esteem, and a lack of anyone to trust or confide in.", [["Suicide", "DISEASE", 0, 7], ["HIV", "SPECIES", 93, 96], ["HIV", "SPECIES", 93, 96], ["pregnancy", "PROBLEM", 77, 86], ["an HIV positive status", "PROBLEM", 90, 112]]], ["In general, AGYW voiced a need for increased access to support, and additional information on mental health.Demographic Characteristics ::: FindingsThe findings presented below are arranged into key thematic areas that emerged during analysis.", [["increased access to support", "TREATMENT", 35, 62]]], ["In selected excerpts, original language terms/words have been included in italicised brackets for the purpose of illustrating the exact words/language used by participants relating to key concepts associated with mental health.", [["participants", "SPECIES", 159, 171]]], ["The rationale for this is that often concepts such as \"depression\u201d have been framed in a universal/Western way, without attention to contextual specificity.", [["depression", "DISEASE", 55, 65], ["depression", "PROBLEM", 55, 65]]], ["Where qualitative research uses translations, there is a danger of the original meaning and concept getting lost in the translation process, as translators seek to find \u2018equivalent\u2019 terms [26].Suicidal Ideation ::: FindingsSuicidal ideation emerged as salient theme across provinces, despite there being no specific question probes relating to suicide.", [["FindingsSuicidal ideation", "PROBLEM", 215, 240]]], ["According to AGYW, issues such as self-harm and having suicidal tendencies were common amongst their peers.", [["suicidal tendencies", "DISEASE", 55, 74], ["suicidal tendencies", "PROBLEM", 55, 74]]], ["One participant expressed hesitancy using the diagnosis of \u2018depression\u2019, but described self-harming and suicidal ideation: \u201cThere are girls, I don\u2019t want to say \u2018depressed\u2019, but who do things like self-harming, some attempt suicide\u201d (15\u201318 years, EC).", [["EC", "ANATOMY", 247, 249], ["depression", "DISEASE", 60, 70], ["suicidal ideation", "DISEASE", 104, 121], ["depressed", "DISEASE", 162, 171], ["EC", "CELL", 247, 249], ["participant", "SPECIES", 4, 15], ["girls", "SPECIES", 134, 139], ["\u2018depression", "PROBLEM", 59, 70]]], ["AGYW made links between low self-esteem and self-worth, and lacking a sense of belonging, with suicidal ideation: \u201cMost girls\u2026 have a low self-esteem\u2026 feel as though they don\u2019t belong in this world.", [["low self-esteem", "DISEASE", 24, 39], ["suicidal ideation", "DISEASE", 95, 112], ["girls", "SPECIES", 120, 125]]], ["That\u2019s why people commit suicide.", [["people", "ORGANISM", 11, 17], ["people", "SPECIES", 11, 17]]], ["I used to have that\u2026 mentality\u2026 suicidal thoughts because of people\u201d (19\u201324 years, NW).Suicidal Ideation ::: FindingsIllustrating the link between SRH and mental health, feelings of emotional isolation leading to suicidal ideation were exacerbated in the case of HIV positive or pregnant AGYW who feel unable to access support: \u201cThis thing of suicide is becoming popular now, even here at school\u2026 especially when girls are pregnant or HIV positive, because they can\u2019t share it with anyone, they don\u2019t trust anyone\u201d (15\u201318 years, WC).", [["suicidal thoughts", "DISEASE", 32, 49], ["suicidal ideation", "DISEASE", 213, 230], ["people", "ORGANISM", 61, 67], ["HIV", "ORGANISM", 263, 266], ["people", "SPECIES", 61, 67], ["HIV", "SPECIES", 263, 266], ["girls", "SPECIES", 413, 418], ["HIV", "SPECIES", 435, 438], ["HIV", "SPECIES", 263, 266], ["HIV", "SPECIES", 435, 438], ["suicidal thoughts", "PROBLEM", 32, 49], ["emotional isolation", "PROBLEM", 182, 201], ["suicidal ideation", "PROBLEM", 213, 230], ["HIV positive", "PROBLEM", 435, 447]]], ["The sense of having no one to trust or confide in, and seek emotional support from, resulted in AGYW feeling emotionally isolated, fostering suicidal ideation: \u201cWe don\u2019t share our sexual and personal life things\u2026 We keep it to ourselves, then some of us commit suicide (sizigcinia kuthi, abanye bethu ke baphela sebezibulala)\u201d (15\u201318 years, WC, isiXhosa).", [["suicidal ideation", "DISEASE", 141, 158], ["WC", "CHEMICAL", 341, 343], ["baphela sebezibulala", "SPECIES", 304, 324]]], ["Suicide was linked to feelings of isolation after an HIV positive diagnosis: \u201c(When) the nurse told her that is she is HIV positive, she didn\u2019t know who to tell\u2026 so she took a rope and hanged herself because she had no one to talk to\u201d (15\u201318 years, WC).Suicidal Ideation ::: FindingsThe discovery of being pregnant was also described as a difficult emotional event.", [["Suicide", "DISEASE", 0, 7], ["WC", "CHEMICAL", 249, 251], ["HIV", "SPECIES", 53, 56], ["HIV", "SPECIES", 119, 122], ["HIV positive", "PROBLEM", 119, 131], ["a difficult emotional event", "PROBLEM", 337, 364]]], ["AGYW in the older age group, 19\u201324 years, described personal experiences with suicidal ideation in this situation: \u201cWhen I found out I was pregnant\u2026 that was very difficult, I even thought about suicide\u2026 it was tough (kwabanzima kakhulu, ngangicabanga ngisho ukuyibulala, ya kwaku tough)\u201d (19\u201324 years, KZN, isiZulu).", [["suicidal ideation", "DISEASE", 78, 95], ["suicidal ideation", "PROBLEM", 78, 95]]], ["Additional links between mental health and SRH were apparent in the narratives of suicidal ideation in relation to the stress of teenage pregnancy, compounded by fear of HIV: \u201cAs a young pregnant girl\u2026 the challenges you face\u2026 maybe you will find out that he (baby\u2019s father) is HIV-positive\u2026 Those are challenges that can be a problem and you end up committing suicide\u2026 A better solution is to kill yourself (Yizona ngqinamba lezo ezingaba inkinga ugcine usu\u2026 usuzibula\u2026 i solutions kuncono ukuthi uzibulale)\u201d (19\u201324 years, KZN, isiZulu).Suicidal Ideation ::: FindingsRespondents suggested that due to social stigma attached to teenage pregnancy, pregnant AGYW fear being judged and gossiped about: \u201cPregnant girls feel sad\u2026 some even contemplate suicide (azive efuna ukuzibulala)\u2026 because of hearing unpleasant things about their life being spoken by other people.", [["suicidal ideation", "DISEASE", 82, 99], ["hearing unpleasant things", "DISEASE", 793, 818], ["baby", "ORGANISM_SUBDIVISION", 260, 264], ["HIV", "ORGANISM", 278, 281], ["people", "ORGANISM", 858, 864], ["HIV", "SPECIES", 170, 173], ["girl", "SPECIES", 196, 200], ["HIV", "SPECIES", 278, 281], ["lezo ezingaba", "SPECIES", 426, 439], ["inkinga ugcine", "SPECIES", 440, 454], ["girls", "SPECIES", 709, 714], ["people", "SPECIES", 858, 864], ["HIV", "SPECIES", 170, 173], ["HIV", "SPECIES", 278, 281], ["Yizona ngqinamba", "SPECIES", 409, 425], ["suicidal ideation", "PROBLEM", 82, 99], ["hearing unpleasant", "PROBLEM", 793, 811]]], ["(15\u201318 years, WC, isiXhosa); \u201cPregnant girls are teased, and then they drop out of school, they don't finish\u2026 here at school\u2026 we gossip about each other in the toilets\u201d (15\u201318 years, WC).", [["girls", "SPECIES", 39, 44]]], ["Parents\u2019 attitudes towards their daughters\u2019 romantic and sexual behaviour prevented AGYW from accessing support: \u201cLike most girls, I got pregnant at an early age.", [["girls", "SPECIES", 124, 129]]], ["Some girls resort to committing suicide (ezibulala) or just run away from home because they cannot face their parents\u201d (15\u201318 years, WC, isiXhosa).", [["girls", "SPECIES", 5, 10]]], ["Getting involved in transactional relationships, compounded by a sense of shame and fear of social judgement, also led to depression and suicidal ideation: \u201cMost girls in the community, they get into those (transactional) relationships, to a point that it damages them\u2026 they end up being depressed\u2026 \u2018Why are you doing this and that to me in front of people?\u2019\u2026 they end up like that and they end up trying to commit suicide\u2026 \u2018he embarrassed me in front of people, tomorrow how will people look at me?\u2019\u201d (19\u201324 years, NW).Stress ::: FindingsThe emotional \u2018burden\u2019 of teenage pregnancy was described as a key contributing factor to poor mental health: \u201cThey say having a child is a good thing, but as a teenager it is a burden, it\u2019s difficult to cope\u201d (15\u201318 years, EC).", [["EC", "ANATOMY", 763, 765], ["depression", "DISEASE", 122, 132], ["suicidal ideation", "DISEASE", 137, 154], ["depressed", "DISEASE", 288, 297], ["people", "ORGANISM", 350, 356], ["people", "ORGANISM", 455, 461], ["people", "ORGANISM", 481, 487], ["EC", "CELL", 763, 765], ["girls", "SPECIES", 162, 167], ["people", "SPECIES", 350, 356], ["people", "SPECIES", 455, 461], ["people", "SPECIES", 481, 487], ["depression", "PROBLEM", 122, 132], ["suicidal ideation", "PROBLEM", 137, 154], ["depressed", "PROBLEM", 288, 297], ["depressed", "OBSERVATION", 288, 297]]], ["Those AGYW who had experienced unexpected discovery of pregnancies described their stress related to being rejected by families, kicked out of school or from home.", [["pregnancies", "PROBLEM", 55, 66]]], ["One participant described her concerns after finding out she was pregnant in Grade 10: \u201cI was confused and didn\u2019t know what to do\u2026 (I told my boyfriend) my dad is strict\u2026 I will be chased away from home\u201d (19\u201324 years, KZN).", [["participant", "SPECIES", 4, 15], ["confused", "PROBLEM", 94, 102]]], ["One young woman described how she wanted to terminate her pregnancy but was told it was already too late to do so, and how this unwanted pregnancy caused her stress: \u201cI had stress\u2026 I only realised when I was 4 months 2 days that I was pregnant\u2026 if I had realised this earlier, I was going to do an abortion\u2026 then I asked the doctor \u2018Is there any other way I can do an abortion?\u2019\u2026 He then said \u2018It\u2019s either you die\u2026 I will not allow you to risk an abortion\u2019\u2026[sigh] I was not ready to have a child at that time\u2026 I knew how my situation was\u2026 the guy I was dating, I was just dating him for fun.", [["woman", "ORGANISM", 10, 15], ["woman", "SPECIES", 10, 15]]], ["I did not see myself having a child with him, or to have future with him\u2026 that was why I was going to abort this baby\u2026 I did not want the child\u2026 everything failed\u2026 I did not eat, I had stress\u2026 the one who impregnated me was staying in a shack\u201d (19\u201324 years, NW).Stress ::: FindingsA lack of emotional support from partners/fathers of children also contributed to stress and depression amongst young mothers: \u201cWhere does the stress go? \u2026to me\u2026 I\u2019m always watching this child, he cries the whole day and I don\u2019t know why\u2026 I\u2019m holding him, gave him his bottle, he continues to cry, I don\u2019t know why he is crying\u2026 you call him (baby\u2019s father)\u2026 (but) he doesn\u2019t take any action\u2026 I become depressed and it affects the child\u201d (19\u201324 years, NW).", [["depression", "DISEASE", 374, 384], ["depressed", "DISEASE", 683, 692], ["children", "ORGANISM", 334, 342], ["baby", "ORGANISM_SUBDIVISION", 624, 628], ["children", "SPECIES", 334, 342], ["stress", "PROBLEM", 363, 369], ["depression", "PROBLEM", 374, 384], ["depressed", "PROBLEM", 683, 692], ["depressed", "OBSERVATION", 683, 692]]], ["The feeling that former dreams and aspirations for the future were shattered by unexpected pregnancies heightened feelings of hopelessness and depression: \u201cIt\u2019s not going to be dark forever, things will be right\u2026 but what I can say? \u2026to be pregnant unexpectedly is not good at all\u2026 life is not good\u2026 Especially if\u2026 you had plans and maybe life does not go the way you had planned\u2026 I am speechless\u2026 for me now, life is not good\u2026 it\u2019s not good\u2026 tough times\u2026\u201d (19\u201324 years, NW).Emotional Support ::: FindingsLacking a supportive social environment negatively impacted on mental health and self-esteem: \u201cWhen people are discouraging me\u2026 I get very sad\u2026 I\u2019m trying\u2026 I\u2019m telling them that\u2026 and they say \u2018You cannot do that\u2026 you\u2019re weak\u2019\u2026 it makes me angry, but\u2026 I don\u2019t defend myself\u201d (19\u201324 years, NW).", [["hopelessness", "DISEASE", 126, 138], ["depression", "DISEASE", 143, 153], ["people", "ORGANISM", 605, 611], ["people", "SPECIES", 605, 611], ["aspirations", "TREATMENT", 35, 46], ["hopelessness", "PROBLEM", 126, 138], ["depression", "PROBLEM", 143, 153], ["right", "ANATOMY_MODIFIER", 206, 211], ["not", "UNCERTAINTY", 433, 436], ["good", "OBSERVATION_MODIFIER", 437, 441]]], ["Some AGYW suggested that they tried to cope without sharing their problems with anyone: \u201cI keep my problems to myself\u2026 I talk to no one\u2026 I keep to myself and own it, I don\u2019t make my problem someone else\u2019s\u2026 if ever I have something troubling me I will keep it to myself\u2026 eventually I will be fine (ndizade ndibe right)\u201d (19\u201324 years, EC, isiXhosa).", [["EC", "CELL", 333, 335]]], ["The lack of emotional support for dealing with traumatic life events, including grief over the death of a loved one, was present in AGYW narratives: \u201cWhen I think about something that happened in the past my heart becomes sore (intliziyo yam ibabuhlungu)\u2026 (like) when I think about my mother\u2026 she passed away\u2026 There is nobody (I talk to at home)\u2026 I don\u2019t feel free talking to them\u2026 I don\u2019t speak to anyone at school (either)\u201d (15\u201318 years, EC, isiXhosa).", [["heart", "ANATOMY", 208, 213], ["grief", "DISEASE", 80, 85], ["death", "DISEASE", 95, 100], ["sore", "DISEASE", 222, 226], ["heart", "ORGAN", 208, 213], ["yam", "SPECIES", 238, 241], ["emotional support", "TREATMENT", 12, 29], ["traumatic life events", "PROBLEM", 47, 68], ["sore", "PROBLEM", 222, 226], ["heart", "ANATOMY", 208, 213]]], ["A minority of AGYW were vocal about receiving emotional support at home: \u201cI know I am loved at home and they show me that they love me because they care for me and stuff\u201d (19\u201324 years, EC).Emotional Support ::: FindingsSexual and romantic relationships with violent and controlling partners were also described by some of the AGYW, who ended up living in a state of fear: \u201cIf I have made friends\u2026 and we want to go out as girls, then he (boyfriend) will refuse and beat you.", [["EC", "ANATOMY", 185, 187], ["EC", "CELL", 185, 187], ["emotional support", "TREATMENT", 46, 63]]], ["Refusal to have sex with a partner also led to violence: \u201csometimes, it happens that he wants to sleep with you, and you don\u2019t want to, then he gets angry and he beats you\u201d (19\u201324 years, KZN).", [["violence", "DISEASE", 47, 55]]], ["Those AGYW who had experienced intimate partner violence explained their reluctance to disclose to her family and friends: \u201cIn most times, you keep quiet and when they ask you \u2018what happened, why are you hurt?\u2019 you just tell them that you got hurt, you turned and bumped into a wall\u201d (19\u201324 years, KZN).", [["wall", "ANATOMY", 278, 282], ["intimate partner violence", "DISEASE", 31, 56], ["wall", "TISSUE", 278, 282]]], ["Experiencing violence negatively impacted AGYW self-esteem and self-worth: \u201cIt has to do with how you perceive yourself, he sees me as not good enough then maybe you will find that boyfriend that hits you, he is the one that you want to stay with because you think where else will you find another boyfriend? \u2026when he hits you that means this person does not see any value on you he beats you, abuses you\u2026 physically you will be injured obviously because that will hurt you\u2026 and she will think that she is not good enough\u201d (15\u201318 years, EC).", [["EC", "ANATOMY", 537, 539], ["violence", "DISEASE", 13, 21], ["EC", "CELL", 537, 539], ["person", "SPECIES", 343, 349]]], ["Pregnancy increased AGYW dependence on partners, even when they are violent: \u201cMy friend is pregnant\u2026 (her boyfriend) beats her\u2026 In her pregnancy the guy did not care for her and he was beating her saying the child is not his\u201d (19\u201324 years, EC).DiscussionOur study did not initially set out to examine mental health amongst AGYW, but narratives around depression, stress and suicide became salient, as did evidence of their interconnection with sexual and reproductive health.", [["EC", "ANATOMY", 240, 242], ["depression", "DISEASE", 351, 361], ["EC", "CELL", 240, 242], ["Pregnancy increased AGYW dependence", "PROBLEM", 0, 35], ["DiscussionOur study", "TEST", 244, 263], ["depression", "PROBLEM", 351, 361], ["stress", "PROBLEM", 363, 369]]], ["Feelings of stress, anxiety and not being able to cope, even to the point of suicide ideation, were associated with HIV status, unexpected discovery of pregnancy, and parenting responsibilities.", [["anxiety", "DISEASE", 20, 27], ["suicide ideation", "DISEASE", 77, 93], ["HIV", "SPECIES", 116, 119], ["stress", "PROBLEM", 12, 18], ["anxiety", "PROBLEM", 20, 27], ["suicide ideation", "PROBLEM", 77, 93], ["HIV status", "PROBLEM", 116, 126], ["pregnancy", "PROBLEM", 152, 161], ["stress", "OBSERVATION", 12, 18]]], ["Violence in relationships, a lack of emotional support from family and partners, and financial insecurity interact to exacerbate AGYW vulnerability to poor mental health and SRH outcomes.DiscussionAGYW in our study who had been pregnant, shared narratives of negative emotions they had experienced on discovering their pregnancy, leading to depression and suicidal ideation.", [["Violence", "DISEASE", 0, 8], ["depression", "DISEASE", 341, 351], ["suicidal ideation", "DISEASE", 356, 373], ["depression", "PROBLEM", 341, 351], ["suicidal ideation", "PROBLEM", 356, 373]]], ["The social causation hypothesis theory posits that stressful circumstances or events increase an individual\u2019s susceptibility to manifesting or experiencing mental health problems [13].", [["mental health problems", "PROBLEM", 156, 178]]], ["It would therefore make sense that the emotional aspects related to the discovery of an unexpected pregnancy or an HIV positive status would act as a stressor and have potentially negative mental health outcomes [16].", [["HIV", "SPECIES", 115, 118], ["an unexpected pregnancy", "PROBLEM", 85, 108], ["an HIV positive status", "PROBLEM", 112, 134]]], ["It is likely that after encountering a stressor, adolescents will experience stress and symptoms of depression and anxiety [13].", [["depression", "DISEASE", 100, 110], ["anxiety", "DISEASE", 115, 122], ["stress and symptoms", "PROBLEM", 77, 96], ["depression", "PROBLEM", 100, 110], ["anxiety", "PROBLEM", 115, 122], ["is likely", "UNCERTAINTY", 3, 12]]], ["The stress related to the discovery of an unexpected pregnancy is compounded by the shame and social stigmatisation of teenage pregnancy, and the ensuring social isolation from family and community increases the risk for psychological distress [7].", [["psychological distress", "DISEASE", 221, 243], ["The stress", "PROBLEM", 0, 10], ["an unexpected pregnancy", "PROBLEM", 39, 62], ["teenage pregnancy", "PROBLEM", 119, 136], ["psychological distress", "PROBLEM", 221, 243]]], ["The framing of pregnancy during adolescence as a social problem means that pregnant teens receive limited social support, which in turn is linked to poor mental health outcomes [2].", [["limited social support", "TREATMENT", 98, 120]]], ["The stress related to the discovery of an unexpected pregnancy is heightened further in the case of a dual discovery of being HIV positive [27].", [["HIV", "ORGANISM", 126, 129], ["HIV", "SPECIES", 126, 129], ["The stress", "PROBLEM", 0, 10], ["an unexpected pregnancy", "PROBLEM", 39, 62], ["HIV positive", "PROBLEM", 126, 138]]], ["The presence of depression, anxiety, and post-traumatic stress disorder in HIV-positive individuals is related to diagnosis and disclosure, and HIV-positive women experiencing \u2018unintended\u2019 pregnancy are at high risk for antenatal depression [27, 28].DiscussionAGYW in our study described a worrying trend of suicidal ideation.", [["depression", "DISEASE", 16, 26], ["anxiety", "DISEASE", 28, 35], ["post-traumatic stress disorder", "DISEASE", 41, 71], ["HIV-positive", "DISEASE", 75, 87], ["HIV-positive", "DISEASE", 144, 156], ["depression", "DISEASE", 230, 240], ["suicidal ideation", "DISEASE", 308, 325], ["HIV", "ORGANISM", 75, 78], ["HIV", "ORGANISM", 144, 147], ["women", "ORGANISM", 157, 162], ["HIV", "SPECIES", 75, 78], ["HIV", "SPECIES", 144, 147], ["women", "SPECIES", 157, 162], ["HIV", "SPECIES", 75, 78], ["HIV", "SPECIES", 144, 147], ["depression", "PROBLEM", 16, 26], ["anxiety", "PROBLEM", 28, 35], ["post-traumatic stress disorder", "PROBLEM", 41, 71], ["HIV", "PROBLEM", 75, 78], ["positive individuals", "PROBLEM", 79, 99], ["HIV", "PROBLEM", 144, 147], ["unintended\u2019 pregnancy", "PROBLEM", 177, 198], ["antenatal depression", "PROBLEM", 220, 240], ["our study", "TEST", 268, 277], ["suicidal ideation", "PROBLEM", 308, 325], ["depression", "OBSERVATION", 16, 26], ["post-traumatic stress disorder", "OBSERVATION", 41, 71]]], ["Thoughts about suicide narrated by AGYW were related to unexpected discovery of pregnancy and its consequences, HIV diagnosis, and feelings of emotional isolation.", [["HIV", "SPECIES", 112, 115], ["HIV", "SPECIES", 112, 115], ["pregnancy", "PROBLEM", 80, 89], ["emotional isolation", "TREATMENT", 143, 162]]], ["Suicide was described as \u201cthe best solution\u201d to situations of stress created by the discovery of unexpected discovery of pregnancy or HIV positive status, lack of material/financial or emotional support for young mothers, and feelings of victimisation as a result of gossip or judgement.", [["Suicide", "DISEASE", 0, 7], ["HIV", "SPECIES", 134, 137], ["HIV", "SPECIES", 134, 137], ["pregnancy", "PROBLEM", 121, 130], ["HIV positive status", "PROBLEM", 134, 153], ["emotional support", "TREATMENT", 185, 202]]], ["Adolescents faced with multiple stressors may experience a sense of being overwhelmed and unable to cope, and view suicide as an escape [13].", [["Adolescents", "SPECIES", 0, 11]]], ["AGYW in our study associated low self-esteem and low self-worth with depression and suicidal ideation.", [["low self-esteem", "DISEASE", 29, 44], ["depression", "DISEASE", 69, 79], ["suicidal ideation", "DISEASE", 84, 101], ["our study", "TEST", 8, 17], ["depression", "PROBLEM", 69, 79], ["suicidal ideation", "PROBLEM", 84, 101], ["low", "OBSERVATION_MODIFIER", 29, 32]]], ["Negative self-cognitions and low self-worth are associated with depression, and positive self-esteem is a critical component of emotional well-being [29].", [["depression", "DISEASE", 64, 74], ["depression", "PROBLEM", 64, 74]]], ["Adolescents\u2019 ability to manage their stress symptoms or address the stressor they encounter may be pivotal to protecting their mental health state, as it may buffer the impact of experienced stress on mental health [13].", [["Adolescents", "SPECIES", 0, 11], ["their stress symptoms", "PROBLEM", 31, 52]]], ["Additionally, self-esteem and social support are amongst the \u2018protective assets\u2019 associated with improved SRH outcomes [30].", [["social support", "TREATMENT", 30, 44]]], ["In our study, AGYW expressed feeling emotionally isolated, lacking people who they felt they could trust and confide in without fear of judgement or recrimination.", [["people", "ORGANISM", 67, 73], ["people", "SPECIES", 67, 73], ["our study", "TEST", 3, 12]]], ["Emotional isolation and lack of support, especially when faced with stressors such as the discovery of an unexpected pregnancy or an HIV diagnosis, negatively impacts mental health.", [["HIV", "SPECIES", 133, 136], ["Emotional isolation", "TREATMENT", 0, 19], ["support", "TREATMENT", 32, 39], ["an unexpected pregnancy", "PROBLEM", 103, 126]]], ["The emotionally distressing aspects of unexpected discovery of pregnancy, or an HIV diagnosis, combined with a lack of social support, contribute to the high rates of depression amongst AGYW [16].DiscussionAGYW in our study described additional stress related to teenage pregnancy and child-bearing relating to concern around the ability to support a baby financially, especially when there was a lack of material and/or emotional support from the father of the child.", [["depression", "DISEASE", 167, 177], ["child", "ORGANISM", 462, 467], ["HIV", "SPECIES", 80, 83], ["HIV", "SPECIES", 80, 83], ["social support", "TREATMENT", 119, 133], ["depression", "PROBLEM", 167, 177], ["our study", "TEST", 214, 223], ["teenage pregnancy", "PROBLEM", 263, 280]]], ["AGYW in South Africa, particularly those in resource-constrained or violent households, face a variety of personal and structural challenges, linked to disempowerment and psychological distress more broadly; an \u2018unintended\u2019 pregnancy can compound pre-existing social and economic vulnerabilities, and result in heightened feelings of stress and unhappiness [31].", [["disempowerment", "DISEASE", 152, 166], ["psychological distress", "PROBLEM", 171, 193], ["stress", "PROBLEM", 334, 340], ["unhappiness", "PROBLEM", 345, 356]]], ["Socio-economic disadvantage compounds other stressors in an adolescents\u2019 life, and when co-occurring with pregnancy or HIV, can lead to poor mental health outcomes and a lack of utilisation of health care services [2, 13].DiscussionOne limitation of this study was that the framing and concept of \u2018unintended\u2019 pregnancy was not investigated in more depth.", [["adolescents", "SPECIES", 60, 71], ["HIV", "SPECIES", 119, 122], ["HIV", "SPECIES", 119, 122], ["HIV", "PROBLEM", 119, 122], ["poor mental health outcomes", "PROBLEM", 136, 163], ["this study", "TEST", 250, 260]]], ["For this reason, we avoid using the term \u2018unintended\u2019, and instead use the words of AGYW respondents themselves when describing their unexpected discovery of a pregnancy, rather than objectively categorising the pregnancies as \u2018unintended\u2019.", [["a pregnancy", "PROBLEM", 158, 169]]], ["In addition, social desirability bias relating to the stigma and shame around mental health may have resulted in a lack of disclosure from AGYW regarding their own feelings of depression or suicide ideation.Integration of Mental Health into SRH Services for AGYW ::: Conclusions and RecommendationsIn line with the syndemic theory suggesting synergistic interactions between epidemics, and the interconnectedness and clustering of psychosocial conditions such as \u2018unintended\u2019 pregnancies, psychosocial distress, and HIV infection in AGYW, there is a need for comprehensive HIV prevention programming inclusive of mental health support [34].", [["depression", "DISEASE", 176, 186], ["suicide ideation", "DISEASE", 190, 206], ["psychosocial distress", "DISEASE", 489, 510], ["HIV infection", "DISEASE", 516, 529], ["HIV", "SPECIES", 516, 519], ["HIV", "SPECIES", 516, 519], ["HIV", "SPECIES", 573, 576], ["the stigma", "PROBLEM", 50, 60], ["depression", "PROBLEM", 176, 186], ["suicide ideation", "PROBLEM", 190, 206], ["epidemics", "PROBLEM", 375, 384], ["psychosocial conditions", "PROBLEM", 431, 454], ["unintended\u2019 pregnancies", "PROBLEM", 464, 487], ["psychosocial distress", "PROBLEM", 489, 510], ["HIV infection", "PROBLEM", 516, 529], ["comprehensive HIV prevention", "TREATMENT", 559, 587]]], ["It is clear that interventions aiming to reduce rates of teenage pregnancy and reduce HIV acquisition amongst AGYW in South Africa, need to incorporate mental health components [35].", [["HIV", "SPECIES", 86, 89], ["HIV", "SPECIES", 86, 89], ["interventions", "TREATMENT", 17, 30], ["teenage pregnancy", "PROBLEM", 57, 74], ["clear", "OBSERVATION", 6, 11]]], ["Recommendations have been made for integrating mental health care into care for patients with chronic non-communicable diseases, as well as communicable diseases such as HIV [10], but few recommendations for integrating mental health into SRH delivery exist [36].", [["chronic non-communicable diseases", "DISEASE", 94, 127], ["communicable diseases", "DISEASE", 140, 161], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["HIV", "SPECIES", 170, 173], ["HIV", "SPECIES", 170, 173], ["chronic non-communicable diseases", "PROBLEM", 94, 127], ["communicable diseases", "PROBLEM", 140, 161]]], ["The links between mental health, HIV status, and \u2018unintended\u2019 pregnancy, exacerbate the need to strengthen the integration of routine mental health screening in SRH and HIV programming in order to enhance the health outcomes amongst AGYW [12].", [["HIV", "SPECIES", 33, 36], ["HIV", "SPECIES", 33, 36], ["HIV", "SPECIES", 169, 172], ["HIV programming", "TREATMENT", 169, 184]]], ["Addressing underlying mental health risks may be an important additional strategy to promote sexual risk reduction, and behavioural interventions which are able to improve mental health are also more effective in preventing negative sexual health outcomes such as HIV infection [22].Mental Health Screening Included in SRH Services ::: Conclusions and RecommendationsThe indication of a dual burden of psychological distress and sexual risk behaviours suggests that screening for mental health disorders should be integrated into SRH services [22].", [["HIV infection", "DISEASE", 264, 277], ["psychological distress", "DISEASE", 402, 424], ["HIV", "ORGANISM", 264, 267], ["HIV", "SPECIES", 264, 267], ["HIV", "SPECIES", 264, 267], ["sexual risk reduction", "TREATMENT", 93, 114], ["behavioural interventions", "TREATMENT", 120, 145], ["HIV infection", "PROBLEM", 264, 277], ["psychological distress", "PROBLEM", 402, 424], ["sexual risk behaviours", "PROBLEM", 429, 451], ["mental health disorders", "PROBLEM", 480, 503]]], ["Despite the evidence of intersecting epidemics, mental health screening is not standard in HIV prevention and care settings and has not been added to the HIV care cascade.", [["HIV", "SPECIES", 91, 94], ["HIV", "SPECIES", 154, 157], ["intersecting epidemics", "PROBLEM", 24, 46], ["mental health screening", "TEST", 48, 71], ["HIV prevention", "TREATMENT", 91, 105], ["care settings", "TREATMENT", 110, 123], ["the HIV care cascade", "TREATMENT", 150, 170], ["evidence of", "UNCERTAINTY", 12, 23], ["intersecting", "OBSERVATION_MODIFIER", 24, 36], ["epidemics", "OBSERVATION", 37, 46]]], ["Combination interventions inclusive of psychological and behavioural components may be able to achieve greater reductions in sexual risk behaviour among adolescents, as incorporating psychological health interventions appears to be a critical part of any comprehensive strategy for mitigating HIV risk [21].", [["HIV", "ORGANISM", 293, 296], ["HIV", "SPECIES", 293, 296], ["Combination interventions", "TREATMENT", 0, 25], ["psychological and behavioural components", "TREATMENT", 39, 79], ["psychological health interventions", "TREATMENT", 183, 217]]], ["Mental health services targeted at AGYW, especially those that are HIV positive and/or pregnant, need to be integrated into SRH services, especially those that aim to be \u201cyouth-friendly\u201d; prevention, diagnosis and management of depressive symptoms should also be included in the package of comprehensive services [14, 19].", [["depressive symptoms", "DISEASE", 228, 247], ["HIV", "SPECIES", 67, 70], ["HIV", "SPECIES", 67, 70], ["HIV positive", "PROBLEM", 67, 79], ["depressive symptoms", "PROBLEM", 228, 247]]], ["Early mental health screening could help catch AGYW who might not yet be diagnostically clinical depressed.", [["depressed", "DISEASE", 97, 106], ["Early mental health screening", "TEST", 0, 29], ["clinical depressed", "PROBLEM", 88, 106]]], ["Given the evidence, it is likely that AGYW have overlapping epidemics that are clinically significant.", [["overlapping epidemics", "PROBLEM", 48, 69], ["is likely", "UNCERTAINTY", 23, 32], ["epidemics", "OBSERVATION", 60, 69]]], ["Practical recommendations for improving mental health care delivery to AGYW include improving mental health, advocacy, decentralization of services, task-shifting and on-the-job training [12, 37].Contextually Relevant Interventions ::: Conclusions and RecommendationsThe way in which mental health issues, such as stress and depression, are defined and conceptualised differs across settings and socio-cultural contexts, and interventions needs to be contextually relevant [1].", [["depression", "DISEASE", 325, 335], ["improving mental health care delivery", "TREATMENT", 30, 67], ["mental health issues", "PROBLEM", 284, 304], ["stress and depression", "PROBLEM", 314, 335], ["interventions", "TREATMENT", 425, 438]]], ["The words \u201cdepression\u201d and \u201canxiety\u201d do not have direct equivalents in some South African languages, with psychological distress, including depression, described behaviourally rather than cognitively, and expressed and/or experienced somatically, or situated within the relational domain [29, 38].", [["depression", "DISEASE", 11, 21], ["anxiety", "DISEASE", 28, 35], ["psychological distress", "DISEASE", 106, 128], ["depression", "DISEASE", 140, 150], ["depression", "PROBLEM", 11, 21], ["anxiety", "PROBLEM", 28, 35], ["psychological distress", "PROBLEM", 106, 128], ["depression", "PROBLEM", 140, 150]]], ["In addition, the term \u201cunintended pregnancy\u201d is problematic, with traditional measurements dichotomously classifying pregnancies as intended or not, based on a woman\u2019s intentions before she became pregnant [39, 40].", [["woman", "ORGANISM", 160, 165], ["woman", "SPECIES", 160, 165]]], ["\u201cUnplanned pregnancies\u201d likewise have been defined as pregnancies which occur when a woman is using contraception or did not desire pregnancy as an outcome [39].", [["woman", "ORGANISM", 85, 90], ["woman", "SPECIES", 85, 90], ["contraception", "TREATMENT", 100, 113]]], ["The construct of \u2018pregnancy acceptability\u2019 may be a more useful way to taking into account the complexity of pregnancy intentions, in the context of women\u2019s lived experiences, emotions, relationships, and socio-economic circumstances [40].", [["women", "ORGANISM", 149, 154], ["women", "SPECIES", 149, 154], ["\u2018pregnancy acceptability", "PROBLEM", 17, 41], ["pregnancy intentions", "PROBLEM", 109, 129]]], ["A woman\u2019s emotions, levels of preparedness, and acceptance of a pregnancy are likely to change in reaction to external factors, which in turn influence health outcomes [40].", [["woman", "ORGANISM", 2, 7], ["woman", "SPECIES", 2, 7], ["a pregnancy", "PROBLEM", 62, 73], ["change in reaction", "PROBLEM", 88, 106], ["external factors", "PROBLEM", 110, 126]]], ["The biomedical/clinical understandings and definitions of \u201cdepression\u201d and \u201cunintended pregnancy\u201d may not always capture an individual\u2019s subjective experiences and articulation of these states [41], and in order for any intervention to be successful, there is a need to be sensitive and reflective of the reality of people\u2019s lives, with an understanding of the language that AGYW use to describe their lived experiences of depression and pregnancy, which is why qualitative research such as the findings we present here, is much needed [40].", [["depression", "DISEASE", 59, 69], ["depression", "DISEASE", 423, 433], ["people", "ORGANISM", 316, 322], ["people", "SPECIES", 316, 322], ["depression", "PROBLEM", 59, 69], ["any intervention", "TREATMENT", 216, 232], ["depression and pregnancy", "PROBLEM", 423, 447]]], ["Indeed, AGYW in South Africa construct \u201cdepression\u201d and pregnancy is a complex phenomenon manifesting in a variety of emotions, thoughts, and behaviours; finding ways to surface contextually congruent understandings of sexual and reproductive health, and mental health can inform the development of interventions that are contextually and population relevant [29].", [["depression", "DISEASE", 40, 50], ["depression", "PROBLEM", 40, 50], ["a complex phenomenon", "PROBLEM", 69, 89], ["interventions", "TREATMENT", 299, 312]]], ["Mental health and SRH interventions and services need to be contextually appropriate and reflective of the reality of people\u2019s lives.", [["people", "ORGANISM", 118, 124], ["people", "SPECIES", 118, 124], ["SRH interventions", "TREATMENT", 18, 35]]], ["Screening tools need to take into account the diversity of understandings of emotional suffering and distress, using appropriate terms, language and concepts.Contextually Relevant Interventions ::: Conclusions and RecommendationsIt is evident that AGYW in South Africa face substantial social adversities and related mental health challenges due to a range of SRH, social, economic, environmental, physiological and interpersonal factors.", [["emotional suffering", "DISEASE", 77, 96], ["Screening tools", "TEST", 0, 15], ["emotional suffering", "PROBLEM", 77, 96], ["distress", "PROBLEM", 101, 109]]], ["Building on previous research that has found associations between depressive symptoms and psychological distress related to pregnancy, combined with a lack of social support amongst South African women [16], our findings provide rich descriptive data on the lived reality of the interconnected psychosocial risks including stress, emotional isolation, feelings of depression and suicidal ideation, with \u2018unintended\u2019 pregnancy and HIV that AGYW in South Africa face, from their own perspectives.", [["depressive symptoms", "DISEASE", 66, 85], ["psychological distress", "DISEASE", 90, 112], ["depression", "DISEASE", 364, 374], ["suicidal ideation", "DISEASE", 379, 396], ["women", "ORGANISM", 196, 201], ["women", "SPECIES", 196, 201], ["HIV", "SPECIES", 430, 433], ["HIV", "SPECIES", 430, 433], ["depressive symptoms", "PROBLEM", 66, 85], ["psychological distress", "PROBLEM", 90, 112], ["pregnancy", "PROBLEM", 124, 133], ["emotional isolation", "TREATMENT", 331, 350], ["depression", "PROBLEM", 364, 374], ["suicidal ideation", "PROBLEM", 379, 396], ["HIV", "PROBLEM", 430, 433]]], ["Framing these interconnections within the syndemic framework can help to inform interventions that seek to address AGYW risk.", [["interventions", "TREATMENT", 80, 93]]], ["As psychological distress is associated with increased risk behaviours, it is critical that efforts to address early pregnancy and HIV infection amongst AGYW incorporate mental health components.", [["psychological distress", "DISEASE", 3, 25], ["HIV infection", "DISEASE", 131, 144], ["HIV", "SPECIES", 131, 134], ["HIV", "SPECIES", 131, 134], ["psychological distress", "PROBLEM", 3, 25], ["increased risk behaviours", "PROBLEM", 45, 70], ["early pregnancy", "PROBLEM", 111, 126], ["HIV infection", "PROBLEM", 131, 144]]], ["Interventions to improve emotional wellbeing and coping mechanisms for AGYW are needed in order to improve sexual and reproductive health outcomes; indeed, in a context where HIV, STIs, early pregnancy are common, it is all the more important to have such interventions integrated into SRH services and part of large-scale programmes for AGYW.", [["HIV, STIs", "DISEASE", 175, 184], ["HIV", "ORGANISM", 175, 178], ["HIV", "SPECIES", 175, 178], ["HIV", "SPECIES", 175, 178], ["Interventions", "TREATMENT", 0, 13], ["AGYW", "TREATMENT", 71, 75], ["HIV", "PROBLEM", 175, 178], ["such interventions", "TREATMENT", 251, 269], ["large-scale programmes", "TREATMENT", 311, 333]]], ["Understanding the context of mental health is crucial in order to design and implement effective mental health programming, and to provide appropriate psycho-social support to young women, and in turn, address sexual and reproductive health challenges.", [["women", "ORGANISM", 182, 187], ["women", "SPECIES", 182, 187]]]], "fd23a9ef3092fe452b0c485e094ce276be2639ef": [["INTRODUCTIONIn recent years an increasing number of bovine herpes virus 4 (BHV4) related disorders, with postpartum metritis as the major sign, have been diagnosed in Belgium (Wellemans et al., 1983) .", [["bovine herpes virus", "DISEASE", 52, 71], ["metritis", "DISEASE", 116, 124], ["bovine", "ORGANISM", 52, 58], ["herpes virus 4", "ORGANISM", 59, 73], ["BHV4", "ORGANISM", 75, 79], ["bovine", "SPECIES", 52, 58], ["herpes virus", "SPECIES", 59, 71], ["bovine herpes virus", "SPECIES", 52, 71], ["BHV4", "SPECIES", 75, 79], ["bovine herpes virus", "PROBLEM", 52, 71], ["related disorders", "PROBLEM", 81, 98], ["postpartum metritis", "PROBLEM", 105, 124], ["increasing", "OBSERVATION_MODIFIER", 31, 41], ["bovine herpes virus", "OBSERVATION", 52, 71]]], ["Clinical metritis was usually observed by day five postpartum and lasted for several weeks.", [["metritis", "DISEASE", 9, 17], ["Clinical metritis", "PROBLEM", 0, 17], ["metritis", "OBSERVATION", 9, 17]]], ["There was only some vaginal outflow of a clear mucus with purulent flecks.", [["vaginal", "ANATOMY", 20, 27], ["mucus", "ANATOMY", 47, 52], ["vaginal", "ORGANISM_SUBDIVISION", 20, 27], ["mucus", "ORGANISM_SUBSTANCE", 47, 52], ["purulent flecks", "PROBLEM", 58, 73], ["vaginal outflow", "ANATOMY", 20, 35], ["clear", "OBSERVATION_MODIFIER", 41, 46], ["mucus", "OBSERVATION", 47, 52], ["purulent flecks", "OBSERVATION", 58, 73]]], ["Repeat-breeding was consistently observed.", [["Repeat", "TEST", 0, 6]]], ["In some farms other signs, such as mastitis, peritonitis, nasal discharge, respiratory problems and sudden death of the neonates were observed.", [["nasal", "ANATOMY", 58, 63], ["respiratory", "ANATOMY", 75, 86], ["mastitis", "DISEASE", 35, 43], ["peritonitis", "DISEASE", 45, 56], ["respiratory problems", "DISEASE", 75, 95], ["death", "DISEASE", 107, 112], ["nasal", "ORGANISM_SUBDIVISION", 58, 63], ["neonates", "ORGANISM", 120, 128], ["some farms other signs", "PROBLEM", 3, 25], ["mastitis", "PROBLEM", 35, 43], ["peritonitis", "PROBLEM", 45, 56], ["nasal discharge", "PROBLEM", 58, 73], ["respiratory problems", "PROBLEM", 75, 95], ["sudden death of the neonates", "PROBLEM", 100, 128], ["mastitis", "OBSERVATION", 35, 43], ["peritonitis", "OBSERVATION", 45, 56], ["nasal", "ANATOMY", 58, 63], ["respiratory", "ANATOMY", 75, 86]]], ["Studies of these cases suggested that BHV4 could also be the causal agent in peritonitis, infertility, respiratory problems and neonatal diarrhoeaoften in association with excretion of Cryptosporidium sp (Van Opdenbosch et al., 1983a; Wellemans et al., 1984) .INTRODUCTIONExperimental work indicated that BHV4 causes a lymphoid-associated persistent infection (Osorio & Reed, 1983) .", [["respiratory", "ANATOMY", 103, 114], ["lymphoid", "ANATOMY", 319, 327], ["BHV4", "CHEMICAL", 38, 42], ["peritonitis", "DISEASE", 77, 88], ["infertility", "DISEASE", 90, 101], ["respiratory problems", "DISEASE", 103, 123], ["diarrhoeaoften", "CHEMICAL", 137, 151], ["BHV4", "CHEMICAL", 305, 309], ["infection", "DISEASE", 350, 359], ["BHV4", "GENE_OR_GENE_PRODUCT", 38, 42], ["Cryptosporidium sp", "ORGANISM", 185, 203], ["BHV4", "GENE_OR_GENE_PRODUCT", 305, 309], ["lymphoid", "ORGAN", 319, 327], ["Cryptosporidium sp (Van Opdenbosch et al., 1983a", "SPECIES", 185, 233], ["BHV4", "PROBLEM", 38, 42], ["peritonitis", "PROBLEM", 77, 88], ["infertility", "PROBLEM", 90, 101], ["respiratory problems", "PROBLEM", 103, 123], ["neonatal diarrhoeaoften", "PROBLEM", 128, 151], ["Cryptosporidium", "PROBLEM", 185, 200], ["a lymphoid-associated persistent infection", "PROBLEM", 317, 359], ["peritonitis", "OBSERVATION", 77, 88], ["respiratory problems", "OBSERVATION", 103, 123], ["lymphoid", "ANATOMY", 319, 327], ["persistent", "OBSERVATION_MODIFIER", 339, 349], ["infection", "OBSERVATION", 350, 359]]], ["Intensive virus multiplication after parturition with an accompanying leucopenia may be the origin of the various infections and signs observed in cattle; seroneutralizing antibodies were not detected in the serum (Wellemans et al., 1986) .", [["serum", "ANATOMY", 208, 213], ["leucopenia", "DISEASE", 70, 80], ["infections", "DISEASE", 114, 124], ["cattle", "ORGANISM", 147, 153], ["serum", "ORGANISM_SUBSTANCE", 208, 213], ["seroneutralizing antibodies", "PROTEIN", 155, 182], ["cattle", "SPECIES", 147, 153], ["cattle", "SPECIES", 147, 153], ["Intensive virus multiplication", "TREATMENT", 0, 30], ["an accompanying leucopenia", "PROBLEM", 54, 80], ["the various infections", "PROBLEM", 102, 124], ["cattle; seroneutralizing antibodies", "TEST", 147, 182], ["leucopenia", "OBSERVATION", 70, 80], ["various", "OBSERVATION_MODIFIER", 106, 113], ["infections", "OBSERVATION", 114, 124]]], ["Only experimental infections and individually diagnosed cases have been previously described (Parks & Kendrick, 1973; Mohanty et al., 1971) .INTRODUCTIONIn this study we present serological, immunological, biochemical and clinical data from two BHV4 infected breeding farms with mixed Belgian Blue and White cattle having a 10 year history of metritis-related fertility problems.", [["infections", "DISEASE", 18, 28], ["metritis", "DISEASE", 343, 351], ["cattle", "SPECIES", 308, 314], ["White cattle", "SPECIES", 302, 314], ["experimental infections", "PROBLEM", 5, 28], ["this study", "TEST", 156, 166], ["metritis", "PROBLEM", 343, 351], ["fertility problems", "PROBLEM", 360, 378], ["infections", "OBSERVATION", 18, 28], ["metritis", "OBSERVATION", 343, 351]]], ["Blood samples (serum and noncoagulated blood) were taken about one week before the suspected calving date and weekly for four weeks after calving.", [["Blood samples", "ANATOMY", 0, 13], ["serum", "ANATOMY", 15, 20], ["blood", "ANATOMY", 39, 44], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["serum", "ORGANISM_SUBSTANCE", 15, 20], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["Blood samples", "TEST", 0, 13], ["serum and noncoagulated blood", "TEST", 15, 44]]], ["A final blood sample from the cows and from the two bulls was taken at the end of April 1986.MATERIALSThe following parameters were measured on the heparinized blood samples: number of red blood cells, number of white blood cells, haematocrit, haemoglobin, mean cell haemoglobin, mean cell volume, mean cell haemoglobin concentration and differential white blood cell count.MATERIALSSodium, potassium, chloride, calcium, inorganic phosphate, total protein, albumin, haptoglobin, glucose, cholesterol, triglycerides, phospholipids, bound urea nitrogen, creatin, total bilirubin, alkaline phosphatase, serum glutamate-oxaloacetate transaminase, serum glutamate-pyruvate transaminase, gamma-glutamine transpeptidase, lactate dehydrogenase and creatin kinase were determined on the serum samples.MATERIALSAntibodies against BHV4 were detected by indirect immunofluorescence (IIF) using the drop method described earlier (Wellemans & Leunen, 1973) .", [["blood sample", "ANATOMY", 8, 20], ["blood samples", "ANATOMY", 160, 173], ["red blood cells", "ANATOMY", 185, 200], ["white blood cells", "ANATOMY", 212, 229], ["cell", "ANATOMY", 262, 266], ["cell", "ANATOMY", 285, 289], ["cell", "ANATOMY", 303, 307], ["white blood cell", "ANATOMY", 351, 367], ["serum", "ANATOMY", 600, 605], ["serum", "ANATOMY", 643, 648], ["serum samples", "ANATOMY", 778, 791], ["MATERIALSSodium", "CHEMICAL", 374, 389], ["potassium", "CHEMICAL", 391, 400], ["chloride", "CHEMICAL", 402, 410], ["calcium", "CHEMICAL", 412, 419], ["inorganic phosphate", "CHEMICAL", 421, 440], ["glucose", "CHEMICAL", 479, 486], ["cholesterol", "CHEMICAL", 488, 499], ["urea nitrogen", "CHEMICAL", 537, 550], ["bilirubin", "CHEMICAL", 567, 576], ["glutamate", "CHEMICAL", 606, 615], ["oxaloacetate", "CHEMICAL", 616, 628], ["glutamate", "CHEMICAL", 649, 658], ["pyruvate", "CHEMICAL", 659, 667], ["gamma-glutamine", "CHEMICAL", 682, 697], ["lactate", "CHEMICAL", 714, 721], ["MATERIALSSodium", "CHEMICAL", 374, 389], ["potassium", "CHEMICAL", 391, 400], ["chloride", "CHEMICAL", 402, 410], ["calcium", "CHEMICAL", 412, 419], ["phosphate", "CHEMICAL", 431, 440], ["glucose", "CHEMICAL", 479, 486], ["cholesterol", "CHEMICAL", 488, 499], ["triglycerides", "CHEMICAL", 501, 514], ["urea", "CHEMICAL", 537, 541], ["nitrogen", "CHEMICAL", 542, 550], ["creatin", "CHEMICAL", 552, 559], ["bilirubin", "CHEMICAL", 567, 576], ["glutamate", "CHEMICAL", 606, 615], ["oxaloacetate", "CHEMICAL", 616, 628], ["glutamate", "CHEMICAL", 649, 658], ["pyruvate", "CHEMICAL", 659, 667], ["gamma-glutamine", "CHEMICAL", 682, 697], ["lactate", "CHEMICAL", 714, 721], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["cows", "ORGANISM", 30, 34], ["blood samples", "ORGANISM_SUBSTANCE", 160, 173], ["red blood cells", "CELL", 185, 200], ["white blood cells", "CELL", 212, 229], ["haematocrit", "ORGANISM_SUBSTANCE", 231, 242], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 244, 255], ["cell", "CELL", 262, 266], ["cell", "CELL", 285, 289], ["cell", "CELL", 303, 307], ["white blood cell", "CELL", 351, 367], ["MATERIALSSodium", "SIMPLE_CHEMICAL", 374, 389], ["potassium", "SIMPLE_CHEMICAL", 391, 400], ["chloride", "SIMPLE_CHEMICAL", 402, 410], ["calcium", "SIMPLE_CHEMICAL", 412, 419], ["inorganic phosphate", "SIMPLE_CHEMICAL", 421, 440], ["albumin", "GENE_OR_GENE_PRODUCT", 457, 464], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 466, 477], ["glucose", "SIMPLE_CHEMICAL", 479, 486], ["cholesterol", "SIMPLE_CHEMICAL", 488, 499], ["triglycerides", "SIMPLE_CHEMICAL", 501, 514], ["phospholipids", "SIMPLE_CHEMICAL", 516, 529], ["urea", "SIMPLE_CHEMICAL", 537, 541], ["nitrogen", "SIMPLE_CHEMICAL", 542, 550], ["creatin", "SIMPLE_CHEMICAL", 552, 559], ["bilirubin", "SIMPLE_CHEMICAL", 567, 576], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 578, 598], ["serum", "ORGANISM_SUBSTANCE", 600, 605], ["glutamate", "SIMPLE_CHEMICAL", 606, 615], ["oxaloacetate", "SIMPLE_CHEMICAL", 616, 628], ["transaminase", "GENE_OR_GENE_PRODUCT", 629, 641], ["serum", "ORGANISM_SUBSTANCE", 643, 648], ["glutamate-pyruvate transaminase", "GENE_OR_GENE_PRODUCT", 649, 680], ["gamma-glutamine transpeptidase", "GENE_OR_GENE_PRODUCT", 682, 712], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 714, 735], ["creatin kinase", "GENE_OR_GENE_PRODUCT", 740, 754], ["serum samples", "ORGANISM_SUBSTANCE", 778, 791], ["BHV4", "GENE_OR_GENE_PRODUCT", 820, 824], ["red blood cells", "CELL_TYPE", 185, 200], ["white blood cells", "CELL_TYPE", 212, 229], ["total protein", "PROTEIN", 442, 455], ["albumin", "PROTEIN", 457, 464], ["haptoglobin", "PROTEIN", 466, 477], ["creatin", "PROTEIN", 552, 559], ["total bilirubin", "PROTEIN", 561, 576], ["alkaline phosphatase", "PROTEIN", 578, 598], ["serum glutamate-oxaloacetate transaminase", "PROTEIN", 600, 641], ["serum glutamate-pyruvate transaminase", "PROTEIN", 643, 680], ["gamma-glutamine transpeptidase", "PROTEIN", 682, 712], ["lactate dehydrogenase", "PROTEIN", 714, 735], ["creatin kinase", "PROTEIN", 740, 754], ["BHV4", "PROTEIN", 820, 824], ["cows", "SPECIES", 30, 34], ["A final blood sample", "TEST", 0, 20], ["the heparinized blood samples", "TEST", 144, 173], ["red blood cells", "TEST", 185, 200], ["white blood cells", "TEST", 212, 229], ["haematocrit", "TEST", 231, 242], ["haemoglobin", "TEST", 244, 255], ["mean cell haemoglobin", "TEST", 257, 278], ["mean cell volume", "TEST", 280, 296], ["mean cell haemoglobin concentration", "TEST", 298, 333], ["differential white blood cell count", "TEST", 338, 373], ["MATERIALSSodium", "TEST", 374, 389], ["potassium", "TEST", 391, 400], ["chloride", "TEST", 402, 410], ["calcium", "TEST", 412, 419], ["inorganic phosphate", "TEST", 421, 440], ["total protein", "TEST", 442, 455], ["albumin", "TEST", 457, 464], ["haptoglobin", "TEST", 466, 477], ["glucose", "TEST", 479, 486], ["cholesterol", "TEST", 488, 499], ["triglycerides", "TEST", 501, 514], ["phospholipids", "TEST", 516, 529], ["bound urea nitrogen", "TEST", 531, 550], ["creatin", "TEST", 552, 559], ["total bilirubin", "TEST", 561, 576], ["alkaline phosphatase", "TEST", 578, 598], ["serum glutamate", "TEST", 600, 615], ["oxaloacetate transaminase", "TEST", 616, 641], ["serum glutamate", "TEST", 643, 658], ["pyruvate transaminase", "TEST", 659, 680], ["gamma", "TEST", 682, 687], ["glutamine transpeptidase", "TEST", 688, 712], ["lactate dehydrogenase", "TEST", 714, 735], ["creatin kinase", "TEST", 740, 754], ["the serum samples", "TEST", 774, 791], ["BHV4", "PROBLEM", 820, 824], ["indirect immunofluorescence", "TEST", 842, 869], ["the drop method", "TREATMENT", 882, 897], ["mean cell haemoglobin", "OBSERVATION", 257, 278], ["mean cell volume", "OBSERVATION", 280, 296], ["mean cell haemoglobin", "OBSERVATION", 298, 319]]], ["PK15 (Pig Kidney I5 cell-line) cell culture was infected with BHV4 virus.", [["Kidney I5 cell-line) cell culture", "ANATOMY", 10, 43], ["PK15", "GENE_OR_GENE_PRODUCT", 0, 4], ["Pig Kidney I5 cell-line) cell", "CELL", 6, 35], ["BHV4 virus", "ORGANISM", 62, 72], ["PK15 (Pig Kidney I5 cell-line) cell culture", "CELL_LINE", 0, 43], ["BHV4 virus", "SPECIES", 62, 72], ["PK15", "TEST", 0, 4], ["Pig Kidney I5 cell", "TREATMENT", 6, 24], ["cell culture", "TEST", 31, 43], ["BHV4 virus", "PROBLEM", 62, 72], ["Kidney", "ANATOMY", 10, 16]]], ["When approximately 30% of the cells were expected to contain antigen, the culture was trypsinized and, after washing, dropped on preprinted glass slides with ten wells.", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["the culture", "TEST", 70, 81]]], ["Each well contained approximately thirty BHV4 infected cells and seventy uninfected PK15 cells.", [["cells", "ANATOMY", 55, 60], ["PK15 cells", "ANATOMY", 84, 94], ["cells", "CELL", 55, 60], ["PK15 cells", "CELL", 84, 94], ["BHV4 infected cells", "CELL_LINE", 41, 60], ["PK15 cells", "CELL_LINE", 84, 94], ["approximately thirty BHV4 infected cells", "PROBLEM", 20, 60], ["seventy uninfected PK15 cells", "PROBLEM", 65, 94], ["approximately", "OBSERVATION_MODIFIER", 20, 33], ["thirty BHV4", "OBSERVATION_MODIFIER", 34, 45], ["infected cells", "OBSERVATION", 46, 60], ["PK15 cells", "OBSERVATION", 84, 94]]], ["BHV4 antibody detection in serial serum dilutions was performed using a FITC (fluorescein isothiocyanate) conjugated anti-bovine IgG preparation.", [["serum", "ANATOMY", 34, 39], ["fluorescein isothiocyanate", "CHEMICAL", 78, 104], ["FITC", "CHEMICAL", 72, 76], ["fluorescein isothiocyanate", "CHEMICAL", 78, 104], ["BHV4", "GENE_OR_GENE_PRODUCT", 0, 4], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["FITC", "SIMPLE_CHEMICAL", 72, 76], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 78, 104], ["BHV4 antibody", "PROTEIN", 0, 13], ["BHV4", "SPECIES", 0, 4], ["BHV4 antibody detection", "TEST", 0, 23], ["serial serum dilutions", "TEST", 27, 49], ["a FITC (fluorescein isothiocyanate) conjugated anti-bovine IgG preparation", "TREATMENT", 70, 144]]], ["The specificity of the IIF test for BHV4 antibody detection was confirmed using monospecific antisera against a range of bovine viruses. including BHVI, BHV2 and BHV3.MATERIALSVirus neutralizing BHV4 antibodies were measured by a microneutralization test in microtiterplates sown with Secondary Fetal Calf Kidney cells (SFCK) after contact with 100 50% Tissue Culture Infecting Doses (TCID) of BHV4 mixed with serum for I h at 37\u00b0C.MATERIALSAntibodies against adeno A and B virus, bovine respiratory syncitial virus (BRSV), para influenza 3 (PI,), bovine viral diarrhoea (BVD) and bovine herpes virus 1 (BHVl) were measured by an ELISA test, as described earlier (Van Opdenbosch etal., 1985) .", [["microtiterplates", "ANATOMY", 258, 274], ["Fetal Calf Kidney cells", "ANATOMY", 295, 318], ["SFCK", "ANATOMY", 320, 324], ["serum", "ANATOMY", 410, 415], ["respiratory syncitial virus", "DISEASE", 488, 515], ["viral diarrhoea", "DISEASE", 555, 570], ["BVD", "DISEASE", 572, 575], ["IIF", "GENE_OR_GENE_PRODUCT", 23, 26], ["BHV4 antibody", "GENE_OR_GENE_PRODUCT", 36, 49], ["bovine", "ORGANISM", 121, 127], ["BHVI", "GENE_OR_GENE_PRODUCT", 147, 151], ["BHV2", "GENE_OR_GENE_PRODUCT", 153, 157], ["BHV4", "GENE_OR_GENE_PRODUCT", 195, 199], ["Fetal Calf Kidney cells", "CELL", 295, 318], ["SFCK", "CELL", 320, 324], ["BHV4", "SIMPLE_CHEMICAL", 394, 398], ["serum", "ORGANISM_SUBSTANCE", 410, 415], ["adeno A and B virus", "ORGANISM", 460, 479], ["bovine respiratory syncitial virus", "ORGANISM", 481, 515], ["BRSV", "ORGANISM", 517, 521], ["para influenza 3", "ORGANISM", 524, 540], ["PI", "GENE_OR_GENE_PRODUCT", 542, 544], ["bovine", "ORGANISM", 548, 554], ["viral diarrhoea", "ORGANISM", 555, 570], ["bovine herpes virus 1", "ORGANISM", 581, 602], ["BHVl", "ORGANISM", 604, 608], ["IIF", "PROTEIN", 23, 26], ["BHV4 antibody", "PROTEIN", 36, 49], ["BHV2", "DNA", 153, 157], ["BHV3", "DNA", 162, 166], ["BHV4 antibodies", "PROTEIN", 195, 210], ["Secondary Fetal Calf Kidney cells", "CELL_LINE", 285, 318], ["bovine", "SPECIES", 121, 127], ["Calf", "SPECIES", 301, 305], ["B virus", "SPECIES", 472, 479], ["bovine", "SPECIES", 481, 487], ["respiratory syncitial virus", "SPECIES", 488, 515], ["BRSV", "SPECIES", 517, 521], ["bovine", "SPECIES", 548, 554], ["bovine", "SPECIES", 581, 587], ["herpes virus 1", "SPECIES", 588, 602], ["BHV4", "SPECIES", 36, 40], ["bovine", "SPECIES", 121, 127], ["BHV4", "SPECIES", 195, 199], ["Calf", "SPECIES", 301, 305], ["adeno A", "SPECIES", 460, 467], ["B virus", "SPECIES", 472, 479], ["bovine respiratory syncitial virus", "SPECIES", 481, 515], ["BRSV", "SPECIES", 517, 521], ["bovine", "SPECIES", 548, 554], ["BVD", "SPECIES", 572, 575], ["bovine herpes virus 1", "SPECIES", 581, 602], ["the IIF test", "TEST", 19, 31], ["BHV4 antibody detection", "TEST", 36, 59], ["monospecific antisera", "TREATMENT", 80, 101], ["bovine viruses", "PROBLEM", 121, 135], ["BHVI", "TEST", 147, 151], ["BHV2", "TREATMENT", 153, 157], ["BHV3", "TREATMENT", 162, 166], ["MATERIALSVirus neutralizing BHV4 antibodies", "TEST", 167, 210], ["a microneutralization test", "TEST", 228, 254], ["microtiterplates", "TEST", 258, 274], ["Secondary Fetal Calf Kidney cells", "PROBLEM", 285, 318], ["BHV4", "TREATMENT", 394, 398], ["MATERIALSAntibodies", "TEST", 432, 451], ["adeno A and B virus", "PROBLEM", 460, 479], ["bovine respiratory syncitial virus", "PROBLEM", 481, 515], ["BRSV", "PROBLEM", 517, 521], ["para influenza", "PROBLEM", 524, 538], ["PI", "TEST", 542, 544], ["bovine viral diarrhoea", "PROBLEM", 548, 570], ["BVD", "PROBLEM", 572, 575], ["bovine herpes virus", "PROBLEM", 581, 600], ["an ELISA test", "TEST", 627, 640], ["bovine viruses", "OBSERVATION", 121, 135], ["Fetal", "ANATOMY_MODIFIER", 295, 300], ["Calf Kidney", "ANATOMY", 301, 312], ["viral diarrhoea", "OBSERVATION", 555, 570]]], ["Briefly, polystyrene microtest plates were coated with the different antigens and uninfected cell cultures were used as controls.", [["cell cultures", "ANATOMY", 93, 106], ["polystyrene", "CHEMICAL", 9, 20], ["cell cultures", "CELL", 93, 106], ["uninfected cell cultures", "CELL_LINE", 82, 106], ["polystyrene microtest plates", "TREATMENT", 9, 37], ["the different antigens", "TREATMENT", 55, 77], ["uninfected cell cultures", "TEST", 82, 106], ["uninfected cell cultures", "OBSERVATION", 82, 106]]], ["The serum samples were tested at a dilution of 1:50.", [["serum samples", "ANATOMY", 4, 17], ["serum samples", "ORGANISM_SUBSTANCE", 4, 17], ["The serum samples", "TEST", 0, 17]]], ["Goat anti-bovine immunoglobulins labelled with horseradish peroxidase were used as conjugate.", [["horseradish peroxidase", "SIMPLE_CHEMICAL", 47, 69], ["Goat anti-bovine immunoglobulins", "PROTEIN", 0, 32], ["horseradish peroxidase", "PROTEIN", 47, 69], ["Goat", "SPECIES", 0, 4], ["horseradish", "SPECIES", 47, 58], ["Goat", "SPECIES", 0, 4], ["Goat anti-bovine immunoglobulins", "TREATMENT", 0, 32], ["horseradish peroxidase", "TREATMENT", 47, 69]]], ["HZ02 and ABTS (2-2 amino di -3 ethyl benz-thiazoline sulfonicacid) was used as the enzyme substrate.", [["HZ02", "CHEMICAL", 0, 4], ["ABTS", "CHEMICAL", 9, 13], ["2-2 amino di -3 ethyl benz-thiazoline sulfonicacid", "CHEMICAL", 15, 65], ["HZ02", "CHEMICAL", 0, 4], ["ABTS", "CHEMICAL", 9, 13], ["2-2 amino di -3 ethyl benz-thiazoline sulfonicacid", "CHEMICAL", 15, 65], ["HZ02", "SIMPLE_CHEMICAL", 0, 4], ["ABTS", "SIMPLE_CHEMICAL", 9, 13], ["2-2 amino di -3 ethyl benz-thiazoline sulfonicacid", "SIMPLE_CHEMICAL", 15, 65], ["HZ02", "TEST", 0, 4], ["ABTS", "TEST", 9, 13], ["amino di -3 ethyl benz", "TREATMENT", 19, 41], ["thiazoline sulfonicacid)", "TREATMENT", 42, 66], ["the enzyme substrate", "TEST", 79, 99]]], ["The plates were read at 405 nm in a Micro ELISA auto Reader M580 (Dynatech).MATERIALSIn the cases of clinical metritis, lochia were taken weekly with an intra-uterine pipette, mixed with phosphate buffered saline (PBS) pH 7.2 and centrifuged.", [["intra-uterine", "ANATOMY", 153, 166], ["metritis", "DISEASE", 110, 118], ["phosphate", "CHEMICAL", 187, 196], ["phosphate", "CHEMICAL", 187, 196], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 187, 212], ["The plates", "TEST", 0, 10], ["clinical metritis", "PROBLEM", 101, 118], ["lochia", "PROBLEM", 120, 126], ["an intra-uterine pipette", "TREATMENT", 150, 174], ["phosphate buffered saline (PBS", "TREATMENT", 187, 217], ["pH", "TEST", 219, 221], ["metritis", "OBSERVATION", 110, 118]]], ["The supernatant was inoculated into SFCK cell cultures in Leighton tubes.", [["supernatant", "ANATOMY", 4, 15], ["SFCK cell cultures", "ANATOMY", 36, 54], ["SFCK cell cultures", "CELL", 36, 54], ["Leighton tubes", "TISSUE", 58, 72], ["SFCK cell cultures", "CELL_LINE", 36, 54], ["The supernatant", "TREATMENT", 0, 15], ["Leighton tubes", "TREATMENT", 58, 72], ["SFCK cell cultures", "OBSERVATION", 36, 54], ["Leighton tubes", "OBSERVATION", 58, 72]]], ["The cell cultures were stained after four days with monospecific anti-BHV4 fluorescent-labelled antibodies and examined by UV microscopy (Van Opdenbosch eraf., 1983b).", [["cell cultures", "ANATOMY", 4, 17], ["cell cultures", "CELL", 4, 17], ["anti-BHV4", "SIMPLE_CHEMICAL", 65, 74], ["cell cultures", "CELL_LINE", 4, 17], ["monospecific anti-BHV4 fluorescent-labelled antibodies", "PROTEIN", 52, 106], ["The cell cultures", "TEST", 0, 17], ["monospecific anti-BHV4 fluorescent", "TEST", 52, 86], ["labelled antibodies", "TEST", 87, 106], ["cell cultures", "OBSERVATION", 4, 17]]], ["Lochia were also collected for bacteriological examination.MATERIALSFormaldehyde inactivated BHV4 antigen, cultivated on SFCK cells, was inoculated intradermally with a Dermoject Syringe two to five months after calving, in June 1986.", [["SFCK cells", "ANATOMY", 121, 131], ["intradermally", "ANATOMY", 148, 161], ["MATERIALSFormaldehyde", "CHEMICAL", 59, 80], ["BHV4 antigen", "GENE_OR_GENE_PRODUCT", 93, 105], ["SFCK cells", "CELL", 121, 131], ["MATERIALSFormaldehyde inactivated BHV4 antigen", "PROTEIN", 59, 105], ["SFCK cells", "CELL_LINE", 121, 131], ["bacteriological examination", "TEST", 31, 58], ["MATERIALSFormaldehyde inactivated BHV4 antigen", "PROBLEM", 59, 105], ["SFCK cells", "PROBLEM", 121, 131], ["a Dermoject Syringe", "TREATMENT", 167, 186]]], ["The skin reaction was evaluated two days later.RESULTSData from farms A and B are presented in Tables I and II respectively.", [["skin", "ANATOMY", 4, 8], ["skin", "ORGAN", 4, 8], ["B", "CELL", 76, 77], ["The skin reaction", "PROBLEM", 0, 17], ["skin", "ANATOMY", 4, 8], ["reaction", "OBSERVATION", 9, 17]]], ["Of thirty-four animals (thirteen heifers) on farm A and twenty-five (eleven heifers) on farm B, twentytwo and eight respectively were.seropositive to BHV4 before calving.", [["BHV4", "CHEMICAL", 150, 154], ["BHV4", "SPECIES", 150, 154]]], ["However, no seroneutralizing antibodies were found.", [["seroneutralizing antibodies", "PROTEIN", 12, 39], ["seroneutralizing antibodies", "PROBLEM", 12, 39], ["no", "UNCERTAINTY", 9, 11], ["seroneutralizing antibodies", "OBSERVATION", 12, 39]]], ["Caesarian section was necessary on fourteen animals (eight heifers) at farm A and sixteen (eleven heifers) at farm B, this being the normal rate of artificial calvings for the Belgian Blue and White breed.RESULTSMetritis was observed postpartum in twenty animals (59%) on farm A and six animals (24%) on farm B. The average duration of metritis was 11.5 and 17.5 days in farms A and B respectively.", [["metritis", "DISEASE", 336, 344], ["Caesarian section", "TREATMENT", 0, 17], ["artificial calvings", "TREATMENT", 148, 167], ["metritis", "PROBLEM", 336, 344], ["metritis", "OBSERVATION", 336, 344]]], ["BHV4 was isolated from eleven and four lochia from farms A and B respectively.", [["BHV4", "GENE_OR_GENE_PRODUCT", 0, 4], ["B", "CELL", 63, 64], ["BHV4", "SPECIES", 0, 4]]], ["Pathogenic bacteria (Cory,rrebacfe~~um pyogenes or Proteus) were isolated from the lochia of five animals on farm A and three animals on farm B. The bulls at both farms were positive on IIF at the end of April.RESULTSLeucopenia involving both the lymphocytes and the neutrophils (Table III) was observed during the postpartum period in 56% and 24% of the animals at farms A and B respectively.", [["lymphocytes", "ANATOMY", 247, 258], ["neutrophils", "ANATOMY", 267, 278], ["rrebacfe~~um pyogenes", "ORGANISM", 26, 47], ["bulls", "ORGANISM", 149, 154], ["lymphocytes", "CELL", 247, 258], ["neutrophils", "CELL", 267, 278], ["lymphocytes", "CELL_TYPE", 247, 258], ["neutrophils", "CELL_TYPE", 267, 278], ["rrebacfe~~um pyogenes", "SPECIES", 26, 47], ["Pathogenic bacteria", "PROBLEM", 0, 19], ["Cory", "TEST", 21, 25], ["rrebacfe", "TEST", 26, 34], ["pyogenes", "PROBLEM", 39, 47], ["Proteus", "PROBLEM", 51, 58], ["IIF", "TEST", 186, 189], ["RESULTSLeucopenia", "TEST", 210, 227], ["bacteria", "OBSERVATION", 11, 19], ["positive", "OBSERVATION", 174, 182], ["both", "ANATOMY_MODIFIER", 238, 242], ["lymphocytes", "ANATOMY", 247, 258], ["neutrophils", "ANATOMY", 267, 278]]], ["The proportion of eosinophils was relatively high, being about 10% in the first two weeks after parturition and about 15% during weeks three to five.RESULTSA significant correlation between metritis and virus isolation or seroconversion was observed in farm B (p = 0.049) and there was some correlation in farm A (P = 0.069) (Tetrachoric correlation factor followed by Student's t-test).RESULTSThe mean values of all other biochemical parameters analysed were within the normal range.RESULTSOn farm A, cow 7 showed clinical signs of peritonitis.", [["eosinophils", "ANATOMY", 18, 29], ["metritis", "DISEASE", 190, 198], ["peritonitis", "DISEASE", 533, 544], ["eosinophils", "CELL", 18, 29], ["cow", "ORGANISM", 502, 505], ["eosinophils", "CELL_TYPE", 18, 29], ["cow", "SPECIES", 502, 505], ["cow", "SPECIES", 502, 505], ["eosinophils", "TEST", 18, 29], ["metritis", "PROBLEM", 190, 198], ["virus isolation", "TREATMENT", 203, 218], ["seroconversion", "TREATMENT", 222, 236], ["Student's t-test", "TEST", 369, 385], ["RESULTSThe mean values", "TEST", 387, 409], ["all other biochemical parameters", "TEST", 413, 445], ["peritonitis", "PROBLEM", 533, 544], ["eosinophils", "OBSERVATION", 18, 29], ["relatively", "OBSERVATION_MODIFIER", 34, 44], ["high", "OBSERVATION_MODIFIER", 45, 49], ["metritis", "OBSERVATION", 190, 198], ["normal range", "OBSERVATION", 471, 483], ["peritonitis", "OBSERVATION", 533, 544]]], ["Animal numbers 4,7, 10 and 13 (all with a seroconversion against BHV4) had severe respiratory problems without any seroconversion to the known respiratory viruses (BRSV, P13, BHVl, adeno A and B, BVD).RESULTSMastitis was observed in animal numbers 7,8,10,19,20,21,23,25,27 and 28 of farm A.RESULTSIn the skin test, eleven and four seropositive animals on farms A and B respectively and two seronegative animals at farm B showed delayed hypersensitivity (approximately 5 cm diameter of clearly palpable thickening).RESULTSNo correlation was observed between the method or number of calving and metritis.DISCUSSIONThe results obtained in this study on two farms with a history of more than ten years postpartum met&is problems are similar to those obtained after experimental BHV4 inoculation (Osorio & Reed, 1983; Wellemans et al., 1986) .", [["respiratory", "ANATOMY", 82, 93], ["skin", "ANATOMY", 304, 308], ["respiratory problems", "DISEASE", 82, 102], ["hypersensitivity", "DISEASE", 436, 452], ["metritis", "DISEASE", 593, 601], ["BHV4", "CHEMICAL", 774, 778], ["BRSV", "ORGANISM", 164, 168], ["adeno A", "GENE_OR_GENE_PRODUCT", 181, 188], ["B", "GENE_OR_GENE_PRODUCT", 193, 194], ["skin", "ORGAN", 304, 308], ["BRSV", "SPECIES", 164, 168], ["Animal numbers", "TEST", 0, 14], ["a seroconversion against BHV4", "TREATMENT", 40, 69], ["severe respiratory problems", "PROBLEM", 75, 102], ["any seroconversion", "PROBLEM", 111, 129], ["the known respiratory viruses", "PROBLEM", 133, 162], ["BRSV", "TEST", 164, 168], ["P13", "TEST", 170, 173], ["BHVl", "TEST", 175, 179], ["adeno A and B", "PROBLEM", 181, 194], ["BVD", "PROBLEM", 196, 199], ["RESULTSMastitis", "TEST", 201, 216], ["animal numbers", "TEST", 233, 247], ["the skin test", "TEST", 300, 313], ["delayed hypersensitivity", "PROBLEM", 428, 452], ["palpable thickening", "PROBLEM", 493, 512], ["metritis", "PROBLEM", 593, 601], ["this study", "TEST", 636, 646], ["postpartum met&is problems", "PROBLEM", 698, 724], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["respiratory", "ANATOMY", 82, 93], ["respiratory viruses", "ANATOMY", 143, 162], ["skin", "ANATOMY", 304, 308], ["delayed", "OBSERVATION_MODIFIER", 428, 435], ["hypersensitivity", "OBSERVATION_MODIFIER", 436, 452], ["approximately 5 cm diameter", "OBSERVATION_MODIFIER", 454, 481], ["palpable", "OBSERVATION_MODIFIER", 493, 501], ["thickening", "OBSERVATION", 502, 512], ["metritis", "OBSERVATION", 593, 601]]], ["Indeed, during the winter 1985-1986 metritis postpartum was observed in 59 and 30% of the animals after parturition.DISCUSSIONWhether the observed pathology is the result of direct action by BHV4 on the uterus is still in question.", [["uterus", "ANATOMY", 203, 209], ["metritis", "DISEASE", 36, 44], ["BHV4", "GENE_OR_GENE_PRODUCT", 191, 195], ["uterus", "ORGAN", 203, 209], ["BHV4", "PROTEIN", 191, 195], ["metritis", "PROBLEM", 36, 44], ["uterus", "ANATOMY", 203, 209]]], ["Uterine lesions were not seen in experimentally induced metritis (Wellemans et al., 1986) .", [["Uterine lesions", "ANATOMY", 0, 15], ["metritis", "DISEASE", 56, 64], ["Uterine lesions", "PATHOLOGICAL_FORMATION", 0, 15], ["Uterine lesions", "PROBLEM", 0, 15], ["experimentally induced metritis", "PROBLEM", 33, 64], ["lesions", "OBSERVATION", 8, 15], ["not seen", "UNCERTAINTY", 21, 29], ["metritis", "OBSERVATION", 56, 64]]], ["Nevertheless BHV4 was frequently isolated from the lochia of animals with metritis (fifteen isolations from twenty-six metritis cases).", [["metritis", "DISEASE", 74, 82], ["metritis", "DISEASE", 119, 127], ["BHV4", "GENE_OR_GENE_PRODUCT", 13, 17], ["BHV4", "PROTEIN", 13, 17], ["BHV4", "PROBLEM", 13, 17], ["metritis", "PROBLEM", 74, 82], ["metritis", "OBSERVATION", 74, 82]]], ["This is a very high rate if one takes into account that isolation of the virus is no easy matter due to its extreme lability and slow adaptation to cell cultures.", [["cell cultures", "ANATOMY", 148, 161], ["cell cultures", "CELL", 148, 161], ["cell cultures", "CELL_LINE", 148, 161], ["the virus", "PROBLEM", 69, 78], ["easy matter", "PROBLEM", 85, 96], ["its extreme lability", "PROBLEM", 104, 124], ["cell cultures", "TEST", 148, 161], ["virus", "OBSERVATION", 73, 78]]], ["We also observed that the sensitivity of the cell cultures varied from one week to another.", [["cell cultures", "ANATOMY", 45, 58], ["cell cultures", "CELL", 45, 58], ["cell cultures", "CELL_LINE", 45, 58], ["the cell cultures", "TEST", 41, 58]]], ["The difficulty in isolation could explain the negative results from cows 19 and 32 at farm A and cow 12 at farm B, despite the clear seroconversion after metritis.", [["metritis", "DISEASE", 154, 162], ["cow", "SPECIES", 97, 100], ["cow", "SPECIES", 97, 100], ["The difficulty in isolation", "PROBLEM", 0, 27], ["cows", "TEST", 68, 72], ["metritis", "PROBLEM", 154, 162], ["clear", "OBSERVATION_MODIFIER", 127, 132], ["seroconversion", "OBSERVATION", 133, 147], ["metritis", "OBSERVATION", 154, 162]]], ["Moreover, other causes (e.g. Corynebacterium pyogenes) 0 0 3 1 1 3 0 3 3 3 3 3 5 2 2 3 0 0 3 0 0 0 0 0 0 3 2 2 2 1 3 2 3 0 0 0 4 1 4 3 3 1 3 2 3 3 5 2 1 3 0 0 5 2 0 0 0 0 0 3 3 3 2 4 4 3 3 0 0 0 3 0 4 3 2 2 2 3 3 3 4 3 2 3 0 0 4 3 0 2 0 0 0 3 ; 4 4 3 3 4 0 1 0 4 1 4 3 2 2 3 4 3 3 5 3 3 4 0 0 4 3 0 5 0 0 0 3 3 2 2 3 4 3 3 2 4 3 4 3 4 4 3 3 0 3 3 3 0 3 3 2 1 ND 4 2 2 3 2 2 2 2 3 3 4 3 3 3 3 3 4 ND 2 ND 3 2 4 3 0 0 0 0 4 ND ND ND ND ND 4 ND 0 0 0 0 W: Weeks before (-) or after (+) calving.", [["Corynebacterium pyogenes", "ORGANISM", 29, 53], ["Corynebacterium pyogenes", "SPECIES", 29, 53], ["Corynebacterium pyogenes", "SPECIES", 29, 53], ["other causes (e.g. Corynebacterium pyogenes", "PROBLEM", 10, 53]]], ["ND: Not done.DISCUSSION*: Days of start and end of clinical metritis signs. t: Leucopenia: less than 5000 white cells/mm3 one or more times during the four weeks after calving. $: BHV4 indirect immunofluorescence test: end point dilutions of serum:DISCUSSIONScore 1: l/80 Score 2: l/320 Score 3: 111280 Score 4: l/5120 Score 5: >1/5120.", [["white cells", "ANATOMY", 106, 117], ["serum", "ANATOMY", 242, 247], ["metritis", "DISEASE", 60, 68], ["cells", "CELL", 112, 117], ["serum", "ORGANISM_SUBSTANCE", 242, 247], ["clinical metritis signs", "PROBLEM", 51, 74], ["Leucopenia", "PROBLEM", 79, 89], ["white cells", "TEST", 106, 117], ["BHV4 indirect immunofluorescence test", "TEST", 180, 217], ["Score", "TEST", 287, 292], ["Score", "TEST", 303, 308], ["metritis", "OBSERVATION", 60, 68], ["Leucopenia", "OBSERVATION", 79, 89]]], ["Most of the cows were already seropositive before parturition.", [["cows", "ORGANISM", 12, 16], ["cows", "SPECIES", 12, 16]]], ["This confirms that a first contact with BHV4 does not induce an effective immunity, as was already observed in experimentally inoculated animals (Wellemans et al., 1986) .DISCUSSIONClear IIF seroconversion was observed after metritis if the initial antibody level was not too high.", [["BHV4", "CHEMICAL", 40, 44], ["metritis", "DISEASE", 225, 233], ["BHV4", "GENE_OR_GENE_PRODUCT", 40, 44], ["BHV4", "TREATMENT", 40, 44], ["IIF seroconversion", "PROBLEM", 187, 205], ["metritis", "PROBLEM", 225, 233], ["the initial antibody level", "TEST", 237, 263]]], ["In cows 17, 30 and 32 at farm A, the antibody response was very rapid (one week), whereas in cow 12 on this farm the anti BHV4 antibodies only appeared after three months.", [["cow", "ORGANISM", 93, 96], ["BHV4", "GENE_OR_GENE_PRODUCT", 122, 126], ["anti BHV4 antibodies", "PROTEIN", 117, 137], ["cow", "SPECIES", 93, 96], ["cow", "SPECIES", 93, 96], ["BHV4", "SPECIES", 122, 126], ["cows", "TEST", 3, 7], ["the antibody response", "TEST", 33, 54], ["the anti BHV4 antibodies", "TEST", 113, 137]]], ["A similar serological pattern was observed in another study (Wellemans et al., 1986) .", [["A similar serological pattern", "PROBLEM", 0, 29], ["another study", "TEST", 46, 59], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["serological pattern", "OBSERVATION", 10, 29]]], ["The BHV4 antibodies in cow 21 on farm B remained at a low level and were not detectable even in the last blood sample.", [["blood sample", "ANATOMY", 105, 117], ["BHV4 antibodies", "GENE_OR_GENE_PRODUCT", 4, 19], ["cow", "ORGANISM", 23, 26], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["BHV4 antibodies", "PROTEIN", 4, 19], ["cow", "SPECIES", 23, 26], ["BHV4", "SPECIES", 4, 8], ["cow", "SPECIES", 23, 26], ["The BHV4 antibodies", "TEST", 0, 19], ["blood sample", "TEST", 105, 117]]], ["On the other hand, a clear seroconversion was noticed in cows 1, 10,ll and 30 on farm A and cow 12 on farm B without signs of clinical metritis.", [["metritis", "DISEASE", 135, 143], ["cows", "SPECIES", 57, 61], ["cow", "SPECIES", 92, 95], ["cows", "SPECIES", 57, 61], ["cow", "SPECIES", 92, 95], ["a clear seroconversion", "PROBLEM", 19, 41], ["cows", "TEST", 57, 61], ["clinical metritis", "PROBLEM", 126, 143], ["clear", "OBSERVATION_MODIFIER", 21, 26], ["seroconversion", "OBSERVATION", 27, 41], ["without signs of", "UNCERTAINTY", 109, 125], ["clinical metritis", "OBSERVATION", 126, 143]]], ["This could be due to the fact that viral multiplication is not always accompanied by clinical signs or that these signs were not evident enough to be detected by a clinical examination without intra-uterine sampling.DISCUSSIONThe study confirmed previous reports that BHV4 infected cattle do not develop virus neutralizing antibodies (Van Opdenbosch et al., 1983a; Osorio & Reed, 1983; Wellemans et al., 1986; Mohanty et al., 1971) .DISCUSSIONThe delayed hypersensitivity test was only positive in a few cases and cannot therefore be recommended as a diagnostic test for BHV4 infected cattle.DISCUSSIONThe fact that the respiratory troubles in four cows on farm A coincided with a clear seroconversion against BHV4 again implicates BHV4 as a possible causal factor in respiratory problems in cattle as suggested by other researchers (Mohanty et al., 1971; Smith et al., 1972) .DISCUSSIONThe importance of the relative increase in eosinophils, although remarkable, is still in question.", [["respiratory", "ANATOMY", 620, 631], ["respiratory", "ANATOMY", 768, 779], ["eosinophils", "ANATOMY", 930, 941], ["hypersensitivity", "DISEASE", 455, 471], ["respiratory troubles", "DISEASE", 620, 640], ["BHV4", "CHEMICAL", 710, 714], ["respiratory problems", "DISEASE", 768, 788], ["BHV4", "ORGANISM", 268, 272], ["cattle", "ORGANISM", 282, 288], ["BHV4", "ORGANISM", 571, 575], ["cattle", "ORGANISM", 585, 591], ["BHV4", "SIMPLE_CHEMICAL", 710, 714], ["BHV4", "GENE_OR_GENE_PRODUCT", 732, 736], ["cattle", "ORGANISM", 792, 798], ["eosinophils", "CELL", 930, 941], ["virus neutralizing antibodies", "PROTEIN", 304, 333], ["BHV4", "PROTEIN", 732, 736], ["eosinophils", "CELL_TYPE", 930, 941], ["cattle", "SPECIES", 282, 288], ["cattle", "SPECIES", 585, 591], ["cows", "SPECIES", 649, 653], ["cattle", "SPECIES", 792, 798], ["cattle", "SPECIES", 282, 288], ["BHV4", "SPECIES", 571, 575], ["cattle", "SPECIES", 585, 591], ["BHV4", "SPECIES", 710, 714], ["cattle", "SPECIES", 792, 798], ["viral multiplication", "PROBLEM", 35, 55], ["these signs", "PROBLEM", 108, 119], ["a clinical examination", "TEST", 162, 184], ["intra-uterine sampling", "TEST", 193, 215], ["BHV4 infected cattle", "PROBLEM", 268, 288], ["The delayed hypersensitivity test", "TEST", 443, 476], ["a diagnostic test", "TEST", 549, 566], ["BHV4 infected cattle", "PROBLEM", 571, 591], ["the respiratory troubles", "PROBLEM", 616, 640], ["BHV4", "TREATMENT", 710, 714], ["BHV4", "TREATMENT", 732, 736], ["respiratory problems", "PROBLEM", 768, 788], ["the relative increase in eosinophils", "PROBLEM", 905, 941], ["could be due to", "UNCERTAINTY", 5, 20], ["viral", "OBSERVATION", 35, 40], ["respiratory", "ANATOMY", 620, 631], ["troubles", "OBSERVATION", 632, 640], ["increase", "OBSERVATION_MODIFIER", 918, 926], ["eosinophils", "OBSERVATION", 930, 941]]]], "a870e73433f162a8fffba4c76a6b8067b8e1ec99": [], "PMC7365666": [["COVID-19 and STEMIMission: Lifeline is the American Heart Association\u2019s national initiative to advance the systems of care for patients with STEMI.1 Under normal operative conditions, a STEMI system of care requires constant oversight and data review to manage continuous quality improvement.", [["STEMI", "DISEASE", 141, 146], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["STEMI", "PROBLEM", 141, 146], ["a STEMI system of care", "TREATMENT", 184, 206], ["data review", "TEST", 239, 250], ["STEMI", "OBSERVATION", 141, 146], ["normal operative", "OBSERVATION", 155, 171]]], ["As a result of the COVID-19 pandemic, disruptions in the most refined systems of care have occurred.COVID-19 and STEMIDelays are anticipated across the continuum of STEMI care.", [["STEMI", "DISEASE", 165, 170], ["the COVID", "TEST", 15, 24], ["pandemic", "PROBLEM", 28, 36], ["disruptions", "PROBLEM", 38, 49], ["COVID", "TEST", 100, 105], ["STEMIDelays", "TREATMENT", 113, 124], ["STEMI care", "TREATMENT", 165, 175], ["STEMI", "OBSERVATION", 165, 170]]], ["US hospitals are reporting substantial declines in patients presenting by emergency medical services (EMS) or by direct presentation with STEMI.2 Patients and family members may be less likely to call 911 for cardiac symptoms because of fear of exposure to the coronavirus.", [["cardiac", "ANATOMY", 209, 216], ["STEMI", "DISEASE", 138, 143], ["cardiac symptoms", "DISEASE", 209, 225], ["coronavirus", "DISEASE", 261, 272], ["patients", "ORGANISM", 51, 59], ["Patients", "ORGANISM", 146, 154], ["cardiac", "ORGAN", 209, 216], ["coronavirus", "ORGANISM", 261, 272], ["patients", "SPECIES", 51, 59], ["Patients", "SPECIES", 146, 154], ["STEMI", "PROBLEM", 138, 143], ["cardiac symptoms", "PROBLEM", 209, 225], ["the coronavirus", "PROBLEM", 257, 272], ["substantial", "OBSERVATION_MODIFIER", 27, 38], ["declines", "OBSERVATION_MODIFIER", 39, 47]]], ["It is also plausible that there is a protective effect of sheltering, improved behaviors, and increased family support.", [["increased family support", "TREATMENT", 94, 118]]], ["More EMS-transported patients are expected to be critically ill requiring mechanical ventilation.", [["critically ill", "DISEASE", 49, 63], ["EMS", "CHEMICAL", 5, 8], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["critically ill", "PROBLEM", 49, 63], ["mechanical ventilation", "TREATMENT", 74, 96], ["mechanical ventilation", "OBSERVATION", 74, 96]]], ["EMS may need to transport patients to temporary facilities or directly to the most appropriate facility based on local resources.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34]]], ["Fleet resources may become limited while ambulances are being decontaminated and restocked with supplies.", [["Fleet resources", "TREATMENT", 0, 15]]], ["Appropriate delays in EMS first medical contact are to be expected as essential precautionary measures are required to minimize COVID-19 exposure and transmission.", [["COVID-19", "CHEMICAL", 128, 136], ["COVID-19", "CHEMICAL", 128, 136], ["COVID", "TEST", 128, 133]]], ["Necessary delays after hospital arrival occur related to new triage protocols requiring personal travel history, additional detailed sign and symptom screening, thoughtful patient assignment based on suspicion of being COVID-19 positive, and new catheterization laboratory preparations/readiness treating patients in full personal protective equipment (PPE).Public Awareness/Call 911 ::: Interim Emergency STEMI Systems of Care GuidanceAlthough the United States is in the midst of the coronavirus crisis, public awareness campaigns are needed to remind individuals of the signs and symptoms of heart attack, with an added emphasis on calling 911 as soon as possible.", [["heart", "ANATOMY", 595, 600], ["coronavirus", "DISEASE", 486, 497], ["heart attack", "DISEASE", 595, 607], ["patient", "ORGANISM", 172, 179], ["patients", "ORGANISM", 305, 313], ["coronavirus", "ORGANISM", 486, 497], ["heart", "ORGAN", 595, 600], ["patient", "SPECIES", 172, 179], ["patients", "SPECIES", 305, 313], ["new triage protocols", "TREATMENT", 57, 77], ["symptom screening", "TEST", 142, 159], ["COVID", "TEST", 219, 224], ["new catheterization", "TEST", 242, 261], ["the coronavirus crisis", "PROBLEM", 482, 504], ["the signs and symptoms", "PROBLEM", 569, 591], ["heart attack", "PROBLEM", 595, 607], ["coronavirus crisis", "OBSERVATION", 486, 504], ["heart", "ANATOMY", 595, 600], ["attack", "OBSERVATION", 601, 607]]], ["Patients must be reassured that appropriate precautions are being taken to protect them and healthcare workers from COVID-19.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["appropriate precautions", "TREATMENT", 32, 55]]], ["Earlier entry into the system of care will help offset the expected delays in care.Prehospital/Emergency Medical Services ::: Interim Emergency STEMI Systems of Care GuidanceIn attempts to mitigate exposure, the Centers for Disease Control and Prevention recommend Emergency Medical Dispatch centers or 911 Public Safety Answering Points dispatchers triage callers, utilizing a series of questions to identify patients (and anyone in the home) who may be experiencing coronavirus signs and symptoms and share this information with prehospital first responders.3Prehospital/Emergency Medical Services ::: Interim Emergency STEMI Systems of Care GuidanceBefore arrival at the scene, EMS should don the appropriate PPE that must be available to all EMS personnel.", [["patients", "ORGANISM", 410, 418], ["coronavirus", "ORGANISM", 468, 479], ["patients", "SPECIES", 410, 418], ["Care GuidanceIn attempts", "TREATMENT", 161, 185], ["Disease Control", "TREATMENT", 224, 239], ["coronavirus signs and symptoms", "PROBLEM", 468, 498]]], ["Once on scene, the EMS provider should screen the patient again to identify high-risk features.", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["high-risk features", "PROBLEM", 76, 94]]], ["If possible, limiting the number of EMS providers evaluating the patient is recommended.", [["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72]]], ["EMS should assume that all patients, regardless of dispatch complaint, may have COVID-19.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["COVID", "TEST", 80, 85]]], ["Minimum recommended PPE for all patient encounters is a surgical mask, eye protection, and gloves.", [["eye", "ANATOMY", 71, 74], ["patient", "ORGANISM", 32, 39], ["eye", "ORGAN", 71, 74], ["patient", "SPECIES", 32, 39], ["PPE", "TREATMENT", 20, 23], ["a surgical mask", "TREATMENT", 54, 69], ["eye protection", "TREATMENT", 71, 85], ["gloves", "TREATMENT", 91, 97], ["surgical mask", "OBSERVATION", 56, 69]]], ["For patients who are deemed to be at high risk for COVID-19, additional PPE is warranted.Prehospital/Emergency Medical Services ::: Interim Emergency STEMI Systems of Care GuidanceOnce EMS has made rapid but safe and protected contact with the patient, acquisition of the 12-lead ECG should be expedited with subsequent interpretation and prompt notification of findings (and likelihood of COVID-19 infection) to the emergency department.", [["STEMI", "DISEASE", 150, 155], ["infection", "DISEASE", 399, 408], ["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 244, 251], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 244, 251], ["COVID", "TEST", 51, 56], ["additional PPE", "TREATMENT", 61, 75], ["COVID-19 infection", "PROBLEM", 390, 408]]], ["For diagnostic ST elevation, prehospital catheterization laboratory activation should occur immediately.", [["diagnostic ST elevation", "PROBLEM", 4, 27], ["prehospital catheterization", "TEST", 29, 56]]], ["However, often prehospital activation requires more thoughtfulness, coordination, and judgment with particular attention to possible STEMI mimics and duration of symptoms.Emergency Department ::: Interim Emergency STEMI Systems of Care GuidanceFor patients presenting through EMS from the field, there should be a standard brief stop in the receiving hospital emergency department before proceeding to the catheterization laboratory, with clear communication between the emergency department physician and the interventional cardiologist.", [["STEMI", "DISEASE", 133, 138], ["patients", "ORGANISM", 248, 256], ["patients", "SPECIES", 248, 256], ["STEMI mimics", "PROBLEM", 133, 145], ["symptoms", "PROBLEM", 162, 170]]], ["Patients should be triaged for consideration of placement to COVID-positive or suspect and COVID-negative areas.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["placement", "TREATMENT", 48, 57], ["COVID", "TEST", 61, 66], ["COVID", "TEST", 91, 96], ["negative", "OBSERVATION", 97, 105]]], ["Testing for COVID-19 should not delay primary percutaneous coronary intervention (PCI) for those with clear STEMI.", [["percutaneous", "ANATOMY", 46, 58], ["coronary", "ANATOMY", 59, 67], ["STEMI", "DISEASE", 108, 113], ["COVID-19", "CHEMICAL", 12, 20], ["coronary", "MULTI-TISSUE_STRUCTURE", 59, 67], ["Testing", "TEST", 0, 7], ["COVID", "TEST", 12, 17], ["primary percutaneous coronary intervention", "TREATMENT", 38, 80], ["PCI", "TREATMENT", 82, 85], ["clear STEMI", "PROBLEM", 102, 113], ["coronary", "ANATOMY", 59, 67], ["STEMI", "OBSERVATION", 108, 113]]], ["Point-of-care ultrasound use may be helpful to delineate left ventricular wall motion abnormality and pulmonary pathology, particularly in suspected STEMI mimics.", [["left ventricular wall", "ANATOMY", 57, 78], ["pulmonary", "ANATOMY", 102, 111], ["STEMI", "DISEASE", 149, 154], ["ventricular wall", "MULTI-TISSUE_STRUCTURE", 62, 78], ["pulmonary", "ORGAN", 102, 111], ["left ventricular wall motion abnormality", "PROBLEM", 57, 97], ["pulmonary pathology", "PROBLEM", 102, 121], ["left ventricular", "ANATOMY", 57, 73], ["wall", "ANATOMY_MODIFIER", 74, 78], ["motion", "OBSERVATION", 79, 85], ["pulmonary", "ANATOMY", 102, 111], ["pathology", "OBSERVATION", 112, 121]]], ["Patients who require mechanical ventilation should be intubated before transport to the catheterization laboratory with a lower than usual threshold to avoid aerosol spread of respiratory secretions.Emergency Department ::: Interim Emergency STEMI Systems of Care GuidanceFibrinolytic administration for patients with true STEMI who cannot receive PCI and coronary reperfusion within 120 minutes when transferred from a STEMI referring-hospital should be considered, consistent with guideline recommendations.4 Absent significant system resource constraints, PCI should remain the primary and preferred reperfusion strategy for patients with classic STEMI based on superior outcomes with PCI including preservation of left ventricular function and lower rates of reinfarction, stroke, and death and in view of the higher prevalence of STEMI mimics.Catheterization Laboratory ::: Interim Emergency STEMI Systems of Care GuidanceConsideration should be given to options to safely increase catheterization laboratory readiness to accept patients with STEMI more quickly from the field and emergency department once screened for coronavirus.", [["respiratory secretions", "ANATOMY", 176, 198], ["coronary", "ANATOMY", 356, 364], ["left ventricular", "ANATOMY", 718, 734], ["STEMI", "DISEASE", 323, 328], ["STEMI", "DISEASE", 420, 425], ["STEMI", "DISEASE", 650, 655], ["reinfarction", "DISEASE", 763, 775], ["stroke", "DISEASE", 777, 783], ["death", "DISEASE", 789, 794], ["STEMI", "DISEASE", 835, 840], ["STEMI", "DISEASE", 1048, 1053], ["coronavirus", "DISEASE", 1125, 1136], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 304, 312], ["coronary", "MULTI-TISSUE_STRUCTURE", 356, 364], ["patients", "ORGANISM", 628, 636], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 718, 734], ["patients", "ORGANISM", 1034, 1042], ["coronavirus", "ORGANISM", 1125, 1136], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 304, 312], ["patients", "SPECIES", 628, 636], ["patients", "SPECIES", 1034, 1042], ["mechanical ventilation", "TREATMENT", 21, 43], ["intubated", "TREATMENT", 54, 63], ["respiratory secretions", "PROBLEM", 176, 198], ["Care GuidanceFibrinolytic administration", "TREATMENT", 259, 299], ["true STEMI", "PROBLEM", 318, 328], ["PCI", "TREATMENT", 348, 351], ["coronary reperfusion", "TREATMENT", 356, 376], ["PCI", "TREATMENT", 559, 562], ["reperfusion strategy", "TREATMENT", 603, 623], ["classic STEMI", "PROBLEM", 642, 655], ["PCI", "TREATMENT", 688, 691], ["left ventricular function", "TEST", 718, 743], ["reinfarction", "PROBLEM", 763, 775], ["stroke", "PROBLEM", 777, 783], ["death", "PROBLEM", 789, 794], ["STEMI mimics", "PROBLEM", 835, 847], ["Care GuidanceConsideration", "TREATMENT", 914, 940], ["STEMI", "PROBLEM", 1048, 1053], ["coronavirus", "PROBLEM", 1125, 1136], ["respiratory", "ANATOMY", 176, 187], ["secretions", "OBSERVATION", 188, 198], ["STEMI", "OBSERVATION", 323, 328], ["coronary", "ANATOMY", 356, 364], ["reperfusion", "OBSERVATION", 365, 376], ["significant", "OBSERVATION_MODIFIER", 518, 529], ["PCI", "OBSERVATION", 688, 691], ["left ventricular", "ANATOMY", 718, 734], ["lower", "OBSERVATION_MODIFIER", 748, 753], ["reinfarction", "OBSERVATION", 763, 775], ["stroke", "OBSERVATION", 777, 783], ["STEMI", "OBSERVATION", 835, 840]]], ["Designation of 1 laboratory for patients who have tested positive for COVID-19, stocked only with the essential equipment needed for all procedures, may be helpful.", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["COVID", "TEST", 70, 75], ["all procedures", "TREATMENT", 133, 147]]], ["Consideration should be given to use of a negative pressure room, limiting staff in the room, and terminal cleaning with possibly a longer 4- to 6-hour clean.", [["a negative pressure room", "TREATMENT", 40, 64], ["terminal cleaning", "TREATMENT", 98, 115]]], ["Because 25% to 50% of patients infected with SARS-CoV-2 are asymptomatic,5 catheterization laboratory personnel should assume that all patients are COVID-19 positive, particularly in high prevalence areas, and don appropriate PPE.Postreperfusion Hospital Care ::: Interim Emergency STEMI Systems of Care GuidanceTriaging patients to proper units after primary PCI is important.", [["SARS", "DISEASE", 45, 49], ["patients", "ORGANISM", 22, 30], ["SARS-CoV-2", "ORGANISM", 45, 55], ["patients", "ORGANISM", 135, 143], ["patients", "ORGANISM", 321, 329], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 135, 143], ["patients", "SPECIES", 321, 329], ["SARS-CoV", "SPECIES", 45, 53], ["SARS", "PROBLEM", 45, 49], ["CoV", "TEST", 50, 53], ["asymptomatic", "PROBLEM", 60, 72], ["COVID", "TEST", 148, 153], ["primary PCI", "TREATMENT", 352, 363], ["high prevalence", "OBSERVATION_MODIFIER", 183, 198], ["PCI", "OBSERVATION", 360, 363]]], ["In uncomplicated cases, disposition to a noncritical care bed should be considered to conserve critical care beds for patients with COVID-19 requiring mechanical ventilation or critical care unit care.", [["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["a noncritical care bed", "TREATMENT", 39, 61], ["COVID", "TREATMENT", 132, 137], ["mechanical ventilation", "TREATMENT", 151, 173], ["critical care unit care", "TREATMENT", 177, 200]]], ["Patients should receive the usual care after myocardial infarction including adherence to guideline directed medical therapy and post\u2013myocardial infarction assessment of left ventricular function with echocardiography.", [["myocardial", "ANATOMY", 45, 55], ["post\u2013myocardial", "ANATOMY", 129, 144], ["left ventricular", "ANATOMY", 170, 186], ["myocardial infarction", "DISEASE", 45, 66], ["post\u2013myocardial infarction", "DISEASE", 129, 155], ["Patients", "ORGANISM", 0, 8], ["myocardial", "MULTI-TISSUE_STRUCTURE", 45, 55], ["post\u2013myocardial", "MULTI-TISSUE_STRUCTURE", 129, 144], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 170, 186], ["Patients", "SPECIES", 0, 8], ["the usual care", "TREATMENT", 24, 38], ["myocardial infarction", "PROBLEM", 45, 66], ["guideline directed medical therapy", "TREATMENT", 90, 124], ["post\u2013myocardial infarction assessment", "TEST", 129, 166], ["left ventricular function", "TEST", 170, 195], ["echocardiography", "TEST", 201, 217], ["myocardial", "ANATOMY", 45, 55], ["infarction", "OBSERVATION", 56, 66], ["infarction", "OBSERVATION", 145, 155], ["left ventricular", "ANATOMY", 170, 186]]], ["When hospital beds are in extreme demand, early discharge between 24 to 48 hours after PCI in patients with uncomplicated STEMI may be considered.STEMI System of Care Guideline Adherence ::: Interim Emergency STEMI Systems of Care GuidanceThe American College of Cardiology (ACC)/AHA STEMI Guideline recommendations continue to provide the foundation of our evidence-based therapies and efforts to meet time-sensitive goals should continue.4 However, during this COVID-19 pandemic, the inherent delays should be considered as nonsystem delays in the context of reporting measures.Telemedicine ::: Postdischarge Care ::: Interim Emergency STEMI Systems of Care GuidanceBecause of the COVID-19 crisis, the value of telemedicine can surge in (STEMI) heart attack systems of care consultation and management.", [["heart", "ANATOMY", 747, 752], ["STEMI", "DISEASE", 122, 127], ["STEMI", "DISEASE", 146, 151], ["STEMI", "DISEASE", 284, 289], ["STEMI", "DISEASE", 740, 745], ["patients", "ORGANISM", 94, 102], ["heart", "ORGAN", 747, 752], ["patients", "SPECIES", 94, 102], ["PCI", "TREATMENT", 87, 90], ["uncomplicated STEMI", "PROBLEM", 108, 127], ["based therapies", "TREATMENT", 367, 382], ["this COVID", "TEST", 458, 468], ["nonsystem delays", "PROBLEM", 526, 542], ["the COVID", "TEST", 679, 688], ["management", "TREATMENT", 793, 803], ["heart", "ANATOMY", 747, 752]]], ["Coordination of care between STEMI receiving centers, with EMS, and with STEMI referring hospitals may benefit from telemedicine capabilities.", [["STEMI", "DISEASE", 29, 34], ["STEMI", "DISEASE", 73, 78], ["telemedicine capabilities", "TEST", 116, 141]]], ["Telemedicine can also help with family communications for patients with STEMI, as many family members are prohibited from entering the hospital.Cardiac Rehabilitation ::: Postdischarge Care ::: Interim Emergency STEMI Systems of Care GuidanceStay-at-home orders and social distancing guidelines have and will continue to have an effect on cardiac rehabilitation opportunities.", [["Cardiac", "ANATOMY", 144, 151], ["cardiac", "ANATOMY", 339, 346], ["STEMI", "DISEASE", 72, 77], ["patients", "ORGANISM", 58, 66], ["Cardiac", "ORGAN", 144, 151], ["cardiac", "ORGAN", 339, 346], ["patients", "SPECIES", 58, 66], ["STEMI", "PROBLEM", 72, 77], ["Cardiac Rehabilitation", "TREATMENT", 144, 166], ["cardiac rehabilitation opportunities", "TREATMENT", 339, 375]]], ["Cardiac rehabilitation can be attended in a healthcare facility\u2013based program or a home health or virtual model, and referral should still be made to a program to facilitate enrollment at a later date.Summary ::: Interim Emergency STEMI Systems of Care GuidanceDespite the effect of the COVID-19 pandemic on STEMI Systems of Care (Figure), evidence-based cardiac care and the tenets of our collective systems of care success should not be abandoned.", [["Cardiac", "ANATOMY", 0, 7], ["cardiac", "ANATOMY", 355, 362], ["STEMI", "DISEASE", 308, 313], ["Cardiac", "ORGAN", 0, 7], ["Cardiac rehabilitation", "TREATMENT", 0, 22], ["the COVID", "TREATMENT", 283, 292], ["based cardiac care", "TREATMENT", 349, 367], ["care success", "TREATMENT", 412, 424], ["cardiac", "ANATOMY", 355, 362]]], ["Regionalization of STEMI care is perhaps more important than ever.", [["STEMI", "DISEASE", 19, 24], ["STEMI care", "TREATMENT", 19, 29], ["STEMI", "OBSERVATION", 19, 24]]], ["Usual monthly review meetings should continue through the pandemic, in a virtual format, to review regional performance and opportunities for improvement.DisclosuresThe Get With The Guidelines Coronary Artery Disease (GWTG-CAD) program is provided by the American Heart Association.", [["Coronary", "ANATOMY", 193, 201], ["Coronary Artery Disease", "DISEASE", 193, 216], ["CAD", "DISEASE", 223, 226], ["Coronary Artery Disease", "PROBLEM", 193, 216], ["Coronary Artery", "ANATOMY", 193, 208], ["Heart", "ANATOMY", 264, 269]]], ["GWTG-CAD is sponsored, in part, by Novartis, Edwards, and Amgen Cardiovascular.", [["GWTG", "CHEMICAL", 0, 4], ["CAD", "DISEASE", 5, 8], ["CAD", "PROBLEM", 5, 8], ["CAD", "OBSERVATION", 5, 8], ["Novartis", "OBSERVATION", 35, 43]]], ["Dr Granger reports no conflicts relevant to the current work.", [["no", "UNCERTAINTY", 19, 21]]], ["Dr Jacobs is a site principal investigator for a trial by Abbott Vascular.", [["Vascular", "MULTI-TISSUE_STRUCTURE", 65, 73], ["Vascular", "ANATOMY", 65, 73]]], ["Drs Ali, Best, Cohen, Goyal, Henry, Hollowell, Jneid, Jollis, Katz, Mason, Menon, Redlener, and Tamis-Holland have no relevant relationships to disclose.", [["Ali", "OBSERVATION", 4, 7]]]], "PMC7127051": [["Nearly 300 professionals working in research, development, manufacturing and supply of vaccines, from 30 countries, gathered in Bangkok.", [["vaccines", "TREATMENT", 87, 95]]], ["DCVMN is the largest alliance of corporate manufacturers, supplying over 300 vaccine types in various presentations to immunisation programmes, and contributing significantly to global public health efforts to eradicate polio, eliminate and control the spread of known and emerging infectious diseases around the world.IntroductionLocal health authorities and global health organisations represented at this meeting included United Nations International Children's Fund (UNICEF), World Health Organization (WHO), Pan-American Health Organization (PAHO), Gavi: The Vaccine Alliance, Centres for Disease Control and Prevention (CDC), International Vaccine Institute (IVI), Centre for Vaccine Ethics and Policy, PATH, Clinton Health Access Initiative (CHAI), Bill & Melinda Gates Foundation, European Vaccine Initiative, International Association of Immunization Managers (IAIM), Sabin Vaccine Institute, M\u00e9decins Sans Fronti\u00e8res (MSF), Hilleman Laboratories, Asian Pacific Alliance for Control of Influenza (APACI), National Institute for Biological Standards and Control (NIBSC), Institute for Translational Vaccinology (Intravacc) and other associations and non-profit organisations.", [["DCVMN", "DISEASE", 0, 5], ["polio", "DISEASE", 220, 225], ["infectious diseases", "DISEASE", 282, 301], ["Influenza", "DISEASE", 995, 1004], ["Children", "SPECIES", 454, 462], ["immunisation programmes", "TREATMENT", 119, 142], ["polio", "PROBLEM", 220, 225], ["emerging infectious diseases", "PROBLEM", 273, 301], ["The Vaccine Alliance", "TREATMENT", 560, 580], ["Disease Control", "TREATMENT", 594, 609], ["Bill & Melinda Gates", "TREATMENT", 756, 776], ["Immunization Managers", "TREATMENT", 847, 868], ["Sabin Vaccine", "TREATMENT", 877, 890], ["Influenza", "PROBLEM", 995, 1004], ["Biological Standards", "TREATMENT", 1037, 1057], ["Translational Vaccinology", "TREATMENT", 1093, 1118], ["largest", "OBSERVATION_MODIFIER", 13, 20], ["infectious", "OBSERVATION", 282, 292]]], ["V. Sitprija, Director of Queen Saovabha Memorial Institute and Mr. V. Vonghangool, President of BioNet-Asia introduced Mr. P. Wannamethee, Secretary General of the Thai Red Cross Society, who inaugurated the meeting by acknowledging the power of preventive medicine to reduce, or even eliminate, disease-related mortality and morbidity.", [["preventive medicine", "TREATMENT", 246, 265], ["morbidity", "PROBLEM", 326, 335]]], ["Prof. S. Khomvilai invited Dr. J.-M. Okwo-Bele, Director at WHO, to speak on the achievements and challenges of the Global Vaccine Action Plan (GVAP).Impact of vaccine procurement and supply in prevention of diseases globallyJ.-M. Okwo-Bele highlighted the achievements of global immunisation: polio eradication is close, with only two countries currently reporting wild poliovirus; measles vaccination has reduced the disease by over 79% from 2000 to 2014 [1]; regional meningitis A epidemics have been eliminated in Africa, with half of the population vaccinated [2]; in all, around 6 million deaths have been averted by vaccination [3].", [["measles", "DISEASE", 383, 390], ["meningitis", "DISEASE", 471, 481], ["deaths", "DISEASE", 595, 601], ["wild poliovirus", "ORGANISM", 366, 381], ["the Global Vaccine", "TREATMENT", 112, 130], ["vaccine procurement", "TREATMENT", 160, 179], ["diseases", "PROBLEM", 208, 216], ["polio eradication", "TREATMENT", 294, 311], ["wild poliovirus", "PROBLEM", 366, 381], ["measles vaccination", "TREATMENT", 383, 402], ["the disease", "PROBLEM", 415, 426], ["regional meningitis A epidemics", "PROBLEM", 462, 493], ["meningitis", "OBSERVATION", 471, 481]]], ["Limitations in vaccine affordability and supply, failures in healthcare integration, disruption of immunisation by geopolitical conflict and poor-quality health data have resulted in stagnant coverage and repeated failure to reach immunisation goals.", [["Limitations in vaccine affordability", "TREATMENT", 0, 36], ["immunisation", "TREATMENT", 99, 111], ["stagnant coverage", "TREATMENT", 183, 200], ["repeated failure", "PROBLEM", 205, 221]]], ["For instance, in 2014, 3.2 million children missed their 3rd dose of DTP1in the Eastern Mediterranean region, mostly in security-compromised countries [4].", [["children", "ORGANISM", 35, 43], ["children", "SPECIES", 35, 43], ["DTP1in the Eastern Mediterranean region", "TREATMENT", 69, 108]]], ["Solutions expected from manufacturers include measures to assure the controlled temperature chain (CTC) where cold-chain facilities are lacking, implementation of improved delivery technologies for ease of use in the field, and assistance in reducing risk of shortages.", [["measures", "TREATMENT", 46, 54], ["improved delivery technologies", "TREATMENT", 163, 193]]], ["The monitoring and accountability framework of GVAP identifies and responds to immunisation challenges.Impact of vaccine procurement and supply in prevention of diseases globallyA.", [["A.", "SPECIES", 178, 180], ["The monitoring", "TEST", 0, 14], ["immunisation challenges", "TREATMENT", 79, 102], ["vaccine procurement", "TREATMENT", 113, 132], ["diseases", "PROBLEM", 161, 169], ["diseases", "OBSERVATION", 161, 169]]], ["Over the past decade, demand for higher-value vaccines has grown.", [["higher-value vaccines", "TREATMENT", 33, 54]]], ["More antigens are incorporated into multi-valent combination vaccines (pentavalent2vaccine replacing DTP, and MMR/MR3replacing measles vaccine) and new, complex vaccines are being introduced.", [["pentavalent2vaccine", "CHEMICAL", 71, 90], ["DTP", "CHEMICAL", 101, 104], ["DTP", "CHEMICAL", 101, 104], ["pentavalent2vaccine", "SIMPLE_CHEMICAL", 71, 90], ["DTP", "SIMPLE_CHEMICAL", 101, 104], ["multi-valent combination vaccines", "TREATMENT", 36, 69], ["pentavalent2vaccine", "TREATMENT", 71, 90], ["DTP", "TREATMENT", 101, 104], ["MMR/MR3replacing measles vaccine", "TREATMENT", 110, 142], ["complex vaccines", "TREATMENT", 153, 169]]], ["A robust vaccine development pipeline is emerging from both industrialised and developing countries.", [["A robust vaccine development pipeline", "TREATMENT", 0, 37]]], ["From the latter, the Serum Institute of India's meningitis A vaccine reached 217 million people in 2015 [5], and it is anticipated that Japanese encephalitis vaccine from Chengdu Institute, China, will reach 290 million people by 2017.", [["meningitis", "DISEASE", 48, 58], ["encephalitis", "DISEASE", 145, 157], ["Serum", "ORGANISM_SUBSTANCE", 21, 26], ["people", "ORGANISM", 89, 95], ["people", "ORGANISM", 220, 226], ["people", "SPECIES", 89, 95], ["people", "SPECIES", 220, 226], ["India's meningitis A vaccine", "TREATMENT", 40, 68]]], ["DCVMN members play an essential role in global vaccine supply, contributing to improving health and driving new markets.", [["global vaccine supply", "TREATMENT", 40, 61]]], ["They are diverse in terms of ownership (state or private), scale, portfolio and market (local providers or emerging new multinational companies, Fig. 1).", [["diverse", "OBSERVATION_MODIFIER", 9, 16]]], ["It is important to understand their role and plan for anticipated changes in global versus national financing and procurement of vaccines.Impact of vaccine procurement and supply in prevention of diseases globallyS.", [["globallyS", "DISEASE", 205, 214], ["global versus national financing", "TREATMENT", 77, 109], ["procurement of vaccines", "TREATMENT", 114, 137], ["vaccine procurement", "TREATMENT", 148, 167], ["diseases globallyS", "PROBLEM", 196, 214], ["diseases", "OBSERVATION", 196, 204]]], ["Regionally, the Association of Southeast Asian Nations (ASEAN, representing 10% of the world's population [6]), has initiated collaboration for regional vaccine security and self-reliance, seeking to understand vaccine needs from ASEAN countries\u2019 perspectives, and to identify areas for cooperation.Impact of vaccine procurement and supply in prevention of diseases globallyThe challenge of harmonising regulatory pathways to improve access to vaccines in developing countries was discussed by M. Ward, from WHO.", [["regional vaccine security", "TREATMENT", 144, 169], ["vaccine procurement", "TREATMENT", 309, 328], ["diseases", "PROBLEM", 357, 365], ["harmonising regulatory pathways", "TREATMENT", 391, 422], ["vaccines", "TREATMENT", 444, 452], ["diseases", "OBSERVATION", 357, 365]]], ["Increasing regulatory convergence at regional and international levels can be achieved by adopting common standards and practices for vaccine regulation, without requiring harmonisation of laws [7].", [["Increasing regulatory convergence", "PROBLEM", 0, 33], ["vaccine regulation", "TREATMENT", 134, 152], ["convergence", "OBSERVATION_MODIFIER", 22, 33]]], ["Collaboration should replace duplication.Impact of vaccine procurement and supply in prevention of diseases globallyH.", [["duplication", "TREATMENT", 29, 40], ["vaccine procurement", "TREATMENT", 51, 70], ["diseases", "PROBLEM", 99, 107], ["diseases", "OBSERVATION", 99, 107]]], ["Deehan from UNICEF briefed the audience on prevention and remediation strategies to manage vaccine supply constraints.", [["remediation strategies", "TREATMENT", 58, 80], ["vaccine supply constraints", "TREATMENT", 91, 117]]], ["UNICEF's procurement and supply of vaccines to countries needing assistance with vaccination programmes has increased significantly over the years.", [["UNICEF's procurement", "TREATMENT", 0, 20], ["vaccines", "TREATMENT", 35, 43], ["vaccination programmes", "TREATMENT", 81, 103], ["increased", "OBSERVATION_MODIFIER", 108, 117]]], ["Recent supply constraints have included BCG4, yellow fever vaccine, and IPV5vaccine to support the polio endgame strategy.", [["BCG4", "CHEMICAL", 40, 44], ["yellow fever", "DISEASE", 46, 58], ["BCG4", "SIMPLE_CHEMICAL", 40, 44], ["yellow fever", "ORGANISM", 46, 58], ["Recent supply constraints", "PROBLEM", 0, 25], ["BCG4", "TREATMENT", 40, 44], ["yellow fever vaccine", "TREATMENT", 46, 66], ["IPV5vaccine", "TREATMENT", 72, 83]]], ["Early and transparent communication with manufacturers and close monitoring of stock levels within countries is required to allow prompt mitigation actions and ultimately reduce risk of interrupted supply.", [["close monitoring of stock levels", "TEST", 59, 91], ["prompt mitigation actions", "TREATMENT", 130, 155]]], ["Deehan invited DCVMN members to work with UNICEF to achieve sustained global supply of affordable vaccines of assured quality.Impact of vaccine procurement and supply in prevention of diseases globallyM.", [["affordable vaccines", "TREATMENT", 87, 106], ["vaccine procurement", "TREATMENT", 136, 155], ["diseases", "PROBLEM", 184, 192], ["diseases", "OBSERVATION", 184, 192]]], ["Malhame, head of market shaping for Gavi, presented Gavi's recent accomplishments and activities.", [["head", "ANATOMY", 9, 13], ["head", "ORGANISM_SUBDIVISION", 9, 13], ["head", "ANATOMY", 9, 13]]], ["Pentavalent, pneumococcal and rotavirus vaccines have been steadily introduced in a growing number of countries, surpassing Gavi expectations.", [["Pentavalent", "CHEMICAL", 0, 11], ["rotavirus", "ORGANISM", 30, 39], ["pneumococcal", "SPECIES", 13, 25], ["rotavirus", "SPECIES", 30, 39], ["Pentavalent", "TREATMENT", 0, 11], ["pneumococcal", "TREATMENT", 13, 25], ["rotavirus vaccines", "TREATMENT", 30, 48], ["pneumococcal", "OBSERVATION", 13, 25]]], ["The volume of vaccines from DCVMs6continues to grow, although the value of vaccines procured from DCVMs remains relatively low.", [["The volume of vaccines", "TREATMENT", 0, 22], ["DCVMs6continues", "TREATMENT", 28, 43], ["vaccines", "TREATMENT", 75, 83], ["DCVMs", "TEST", 98, 103]]], ["To secure global supply, Gavi has fostered procurement from multiple countries and manufacturers (Fig. 2A and B).", [["Gavi", "CHEMICAL", 25, 29]]], ["Gavi's strategic goals for 2016\u20132020 include a vaccine goal: to accelerate equitable uptake and coverage of vaccines, a health system goal: to increase effectiveness and efficiency of immunisation delivery as a part of strengthened health systems, a financing goal: to improve sustainability of national immunisation programs, and a market-shaping goal: to shape markets for vaccines and other immunisation products [8].", [["a vaccine goal", "TREATMENT", 45, 59], ["coverage of vaccines", "TREATMENT", 96, 116], ["immunisation delivery", "TREATMENT", 184, 205], ["national immunisation programs", "TREATMENT", 295, 325], ["vaccines", "TREATMENT", 375, 383], ["other immunisation products", "TREATMENT", 388, 415]]], ["With these goals, Gavi hopes to immunise 300 million additional children around the world by the end of 2020.Impact of vaccine procurement and supply in prevention of diseases globallyD.", [["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72], ["vaccine procurement", "TREATMENT", 119, 138], ["diseases", "PROBLEM", 167, 175], ["diseases", "OBSERVATION", 167, 175]]], ["Rodriguez, from the PAHO Revolving Fund for vaccine procurement took a moment to celebrate the Americas region's success, in 2015, as the first region to eliminate rubella.", [["rubella", "DISEASE", 164, 171], ["vaccine procurement", "TREATMENT", 44, 63], ["rubella", "PROBLEM", 164, 171], ["rubella", "OBSERVATION", 164, 171]]], ["This was enabled by the commitment of member countries to regional goals, the PAHO Revolving Fund and vaccine manufacturers.", [["Fund and vaccine manufacturers", "TREATMENT", 93, 123]]], ["He then outlined challenges faced with vaccine shortages and strategies to overcome these.", [["vaccine shortages", "TREATMENT", 39, 56], ["strategies", "TREATMENT", 61, 71]]], ["Latin American populations are under the threat from yellow fever virus because vaccine demand exceeds the number of doses available annually by 6\u20138 million [9].", [["yellow fever", "DISEASE", 53, 65], ["yellow fever virus", "ORGANISM", 53, 71], ["yellow fever virus", "SPECIES", 53, 71], ["yellow fever virus", "SPECIES", 53, 71], ["Latin American populations", "TREATMENT", 0, 26], ["yellow fever virus", "PROBLEM", 53, 71], ["vaccine demand", "TREATMENT", 80, 94]]], ["To avoid supply shortages, countries need concrete demand planning, secured budgets for vaccine purchases and careful stock management.", [["concrete demand planning", "TREATMENT", 42, 66], ["vaccine purchases", "TREATMENT", 88, 105], ["careful stock management", "TREATMENT", 110, 134]]], ["Prevention of shortages starts at country level, while PAHO acts regionally to facilitate timely and sufficient supply, and vaccine manufacturers worldwide are essential for assured global supply.Impact of vaccine procurement and supply in prevention of diseases globallyD.", [["vaccine manufacturers", "TREATMENT", 124, 145], ["vaccine procurement", "TREATMENT", 206, 225], ["diseases", "PROBLEM", 254, 262], ["diseases", "OBSERVATION", 254, 262]]], ["Steele, Bill & Melinda Gates Foundation, emphasised the importance to address global challenges for diarrheal disease vaccines.", [["diarrheal disease", "DISEASE", 100, 117], ["global challenges", "TREATMENT", 78, 95], ["diarrheal disease vaccines", "TREATMENT", 100, 126]]], ["International partnerships with globally funded Product Development Partnerships and DCVMs have already delivered two vaccines for the prevention of leading causes of diarrheal mortality, demonstrating the power of partnerships.", [["DCVMs", "TREATMENT", 85, 90], ["two vaccines", "TREATMENT", 114, 126], ["diarrheal mortality", "PROBLEM", 167, 186]]], ["First, a cholera vaccine was developed through partnership with Vabiotech, Shantha Biotechnics, and the IVI [10].", [["cholera", "DISEASE", 9, 16], ["a cholera vaccine", "TREATMENT", 7, 24], ["Vabiotech", "TREATMENT", 64, 73], ["Shantha Biotechnics", "TREATMENT", 75, 94]]], ["The vaccine is WHO pre-qualified and is widely utilised in countries with endemic cholera.", [["cholera", "DISEASE", 82, 89]]], ["Second, a rotavirus vaccine was developed in partnership with Bharat Biotech, Indian Department of Biotechnology and PATH [11].", [["rotavirus", "ORGANISM", 10, 19], ["rotavirus", "SPECIES", 10, 19], ["a rotavirus vaccine", "TREATMENT", 8, 27]]], ["The vaccine is licensed in India for introduction in early 2016 and a dossier is ready for WHO prequalification.Impact of vaccine procurement and supply in prevention of diseases globallyC.", [["globallyC", "DISEASE", 179, 188], ["The vaccine", "TREATMENT", 0, 11], ["vaccine procurement", "TREATMENT", 122, 141], ["diseases globallyC", "PROBLEM", 170, 188], ["diseases", "OBSERVATION", 170, 178]]], ["Egerton-Warburton elaborated on the goal of the Global Health Investment Fund (GHIF): to invest in quality by supporting late-stage clinical trials and early-stage commercialisation of vaccines, drugs, diagnostics and devices required for control of infectious diseases in low-income countries, as to the World Bank classification7.", [["infectious diseases", "DISEASE", 250, 269], ["early-stage commercialisation of vaccines", "TREATMENT", 152, 193], ["drugs", "TREATMENT", 195, 200], ["diagnostics and devices", "TREATMENT", 202, 225], ["infectious diseases", "PROBLEM", 250, 269], ["infectious", "OBSERVATION", 250, 260]]], ["An example is the investment in the Eubiologics manufacturing facility for oral cholera vaccine, prequalified by the WHO in December 20158, testifies the impact of financial support to start up manufacturers.", [["oral", "ANATOMY", 75, 79], ["oral", "ORGANISM_SUBDIVISION", 75, 79], ["cholera", "ORGANISM", 80, 87], ["oral cholera vaccine", "TREATMENT", 75, 95], ["financial support", "TREATMENT", 164, 181]]], ["Egerton-Warburton noted that new and innovative financing mechanisms, which complement the newly-proposed revolving fund at UNICEF, may be required to support immunisation in non-Gavi countries.Novel vaccines and technologiesWhile a large portfolio of new vaccines is under development by manufacturers in developing countries, the conference focused on a few novel and relevant results, due to time limitations.", [["immunisation", "TREATMENT", 159, 171], ["Novel vaccines", "TREATMENT", 194, 208], ["new vaccines", "TREATMENT", 252, 264], ["large", "OBSERVATION_MODIFIER", 233, 238], ["new", "OBSERVATION_MODIFIER", 252, 255]]], ["A. Precioso, Director of Clinical Trials and Pharmacovigilance at Butantan, reviewed the clinical development of a live, attenuated dengue vaccine.", [["dengue", "DISEASE", 132, 138], ["dengue", "SPECIES", 132, 138], ["Pharmacovigilance at Butantan", "TREATMENT", 45, 74], ["attenuated dengue vaccine", "TREATMENT", 121, 146]]], ["The tetravalent vaccine is expected to protect against all 4 dengue serotypes, inducing both humoral and cellular immune responses, and requires only one or two doses to provide life-long immunity.", [["cellular", "ANATOMY", 105, 113], ["dengue", "DISEASE", 61, 67], ["cellular", "CELL", 105, 113], ["dengue", "SPECIES", 61, 67], ["The tetravalent vaccine", "TREATMENT", 0, 23], ["all 4 dengue serotypes", "PROBLEM", 55, 77], ["cellular immune", "OBSERVATION", 105, 120]]], ["Phase I clinical trials in the US by NIH showed that one dose of vaccine was safe and immunogenic in both flavivirus-na\u00efve and seropositive adults.", [["flavivirus-na\u00efve", "DISEASE", 106, 122], ["flavivirus", "ORGANISM", 106, 116], ["adults", "ORGANISM", 140, 146], ["the US", "TEST", 27, 33], ["vaccine", "TREATMENT", 65, 72], ["immunogenic", "PROBLEM", 86, 97]]], ["Butantan is currently finalizing a Phase II clinical trial, and ethical and regulatory approval for a Phase III trial in Brazil is underway [12].Novel vaccines and technologiesH.T. Pham, CEO of BioNet-Asia, outlined the development of a recombinant pertussis vaccine in response to the resurgence of pertussis around the world.", [["Butantan", "CHEMICAL", 0, 8], ["pertussis", "DISEASE", 300, 309], ["Butantan", "CHEMICAL", 0, 8], ["Butantan", "SIMPLE_CHEMICAL", 0, 8], ["BioNet-Asia", "ORGANISM", 194, 205], ["a Phase III trial", "TREATMENT", 100, 117], ["Novel vaccines", "TREATMENT", 145, 159], ["a recombinant pertussis vaccine", "TREATMENT", 235, 266], ["pertussis", "PROBLEM", 300, 309]]], ["BioNet has constructed new proprietary Bordetella pertussis strains which produce non-toxic, genetically-inactivated pertussis toxin (rPT) [13].", [["Bordetella pertussis strains", "ORGANISM", 39, 67], ["pertussis toxin", "SIMPLE_CHEMICAL", 117, 132], ["rPT", "SIMPLE_CHEMICAL", 134, 137], ["pertussis toxin", "PROTEIN", 117, 132], ["Bordetella pertussis", "SPECIES", 39, 59], ["Bordetella pertussis", "SPECIES", 39, 59], ["constructed new proprietary Bordetella pertussis strains", "PROBLEM", 11, 67], ["inactivated pertussis toxin", "PROBLEM", 105, 132], ["new", "OBSERVATION_MODIFIER", 23, 26]]], ["In a Phase I/II clinical trial, the rPT-containing vaccines were safe and immunogenic in healthy adults, and elicited significantly higher anti-PT titres than the conventional DTaP vaccine.", [["rPT", "CHEMICAL", 36, 39], ["DTaP", "CHEMICAL", 176, 180], ["rPT", "SIMPLE_CHEMICAL", 36, 39], ["DTaP", "SIMPLE_CHEMICAL", 176, 180], ["the rPT-containing vaccines", "TREATMENT", 32, 59], ["significantly higher anti-PT titres", "PROBLEM", 118, 153], ["the conventional DTaP vaccine", "TREATMENT", 159, 188]]], ["Another Phase I study will soon evaluate rPT vaccine with an epi-cutaneous delivery system [14].Novel vaccines and technologiesL.", [["Another Phase I study", "TEST", 0, 21], ["rPT vaccine", "TREATMENT", 41, 52], ["an epi-cutaneous delivery system", "TREATMENT", 58, 90], ["Novel vaccines", "TREATMENT", 96, 110]]], ["He reviewed the strong causal relationship between HPV infection and cervical cancer.", [["cervical cancer", "ANATOMY", 69, 84], ["HPV infection", "DISEASE", 51, 64], ["cervical cancer", "DISEASE", 69, 84], ["HPV", "ORGANISM", 51, 54], ["cervical cancer", "CANCER", 69, 84], ["HPV", "SPECIES", 51, 54], ["HPV infection", "PROBLEM", 51, 64], ["cervical cancer", "PROBLEM", 69, 84], ["infection", "OBSERVATION", 55, 64], ["cervical", "ANATOMY", 69, 77], ["cancer", "OBSERVATION", 78, 84]]], ["Zerun's bivalent HPV (16/18) recombinant vaccine candidate, produced in the yeast, Pichia pastoris, is currently in a Phase III clinical trial, and is expected to be on the Chinese market by 2019, and to obtain WHO PQ thereafter.", [["Zerun", "CHEMICAL", 0, 5], ["PQ", "CHEMICAL", 215, 217], ["Zerun", "GENE_OR_GENE_PRODUCT", 0, 5], ["HPV", "ORGANISM", 17, 20], ["16/18", "ORGANISM", 22, 27], ["Pichia pastoris", "ORGANISM", 83, 98], ["PQ", "SIMPLE_CHEMICAL", 215, 217], ["yeast", "SPECIES", 76, 81], ["Pichia pastoris", "SPECIES", 83, 98], ["yeast", "SPECIES", 76, 81], ["Pichia pastoris", "SPECIES", 83, 98], ["Zerun's bivalent HPV", "TREATMENT", 0, 20], ["recombinant vaccine", "TREATMENT", 29, 48], ["Pichia pastoris", "PROBLEM", 83, 98], ["Pichia pastoris", "OBSERVATION", 83, 98]]], ["In addition, a novel recombinant HPV vaccine candidate based on Escherichia coli expression systems, developed by another manufacturer in China, is also in phase 3 clinical trials, as previously reported [15].Novel vaccines and technologiesL.", [["HPV", "ORGANISM", 33, 36], ["Escherichia coli", "ORGANISM", 64, 80], ["Escherichia coli", "SPECIES", 64, 80], ["HPV", "SPECIES", 33, 36], ["Escherichia coli", "SPECIES", 64, 80], ["a novel recombinant HPV vaccine", "TREATMENT", 13, 44], ["Escherichia coli expression systems", "PROBLEM", 64, 99], ["Novel vaccines", "TREATMENT", 209, 223], ["Escherichia coli", "OBSERVATION", 64, 80]]], ["Castello-Branco, Scientific Director at Funda\u00e7\u00e3o Ataulpho de Paiva (FAP), presented an overview of the BCG vaccine (Moreau sub-strain).", [["Castello", "TEST", 0, 8], ["the BCG vaccine", "TREATMENT", 99, 114]]], ["This vaccine was developed in Brazil in the 1930s and used as an oral vaccine in the National Program on Immunisation until 1974 [16].", [["oral", "ANATOMY", 65, 69], ["oral", "ORGANISM_SUBDIVISION", 65, 69], ["This vaccine", "TREATMENT", 0, 12], ["an oral vaccine", "TREATMENT", 62, 77]]], ["Genetic data shows that the sub-strain is similar to the Japanese and Russian sub-strains [17].", [["Genetic data", "TEST", 0, 12], ["the sub-strain", "PROBLEM", 24, 38]]], ["Safety and efficacy of intradermal BCG-Moreau vaccine has been demonstrated in large clinical trials.", [["intradermal BCG", "TREATMENT", 23, 38], ["Moreau vaccine", "TREATMENT", 39, 53], ["large", "OBSERVATION_MODIFIER", 79, 84]]], ["It is the only BCG administered to babies born to HIV positive mothers in Brazil10and it is licensed for use for intravesical therapy of bladder cancer [18].", [["bladder cancer", "ANATOMY", 137, 151], ["Brazil10and", "CHEMICAL", 74, 85], ["bladder cancer", "DISEASE", 137, 151], ["babies", "ORGANISM", 35, 41], ["HIV", "ORGANISM", 50, 53], ["mothers", "ORGANISM", 63, 70], ["bladder cancer", "CANCER", 137, 151], ["HIV", "SPECIES", 50, 53], ["HIV", "SPECIES", 50, 53], ["BCG", "TREATMENT", 15, 18], ["intravesical therapy", "TREATMENT", 113, 133], ["bladder cancer", "PROBLEM", 137, 151], ["bladder", "ANATOMY", 137, 144], ["cancer", "OBSERVATION", 145, 151]]], ["FAP is now expanding the manufacturing capacity to supply BCG globally.Novel vaccines and technologiesG.", [["FAP", "DISEASE", 0, 3], ["Novel vaccines", "TREATMENT", 71, 85]]], ["To accelerate eradication of circulating polioviruses from live polio vaccines, WHO launched an initiative to develop IPV.", [["circulating polioviruses", "PROBLEM", 29, 53], ["live polio vaccines", "TREATMENT", 59, 78], ["IPV", "PROBLEM", 118, 121], ["eradication", "OBSERVATION_MODIFIER", 14, 25]]], ["IMBCAMS started Sabin-IPV development 1983.", [["IMBCAMS", "CHEMICAL", 0, 7]]], ["A successful phase III clinical trial was completed in March 2013, and the world's first Sabin-IPV vaccine was launched on the Chinese Market in July 2015.", [["Sabin", "ORGANISM", 89, 94], ["IPV vaccine", "TREATMENT", 95, 106]]], ["IMBCAMS is planning to increase production capacity from the current 10 million to 60 million doses per annum, to develop a combination vaccine and to obtain WHO PQ11to enable global supply [19].Novel vaccines and technologiesK.", [["IMBCAMS", "CHEMICAL", 0, 7], ["increase production capacity", "PROBLEM", 23, 51], ["a combination vaccine", "TREATMENT", 122, 143], ["Novel vaccines", "TREATMENT", 195, 209]]], ["Ella, Bharat Biotech, presented their Chikungunya vaccine, an inactivated, whole-virion CHIKV derived from an Indian isolate [20].", [["Chikungunya", "DISEASE", 38, 49], ["Chikungunya", "ORGANISM", 38, 49], ["CHIKV", "ORGANISM", 88, 93], ["CHIKV", "SPECIES", 88, 93]]], ["CHIKV was established to high titre in Vero cells.", [["Vero cells", "ANATOMY", 39, 49], ["CHIKV", "ORGANISM", 0, 5], ["Vero cells", "CELL", 39, 49], ["Vero cells", "CELL_LINE", 39, 49], ["CHIKV", "SPECIES", 0, 5], ["CHIKV", "PROBLEM", 0, 5], ["high titre in Vero cells", "PROBLEM", 25, 49], ["high titre", "OBSERVATION_MODIFIER", 25, 35], ["Vero cells", "OBSERVATION", 39, 49]]], ["Pre-clinical toxicity studies demonstrated safety with 100 times the dose proposed for Phase I testing.", [["toxicity", "DISEASE", 13, 21], ["Pre-clinical toxicity studies", "TEST", 0, 29], ["Phase I testing", "TEST", 87, 102]]], ["Phase I dose ranges were based on a comparative study of protective correlates in 85 convalescent patients and data from immunogenicity testing in laboratory animals.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["a comparative study", "TEST", 34, 53], ["immunogenicity testing", "TEST", 121, 143]]], ["A Phase I study is proposed in India.", [["Phase I study", "TEST", 2, 15]]], ["Vaccine methodology is protected by patents in several countries.Novel vaccines and technologiesM.", [["Vaccine methodology", "TREATMENT", 0, 19], ["Novel vaccines", "TREATMENT", 65, 79]]], ["Bottazzi, from Sabin Vaccine Institute, reviewed novel technologies for vaccines against neglected tropical diseases.", [["Bottazzi", "CHEMICAL", 0, 8], ["tropical diseases", "DISEASE", 99, 116], ["vaccines", "TREATMENT", 72, 80], ["neglected tropical diseases", "PROBLEM", 89, 116]]], ["Seventeen tropical diseases, including leprosy, trematodiasis, leishmaniasis, dengue, Chagas disease, filariasis and helminth infections are highly prevalent among the poor, and are endemic in 149 countries, affecting 1.4 billion people [21].", [["leprosy", "DISEASE", 39, 46], ["trematodiasis", "DISEASE", 48, 61], ["leishmaniasis", "DISEASE", 63, 76], ["dengue", "DISEASE", 78, 84], ["Chagas disease", "DISEASE", 86, 100], ["filariasis", "DISEASE", 102, 112], ["helminth infections", "DISEASE", 117, 136], ["people", "SPECIES", 230, 236], ["Seventeen tropical diseases", "PROBLEM", 0, 27], ["leprosy", "PROBLEM", 39, 46], ["trematodiasis", "PROBLEM", 48, 61], ["leishmaniasis", "PROBLEM", 63, 76], ["dengue", "PROBLEM", 78, 84], ["Chagas disease", "PROBLEM", 86, 100], ["filariasis", "PROBLEM", 102, 112], ["helminth infections", "PROBLEM", 117, 136], ["tropical", "OBSERVATION_MODIFIER", 10, 18], ["diseases", "OBSERVATION", 19, 27], ["leprosy", "OBSERVATION", 39, 46], ["leishmaniasis", "OBSERVATION", 63, 76], ["Chagas disease", "OBSERVATION", 86, 100], ["filariasis", "OBSERVATION", 102, 112], ["helminth", "OBSERVATION_MODIFIER", 117, 125], ["infections", "OBSERVATION", 126, 136]]], ["The Sabin Vaccine Institute focuses on product development partnerships to develop effective, low-cost vaccines.", [["The Sabin Vaccine", "TREATMENT", 0, 17], ["low-cost vaccines", "TREATMENT", 94, 111]]], ["The human hookworm vaccine initiative illustrates these efforts against a leading cause of maternal and childhood anaemia, which afflicts 440 million people.", [["anaemia", "DISEASE", 114, 121], ["human", "ORGANISM", 4, 9], ["people", "ORGANISM", 150, 156], ["human", "SPECIES", 4, 9], ["people", "SPECIES", 150, 156], ["human", "SPECIES", 4, 9], ["The human hookworm vaccine", "TREATMENT", 0, 26], ["maternal and childhood anaemia", "PROBLEM", 91, 121], ["anaemia", "OBSERVATION", 114, 121]]], ["Two candidate vaccines have been manufactured and are currently being tested in Brazil and Gabon.", [["Two candidate vaccines", "TREATMENT", 0, 22]]], ["The Institute is seeking partnership with manufacturers from developing countries to advance the product and clinical development of various candidate vaccines.Novel vaccines and technologiesThe Eubiologics oral cholera vaccine (OCV) was presented by S. Park.", [["oral", "ANATOMY", 207, 211], ["oral cholera", "CHEMICAL", 207, 219], ["oral cholera", "ORGANISM", 207, 219], ["OCV", "SPECIES", 229, 232], ["the product", "TREATMENT", 93, 104], ["various candidate vaccines", "TREATMENT", 133, 159], ["Novel vaccines", "TREATMENT", 160, 174], ["technologies", "TREATMENT", 179, 191], ["The Eubiologics oral cholera vaccine", "TREATMENT", 191, 227]]], ["Eubiologics has a contract manufacturing agreement with IVI for production and supply of cholera vaccines.", [["IVI", "TREATMENT", 56, 59], ["cholera vaccines", "TREATMENT", 89, 105]]], ["The stockpile is expected to aid global response to outbreaks, improve overall availability and supply of OCV, attract new manufacturers and incentivize new developments.", [["stockpile", "OBSERVATION", 4, 13]]], ["This vaccine was approved in 2015 in Korea.", [["This vaccine", "TREATMENT", 0, 12]]], ["A prequalification dossier has been approved by WHO demonstrating the impact of partnerships among manufacturers.Novel vaccines and technologiesDelivery of OCV was discussed by J. Deen, from the Delivering Oral Vaccines Effectively (DOVE) project at the Johns Hopkins Bloomberg School of Public Health.", [["Novel vaccines", "TREATMENT", 113, 127], ["the Delivering Oral Vaccines", "TREATMENT", 191, 219]]], ["Globally, there are an estimated 2.8 million cases of cholera and nearly 100 000 deaths annually.", [["cholera", "DISEASE", 54, 61], ["deaths", "DISEASE", 81, 87], ["cholera", "PROBLEM", 54, 61], ["2.8 million", "OBSERVATION", 33, 44]]], ["Oral cholera vaccines provide direct and indirect (herd12) protection.", [["Oral", "ANATOMY", 0, 4], ["Oral cholera vaccines", "TREATMENT", 0, 21], ["indirect (herd12) protection", "TREATMENT", 41, 69]]], ["In 2012 a global stockpile of 2 million doses of oral cholera vaccines was created by WHO primarily for epidemic response [23].", [["oral", "ANATOMY", 49, 53], ["oral", "ORGANISM_SUBDIVISION", 49, 53], ["oral cholera vaccines", "TREATMENT", 49, 70]]], ["Vaccine supply is insufficient to meet epidemic and endemic needs.", [["Vaccine supply", "TREATMENT", 0, 14]]], ["If vaccine supply is increased, OCV use can be expanded to endemic countries to protect populations at risk and stop cholera.Novel vaccines and technologiesK.", [["cholera", "DISEASE", 117, 124], ["OCV", "SPECIES", 32, 35], ["vaccine supply", "TREATMENT", 3, 17], ["endemic countries", "TREATMENT", 59, 76], ["Novel vaccines", "TREATMENT", 125, 139], ["increased", "OBSERVATION_MODIFIER", 21, 30]]], ["Hun presented the novel cell-based seasonal influenza vaccine from SK Chemicals, licensed in Korea in 2014.The power of multi-centre clinical trials ::: Executive discussion panelsA discussion was moderated by O. Leroy, Executive Director of the European Vaccine Initiative, with panellists A. Precioso, W. Huang, D. Curry and V. Verez, about collaboration in clinical trials, using vaccines developed at DCVMs Innovax and Finlay Institute as examples.", [["cell", "ANATOMY", 24, 28], ["influenza", "DISEASE", 44, 53], ["SK", "CHEMICAL", 67, 69], ["cell", "CELL", 24, 28], ["the novel cell", "PROBLEM", 14, 28], ["seasonal influenza vaccine", "TREATMENT", 35, 61], ["vaccines", "TREATMENT", 383, 391]]], ["Innovax has produced the world's first hepatitis E vaccine [24], and is now using the recombinant technology platform to produce, potentially, the world's 3rd commercialised HPV vaccine.", [["Innovax", "CHEMICAL", 0, 7], ["hepatitis E", "DISEASE", 39, 50], ["hepatitis E", "ORGANISM", 39, 50], ["HPV", "ORGANISM", 174, 177], ["hepatitis E vaccine", "TREATMENT", 39, 58], ["HPV vaccine", "TREATMENT", 174, 185]]], ["Finlay is developing a 7-valent pneumococcal vaccine.", [["pneumococcal", "ORGANISM", 32, 44], ["pneumococcal", "SPECIES", 32, 44], ["a 7-valent pneumococcal vaccine", "TREATMENT", 21, 52], ["7-valent", "OBSERVATION_MODIFIER", 23, 31]]], ["Verez noted that, as 70% of the world's infants are not yet vaccinated against pneumococcal disease, it may be useful to have an affordable 7-valent vaccine that protects against regional disease strains, while waiting for higher valency vaccines to become accessible to middle and low-income populations.", [["pneumococcal disease", "DISEASE", 79, 99], ["infants", "ORGANISM", 40, 47], ["infants", "SPECIES", 40, 47], ["pneumococcal", "SPECIES", 79, 91], ["pneumococcal disease", "PROBLEM", 79, 99], ["an affordable 7-valent vaccine", "TREATMENT", 126, 156], ["regional disease strains", "PROBLEM", 179, 203], ["higher valency vaccines", "TREATMENT", 223, 246]]], ["Head-to-head studies may help understand the impact of multivalent vaccines compared to regionally relevant formulations.", [["Head-to-head studies", "TEST", 0, 20], ["multivalent vaccines", "TREATMENT", 55, 75], ["regionally relevant formulations", "TREATMENT", 88, 120], ["head", "ANATOMY", 8, 12]]], ["Leroy asked how a manufacturer such as Innovax could accelerate WHO PQ and how DCVMN members could support their clinical development.", [["Innovax", "CHEMICAL", 39, 46], ["PQ", "CHEMICAL", 68, 70], ["PQ", "SIMPLE_CHEMICAL", 68, 70]]], ["Harmonisation of the quality of clinical trials and DCVMN's role in calling for convergence between regulators was encouraged.", [["clinical trials", "TREATMENT", 32, 47], ["DCVMN's", "TREATMENT", 52, 59]]], ["A. Precioso commented that DCVMN has several initiatives, including workshops on clinical trial management to harmonise practices and support WHO prequalification of vaccines.", [["DCVMN", "CHEMICAL", 27, 32], ["clinical trial management", "TREATMENT", 81, 106], ["harmonise practices", "TREATMENT", 110, 129], ["vaccines", "TREATMENT", 166, 174]]], ["DCVMN needs time to develop such complex initiatives, and collaborations between companies can contribute, by enabling joint-clinical development and international multicentric clinical trials.", [["joint", "ANATOMY", 119, 124]]], ["D. Curry (Centre for Vaccine Ethics and Policy), whose expertise lies in ethical and legal requirements for and oversight of clinical trials, suggested that one area of support to DCVMs might be development of ethical frameworks to guide clinical trial design, conduct and assessment.Vaccine security ::: Executive discussion panelsA discussion on vaccine security was moderated by J. Kim, Director General of IVI, with H. Deehan of UNICEF, M. Makhoana of Biovac, N. Premsri and T. Mahmoud as contributors.", [["support to DCVMs", "TREATMENT", 169, 185], ["conduct and assessment", "TEST", 261, 283], ["vaccine security", "TREATMENT", 348, 364], ["Biovac", "TREATMENT", 456, 462]]], ["UNICEF and Gavi are steadily increasing vaccine funding and procurement for developing countries in response to increasing demand.", [["steadily increasing vaccine funding", "TREATMENT", 20, 55], ["increasing demand", "PROBLEM", 112, 129]]], ["H. Deehan noted that, while sourcing vaccine from multiple suppliers helps prevent global vaccine shortages, it also creates fierce competition, and noted the difficulty of finding the balance in having an ideal number of suppliers and fostering a sustainable, competitive market.", [["sourcing vaccine", "TREATMENT", 28, 44]]], ["Kim turned attention to the recent Ebola outbreak in Africa, which was brought under control without a vaccine [25].", [["Ebola", "DISEASE", 35, 40], ["Ebola", "ORGANISM", 35, 40], ["a vaccine", "TREATMENT", 101, 110], ["Ebola", "OBSERVATION_MODIFIER", 35, 40]]], ["M. Makhoana agreed that future outbreaks may come, and emphasised that the understanding of the infectious agent must precede product development.", [["the infectious agent", "TREATMENT", 92, 112]]], ["Vaccines then need to be part of broader strengthening of health systems.", [["Vaccines", "TREATMENT", 0, 8]]], ["Ultimately, responses tackling African diseases may need to come from within Africa.", [["African diseases", "PROBLEM", 31, 47]]], ["N. Premsri related Thailand's philosophy of self-reliance, with the ideal to have capacity to produce essential vaccines and an adequate stockpile from multiple regional manufacturers in order to respond to outbreaks or shortages.", [["self-reliance", "PROBLEM", 44, 57], ["essential vaccines", "TREATMENT", 102, 120], ["multiple regional manufacturers", "TREATMENT", 152, 183], ["adequate", "OBSERVATION_MODIFIER", 128, 136], ["stockpile", "OBSERVATION", 137, 146], ["multiple", "OBSERVATION_MODIFIER", 152, 160], ["regional manufacturers", "OBSERVATION", 161, 183]]], ["T. Mahmoud described vaccine-supply challenges in Saudi Arabia, where the objective of high vaccination coverage is undermined by vaccine shortages and lack of expertise in vaccine manufacturing in the region.", [["high vaccination coverage", "TREATMENT", 87, 112], ["region", "ANATOMY_MODIFIER", 202, 208]]], ["Technology transfer with the appropriate partners and a competent team of manufacturers will accelerate efforts to secure high vaccination coverage regionally.Developing markets ::: Executive discussion panelsThe discussion on developing markets was moderated by J. Chu, Senior Director of Vaccine Markets at the Clinton Health Access Initiative (CHAI).", [["secure high vaccination coverage regionally", "TREATMENT", 115, 158]]], ["Changes in regulatory standards can cause disruption and delays in lot release and registration.", [["Changes in regulatory standards", "PROBLEM", 0, 31], ["disruption", "PROBLEM", 42, 52]]], ["Despite the challenges, DCVMN members have been contributing significantly to increasing access to vaccines globally.", [["increasing access to vaccines", "TREATMENT", 78, 107]]], ["In 2013, the human-vaccine market was estimated at US$25 billion and it is forecasted to reach US$38 billion by 2020 [26].", [["human", "ORGANISM", 13, 18], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["the human-vaccine market", "TREATMENT", 9, 33]]], ["M. Malhame (Gavi) raised the balance between affordability and sustainability of vaccine supply, explaining that Gavi evaluates any new vaccine that has passed phase II clinical trials for inclusion in the vaccines\u2019 portfolio financed by Gavi.", [["Gavi", "CHEMICAL", 113, 117], ["vaccine supply", "TREATMENT", 81, 95], ["new vaccine", "TREATMENT", 132, 143]]], ["This evaluation is data-driven, and includes parameters such as disease burden, feasibility and cost-effectiveness of disease prevention.", [["This evaluation", "TEST", 0, 15], ["disease burden", "PROBLEM", 64, 78], ["disease prevention", "TREATMENT", 118, 136]]], ["She also commented that the high costs of vaccine development, relative to those of drugs or diagnostics, could be overcome in part by technologies to improve manufacturing processes.", [["vaccine development", "TREATMENT", 42, 61], ["drugs", "TREATMENT", 84, 89]]], ["K. Ella (Bharat Biotech) shared insights on building successful international partnerships and balancing private and public contributions.", [["K", "CHEMICAL", 0, 1], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["K", "TEST", 0, 1]]], ["Privatisation of manufacturing has resulted in stable vaccine supply in many countries, and private enterprise can enhance supply of public-sector.", [["stable", "OBSERVATION_MODIFIER", 47, 53]]], ["Walvax is prioritizing product-portfolio investments to allow supply of vaccines internationally.", [["Walvax", "TREATMENT", 0, 6], ["vaccines", "TREATMENT", 72, 80]]], ["Large manufacturing capacity is required to satisfy both domestic and international markets and many Chinese companies have this capacity, thus the world is likely to see more vaccines from Chinese manufacturers in future.", [["Large manufacturing capacity", "PROBLEM", 0, 28], ["this capacity", "PROBLEM", 124, 137], ["manufacturing capacity", "OBSERVATION", 6, 28]]], ["F. Lobos described Sinergium's journey into the vaccine market in South America.", [["Sinergium", "CHEMICAL", 19, 28]]], ["Sinergium was a spin-off from a veterinarian vaccine manufacturer in 2009.", [["Sinergium", "CHEMICAL", 0, 9], ["a veterinarian vaccine manufacturer", "TREATMENT", 30, 65]]], ["It established technology transfer agreements with large multinationals, primarily to satisfy the national needs for influenza, pneumococcal and HPV vaccines.", [["influenza", "DISEASE", 117, 126], ["pneumococcal", "ORGANISM", 128, 140], ["HPV", "ORGANISM", 145, 148], ["pneumococcal", "SPECIES", 128, 140], ["HPV", "SPECIES", 145, 148], ["influenza", "PROBLEM", 117, 126], ["pneumococcal and HPV vaccines", "TREATMENT", 128, 157]]], ["Importantly, partnerships with government accelerated their progress: technical support was received from the local regulatory agency in building a world-class facility complying with international standards; also, a multi-year governmental supply contract secured stability for the company.", [["technical support", "TREATMENT", 70, 87]]], ["Now, with modern facilities and equipment, the company aims to expand partnerships with DCVMs.Trust in vaccines ::: Executive discussion panelsS.", [["DCVMs", "TREATMENT", 88, 93]]], ["S. Jadhav described the experiences of the Serum Institute of India, one of the largest and most successful manufacturers from emerging countries, with 23 WHO-prequalified vaccines.", [["Serum", "ORGANISM_SUBSTANCE", 43, 48], ["prequalified vaccines", "TREATMENT", 159, 180], ["largest", "OBSERVATION_MODIFIER", 80, 87]]], ["Still reluctance to purchase products from developing countries on the basis of perceived higher reactogenicity or preference for known brands is a barrier to acceptance of new products.", [["new products", "TREATMENT", 173, 185]]], ["Measles vaccine was prequalified by WHO in 1993, however UNICEF did not immediately take it up.", [["Measles vaccine", "TREATMENT", 0, 15]]], ["Serum Institute supplied more than 90% of the measles-containing vaccines used to achieve measles and rubella eradication in Latin America.", [["Serum", "ANATOMY", 0, 5], ["measles and rubella", "DISEASE", 90, 109], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["measles", "SPECIES", 90, 97], ["rubella", "SPECIES", 102, 109], ["the measles-containing vaccines", "TREATMENT", 42, 73], ["measles", "PROBLEM", 90, 97], ["rubella eradication", "PROBLEM", 102, 121]]], ["For the introduction of meningitis A vaccine in African countries, community leaders were informed about benefits, resulting in high acceptance and very successful prevention of disease.", [["meningitis", "DISEASE", 24, 34], ["meningitis", "PROBLEM", 24, 34], ["disease", "PROBLEM", 178, 185], ["meningitis", "OBSERVATION", 24, 34], ["disease", "OBSERVATION", 178, 185]]], ["A. Batson noted that vaccine hesitancy is often specific to a country or situation, rather than a global issue, and strongly agreed that engaging the local community leaders can have significant impact on uptake.", [["vaccine hesitancy", "PROBLEM", 21, 38]]], ["Interestingly, mobile phones have proven useful to advocate for vaccines for teenagers, such as HPV vaccines.", [["HPV", "ORGANISM", 96, 99], ["HPV", "SPECIES", 96, 99], ["vaccines", "TREATMENT", 64, 72], ["HPV vaccines", "TREATMENT", 96, 108]]], ["K. Sampson discussed the confidence in influenza vaccines, where there is a risk that the strains that make up the vaccine may not fully match those causing disease, due to antigenic drift.", [["K", "CHEMICAL", 0, 1], ["influenza", "DISEASE", 39, 48], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["K", "TEST", 0, 1], ["Sampson", "TREATMENT", 3, 10], ["influenza vaccines", "TREATMENT", 39, 57], ["the strains", "PROBLEM", 86, 97], ["the vaccine", "TREATMENT", 111, 122], ["disease", "PROBLEM", 157, 164], ["antigenic drift", "PROBLEM", 173, 188], ["antigenic drift", "OBSERVATION", 173, 188]]], ["He noted that Asia has a large ethnically and socio-culturally heterogeneous population and a vaccine may not suit all patients.", [["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["a vaccine", "TREATMENT", 92, 101], ["large", "OBSERVATION_MODIFIER", 25, 30]]], ["Decision-making on influenza vaccination is driven by whether it is likely to protect the vaccinated individual, and also, whether is it likely to help protect others through herd immunity.", [["influenza", "DISEASE", 19, 28], ["influenza", "ORGANISM", 19, 28], ["herd", "ORGANISM_SUBDIVISION", 175, 179], ["influenza vaccination", "TREATMENT", 19, 40]]], ["P. Carrasco elaborated further on the role of health workers delivering vaccines, noting that they build patient trust by imparting their knowledge of the vaccines and vaccination, but also inspire confidence when they clearly trust the intervention themselves.", [["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 105, 112], ["vaccines", "TREATMENT", 72, 80], ["the vaccines", "TREATMENT", 151, 163], ["vaccination", "TREATMENT", 168, 179]]], ["New tools, such as smart phones, are within reach of most health workers, even in low-income countries.ConclusionsThe DCVMN 2015 Annual General Meeting gave rich insights into advances in vaccine technologies and development of new vaccines, and provided valuable opportunity for vaccine manufacturers, regulatory authorities and international organisations to have face-to-face interactions.", [["vaccine technologies", "TREATMENT", 188, 208], ["new vaccines", "TREATMENT", 228, 240], ["vaccine manufacturers", "TREATMENT", 280, 301]]], ["To achieve global immunisation, local authorities and community leaders play an important role in the decision-making in vaccine introduction and uptake, based on the ability of vaccines to protect vaccinated people and protect non-vaccinated in the community through herd immunity.", [["people", "ORGANISM", 209, 215], ["herd", "ORGANISM_SUBDIVISION", 268, 272], ["people", "SPECIES", 209, 215], ["vaccines", "TREATMENT", 178, 186]]], ["Reducing the risk of vaccine shortages can be achieved by increasing regulatory convergence at regional and international levels.", [["vaccine shortages", "TREATMENT", 21, 38]]], ["Combatting preventable diseases outbreaks remains challenging, and collective efforts for improving multi-centre clinical trials including various populations, creating regional relevant vaccine manufacturing and stockpiling security strategies, fostering stable vaccine markets and procurement, and building trust in vaccines are recommended approaches.", [["preventable diseases outbreaks", "PROBLEM", 11, 41], ["various populations", "TREATMENT", 139, 158], ["creating regional relevant vaccine manufacturing", "TREATMENT", 160, 208], ["stockpiling security strategies", "TREATMENT", 213, 244]]], ["The DCVMN members will continue to collaborate with one another, with partners and with regulators towards the goal of improving global access to immunisation, through sustainable supply of vaccines to match demand, as well as greater capacity to rapidly respond to outbreaks.", [["immunisation", "TREATMENT", 146, 158], ["vaccines", "TREATMENT", 190, 198]]], ["The aim is to provide high quality vaccines for all people.Conflict of interest statementThe authors are employees of the respective indicated organisations, and have no conflict of interest to declare.", [["people", "ORGANISM", 52, 58], ["people", "SPECIES", 52, 58], ["high quality vaccines", "TREATMENT", 22, 43]]]]}